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INTESTINAL INFECTIONS
Incidence and causes of intestinal infection
Intestinal infections are a widespread and still an emerging public health problem, 
in both developed and developing countries (1), and represent significant health 
care and economic costs in many countries (2,3). Infection of the intestinal tract 
with an increasingly recognized array of bacterial, parasitic and viral pathogens is 
largely related to waterborne and foodborne outbreaks (4). These foodborne infec-
tions can profoundly disrupt intestinal function. The global incidence of food-
borne disease is difficult to estimate, but it has been reported that in 2005 alone 
1.8 million people died from this disease (5). In industrialized countries, the per-
centage of the population suffering from foodborne diseases each year has been 
reported to be up to 30 %. In the USA, for example, around 76 million cases of 
foodborne diseases, resulting in 325,000 hospitalizations and 5,000 deaths, are esti-
mated to occur each year (5). Moreover, acute intestinal infection is a risk factor 
for various chronic diseases like inflammatory bowel disease (IBD) (6), irritable 
bowel syndrome (7) and reactive arthritis (8). Reports of intestinal infections con-
tinue to increase (4) partly because elderly people are more prone to developing 
an infection. While less documented, developing countries have a high occurrence 
of foodborne disease due to major underlying food safety problems (5). Some 
well recognized foodborne diseases are considered as emerging because they have 
recently become more common. For example, outbreaks of salmonellosis have 
been reported for decades, but within the past 25 years the incidence of the disease 
has increased on many continents (1). In the Western hemisphere and in Europe, 
Salmonella serotype Enteritidis has become the predominant strain (1).
In 2008 Salmonella serotype Saintpaul enteritidis was diagnosed in 1407 
persons in the United States and Canada (9). A second outbreak concerned 600 
persons in Canada who were diagnosed with S. typhimurium Enteritidis. Both 
strains involved were traced to food sources that had never been found contami-
nated previously. The first outbreak was caused by a strain detected in jalapeño 
and Serrano peppers, whereas the second outbreak concerned peanut butter, 
which was also used in various processed foods (9).
In a healthy host, intestinal infections generally result in a self-limiting 
gastroenteritis and there is no evidence that administration of antibiotics shortens 
the duration of the symptoms. In contrast, in young children, the elderly, immu-
nocompromised people receiving immunosuppressive drugs, IBD patients and 
patients receiving parenteral nutrition, these infections may lead to serious compli-
cations and antibiotic therapy may be needed (10). Growing resistance of bacterial 
pathogens, including Salmonella species, to generally applied antibiotics is a major 
concern (3,11-13) and untreatable infections in the future are feared. Prevention 
of infections is of utmost importance and hygiene improvement is the first step. 
This not only applies to a large food safety problem in many developing countries 
(5), but also to enormous shifts during the past half century in food production 
in the West, where food is imported or grown and processed on a vast industrial 
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scale (9). Moreover, it is important to understand how foodborne pathogens cause 
disease, how and which host defence mechanisms are involved, and whether these 
host defence mechanisms can be improved. 
Mechanisms and crucial steps of foodborne infections
The ingested microorganism must adhere to host cells in order to infect the 
host (14). Adherent microorganisms bind to the apical pole of the intestinal 
epithelium via a large and diverse array of adhesion and invasion molecules 
that enable them to exploit a variety of host-cell surface components. Fim-
briae, also called pili, are adhesive hair-like organelles that protrude from the 
surface of bacteria and are involved in adhesion of e.g. Escherichia coli (14,15). 
Besides pili and fimbriae, a plethora of different bacterial nonpolymeric adhes-
ins exist which recognize many different elements on the host surface compo-
nents like integrins, cadherins, selectins and carcinoembryonic antigen-related 
adhesion molecules (CEACAMs) (14). These are receptors of many pathogens 
involved in adhesion and sometimes cell entry. Certain pathogens infect the 
host by cellular invasion (Fig 1) (14). These invasive bacteria actively induce 
	  
Figure 1. Electron micrograph demonstrating Salmonella invasion in guinea pig ileal 
epithelial cells. Arrows point to invading Salmonella organisms. (Courtesy Dr. S. Baron, 
the University of Texas Medical Branch at Galveston) 
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their own uptake by phagocytosis in normally non-phagocytic cells, such as 
epithelial cells, and then either establish a protected niche in which they sur-
vive and replicate, or disseminate from cell to cell by means of an actin-based 
motility process (16). The mechanisms underlying bacterial entry, phagosome 
maturation, and dissemination reveal common strategies as well as unique tac-
tics evolved by individual species to establish infection (16). For example, Sal-
monella are capable of traversing the intestinal epithelium via three routes. The 
first route is via invasion into specialized epithelial cells called M cells, which 
sample antigens from the intestinal lumen for immune system maturation. 
Another route is through dendritic cells (DC) that intercalate epithelial cells 
by extending protrusions into the gut lumen. The third route involves binding 
of Salmonella to epithelial cells by the type III secretory system (TTSS) of this 
pathogen (17,18). 
After traversing the epithelial cell by one of these mechanisms, the bac-
teria encounter the basal membrane, and the invaders are ingested by macro-
phages or other phagocytic cells and are transported to the mesenteric lymph 
nodes (Fig 2). When massive translocation occurs, bacteria will spread to the 
bloodstream, denoted as septicaemia or bacteraemia, and may invade other 
organs (19), generally causing a life-threatening infection.
Figure 2. Schematic representation of the pathogenesis of Salmonella adherence and trans-
location through the intestinal epithelial cells causing enterocolitis and diarrhoea (20).
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Symptoms and pathology
Invasion of foodborne enteric pathogens, such as specific types of Salmonella, 
and translocation from the gut lumen to extra-intestinal organs (16,20) is often 
accompanied by increased mucosal paracellular permeability (21,22). Not only 
invasion itself but also the release of toxins and virulence factors (23) have disas-
trous effects. Three major physiological functions of the intestinal epithelium 
can be affected (Fig 3). These include alterations in the structure and function of 
the tight junction barrier, induction of fluid and electrolyte secretion (Fig 2), and 
activation of the inflammatory cascade (24). It is noteworthy that while some 
pathogens primarily activate one of the above mentioned pathways, others such 
as Salmonella and E. coli are well versed in all three languages.
The intestinal epithelium has a remarkable capacity for fluid and elec-
trolyte absorption. In humans, approximately 8-9 L of fluid enters the gut on a 
daily basis and all except for 100-200 ml/day is reabsorbed under normal condi-
tions (24). Multifaceted transport pathways, under tight control of various neu-
rotransmitters, hormones, inflammatory mediators and intraluminal contents, 
exist to carry out this function. Disruption of this system upon bacterial infec-
tion may result in diarrhoea. Chloride secretion is the principal determinant of 
luminal hydration. With chloride secretion, paracellular movement of sodium 
follows. The resulting accumulation of luminal sodium chloride provides an 
osmotic gradient for the diffusion of water. Increased intestinal chloride and 
concomitant water secretion results in secretory diarrhoea (25). Various patho-
gens, including E. coli, Campylobacter jejuni and Salmonella are known to medi-
ate chloride secretion, usually accomplished by elaboration of enterotoxins. The 
enterotoxins increase cyclic AMP or cyclic GMP in epithelial cells (24,26,27) and 
stimulate chloride transporters like the cystic fibrosis transmembrane conduc-
tance regulator (CFTR). In addition to bacterial toxins that function directly as 
secretagogues, bacterial infection of intestinal epithelial cells can also upregu-
late the expression of host derived products that, through autocrine or paracrine 
effects, also stimulate intestinal, primarily chloride, secretion. The other affected 
functions, including the tight junction barrier and inflammatory cascade, will be 
discussed below.
DEFENCE MECHANISMS OF THE GASTROINTESTINAL TRACT
The gastrointestinal (GI) tract is the site where the divergent needs of nutrient 
absorption and host defence collide. Nutrient absorption requires a large surface 
area and a thin epithelium. In adult humans the GI tract represents a surface of 
approximately 400 m2, largely because it is formed into millions of finger-like 
villi in the small bowel (28). The human intestinal surface is 100 times larger 
than the surface of the skin. In rats, the intestinal surface is 25 times larger than 
the skin (29). This intestinal surface is continuously in contact with the external 
environment, which makes the intestinal mucosa prone to harmful components, 
such as pathogenic microorganisms, toxins or harmful dietary components. 
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Fortunately the GI tract is equipped with several innate and adaptive mecha-
nisms that continuously interact with each other to prevent survival of ingested 
microbes (Fig 3). 
Innate defence mechanisms against foodborne infections
Gastric acidity
A complex set of defence mechanisms operating in the host, from the mouth to 
the rectum, helps to protect against ingested infectious pathogens. In an empty 
stomach a foodborne pathogen has to cope with the low pH, < 3.0, and proteo-
lytic enzyme activity of gastric juice. This is, after passage through the orophar-
ynx and oesophagus, the first line of defence of the GI tract. Many foodborne 
pathogens are acid sensitive (30,31) and will not survive gastric passage. Many 
environmental factors, like the concomitant presence of food or use of medica-
tion (e.g. antacids) can increase pH of the gastric content or physically protect 
bacteria. These factors can increase the likelihood of a pathogen surviving the 
gastric barrier (31-33).
Figure 3. Cascade of Salmonella infection (stages shown in boxes) in rats and host defence 
mechanisms involved (italics). On the left pathophysiological consequences known to 
occur or increase upon infection are depicted in random order. It should be noted that 
events can influence each other; therefore e.g. colonization and translocation can not be 
separately linked to a single pathophysiological effect.
Oral Salmonella infection
Initial survival
Translocation
Intestinal colonization
– Low gastric pH
– Proteolytic enzymes
– Intestinal motility
– Pancreatic and intestinal enzymes
– Mucus
– Secretory immunoglobulin A
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Intestinal motility and mucus
Throughout the whole intestine a thick mucus layer covers the epithelium, 
whereas a discontinous thinner layer covers the small intestine; the colon 
mucus layer gradually increases in thickness from colon to the rectum (34-37). 
The mucus layer acts as a lubricant for propulsion of the intestinal contents. 
Moreover, this mucus protects the underlying epithelial cells from gastric acid, 
bile acids, chemical irritants and physical damage. The mucus layer is orga-
nized around the highly glycosylated MUC 2 mucin (36) and includes sta-
bilization proteins, denoted as trefoil factors (TFF). The sugar chains of the 
glycoproteins mimic epithelial receptors for bacteria and act like a physical 
sieve trapping microbes and bringing them in close contact with secreted anti-
bodies (sIgA) and antibacterials like lactoferrin, lysozyme and lactoperoxi-
dase (36,38). The adhesion of pathogens to the mucosal epithelium is further 
decreased by specific patterns of the intensive motility of the small intestine, 
designated the interdigestive migrating motor complex. Due to these features, 
subsequent bacterial overgrowth can be prevented (32). 
Intestinal microbiota
The combination of gastric acid, bile salts, pancreatic enzymes and rapid flow 
of contents makes the upper GI tract not a favourable site for bacteria to reside. 
A relatively small population of indigenous microorganisms colonizes the ileal 
mucosa and may be important for host defence against pathogens in the small 
intestine, which is the main region in the GI tract where foodborne pathogens 
exert their noxious effects (39).
In contrast with the small intestine, myriad bacteria reside in the 
colon; these are crucial for metabolism of non-digested nutrients, but also play 
an important role in defence of the host (32). Here the intestinal contents move 
slowly, which provides a good environment for a dense population of micro-
biota that accounts for nearly half of the human colonic content (40). Pertur-
bation of the intestinal microbiota not only lowers resistance of the host to 
opportunistic bacteria like Clostridium difficile, but also increases host suscep-
tibility to enteric pathogens like Salmonella (41). Eradication or suppression 
of parts of the indigenous microbiota decreases the colonization resistance of 
the host (42,43). Colonization resistance is a complex mechanism in which the 
host and the resident microbiota cooperate to prevent the overgrowth of other 
potentially pathogenic bacteria. Competition for mucosal adhesion sites and 
growth substrates by the indigenous microbiota can increase and thus inhibit 
intestinal colonization of bacterial pathogens (44-47). Lactic acid, short-chain 
fatty acids and bacteriocins produced by the microbiota are other mechanisms 
that have been shown to inhibit growth of pathogenic bacteria (20,32). 
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The gut epithelium
Epithelial cells in the intestine form a physical barrier for all luminal contents, 
including bacteria. Each epithelial cell maintains an intimate association with its 
neighbours and seals the surface of the gut with the help of tight junctions (TJs). 
TJs are lipid-protein complexes at the apical junctions of epithelial cells, which 
form a controllable barrier between the luminal and serosal sides of the epi-
thelial monolayer (barrier function) (23). The TJ can be affected by pathogens, 
cytotoxic compounds, cytokines (24,48) and probably many other still unidenti-
fied factors. TJ function can also be regulated by bacteria from the indigenous 
microbiota, e.g. via toll-like receptor 2 (TLR2) activation as recently shown for 
the bacterium Lactobacillus plantarum (49). Bacterial invasion through epithe-
lial gaps, which can occur due to loss of damaged cells or apoptosis, is prevented 
by rapid migration of adjacent epithelial cells (50). This regenerating process is a 
tightly regulated balance between proliferation and apoptosis, which is necessary 
to maintain the epithelial layer.
Epithelial cells in the intestinal mucosa are not all similar and specific 
types with different functions occur along the various segments of the intestine. 
The most abundant cell type in the intestinal epithelium is the enterocyte. The 
enterocyte is not only important in nutrient absorption, but also actively com-
municates with the immune system by producing cytokines and chemokines 
(48). Another dominating cell type is the goblet cell, which produces the above 
described protective mucus layer in the small and large intestine. 
Antimicrobial peptides
Deep down in the crypt of the small intestine reside specialized Paneth cells. 
These Paneth cells produce a variety of antimicrobial peptides like defensins and 
bacteriolytic enzymes such as trypsin, lysozyme and group IIA phospholipase 
A2. These Paneth cell secretions protect mucosal surfaces and crypts, containing 
intestinal stem cells, against invading microbes. There is constitutive expression 
of antimicrobials at low levels and expression is induced by pro-inflammatory 
cytokines and exposure to bacteria. In this way Paneth cell products not only 
control the bacterial milieu in the intestine but also serve as signalling molecules 
that communicate between the innate and adaptive immune response (51,52).
Oxidative defence
In response to mucosal invasion of pathogens, but also upon translocation of 
bacterial components like endotoxin, epithelial cells and macrophages express 
pro-inflammatory cytokines, e.g. interleukin-1β (IL-1β), to recruit neutrophils 
(53,54). These efficient killers of microbes (55) contain high concentrations of 
the enzyme myeloperoxidase (MPO) (55,56), which participates in the innate 
immune defence through formation of powerful reactive oxidants (55,56). 
Oxygen or nitrogen radicals and antioxidant enzymes are produced in order to 
inhibit or kill the bacterial invaders. Activated antigen-presenting cells produce 
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high amounts of nitric oxide (NO) from L-arginine, which can kill pathogens 
especially intracellular organisms, such as Salmonella (55,57,58). Released into 
the bloodstream, most of the highly-reactive NO is rapidly bound to haemoglob-
ulin and converted into nitrate, which is subsequently excreted in urine (59,60). 
As a result, NO metabolites accumulate in urine during bacterial translocation 
(61) and systemic infectious disease (62-64). An unfortunate side-effect of this 
defence machinery is that the anti-bacterial reactive oxygen species also react 
with cellular organic molecules, more specifically with lipids, proteins and DNA, 
and have the potential to induce oxidative host tissue damage (55,56,65). For 
example, in the inflamed mucosa of ulcerative colitis patients MPO is associated 
with oxidative stress-related damage (66). Oxidative damage can affect DNA 
and protein function, but is also mentioned to potentially impair the mucosal 
barrier function (67). Disruption of perijunctional actin and redistribution of 
TJ proteins caused by oxidants have been shown to affect TJ function, result-
ing in a compromised epithelial barrier (67). Therefore antioxidant defence 
mechanisms, including antioxidant enzymes, such as glutathione-S-transferase, 
and non-enzymatic antioxidant molecules, such as glutathione, are essential for 
maintaining a balance between the generation of reactive oxygen species and the 
antioxidant capacity to restrict tissue damage. Glutathione is a tripeptide com-
posed of γ-glutamic acid, cysteine and glycine and is quantitatively the most 
important low-molecular-weight (non-protein) thiol in tissues, including those 
of the intestinal tract (65,68,69). Glutathione, synthesized by most mammalian 
cells but mainly in the liver (68,70), is an active free-radical-scavenging com-
pound found in virtually all animal cells (65,68,70). In comparison with a num-
ber of other tissues the liver has a particularly high content of glutathione (68). A 
relatively high concentration of glutathione is also detected in the intestinal epi-
thelium (71). Here glutathione has been shown to play an important role in the 
protection of the intestinal mucosa against oxidative stress both in vitro (72,73) 
and in vivo (71,74). However, the role of glutathione in the course of an intestinal 
infection is unknown.
The immune system
The epithelial layer has the complex task of accurately identifying threats besides 
providing a physical barrier. The supportive immune system has to react to 
pathogens and harmful compounds, but it must tolerate the constant flow of 
food antigens and the abundant non-pathogenic commensal microbiota. The 
intestine is responsible for about 70-80 % of the body’s immune system, indicat-
ing its importance in general defence (75). The immune system can be divided 
into the rapid non-specific innate immune response and the more specific adap-
tive immune response. The former is already active in the first few days of infec-
tion and activates the adaptive immune system, which plays a role at later stages 
of infectious disease (76). 
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The immune response of the intestine depends on specialized immune 
tissues, including the Peyer’s patches and mesenteric lymph nodes (MLN). 
Besides these tissues, the immune system consists of several cell types that 
are scattered through the epithelial mucosal layer, such as DC, IgA-producing 
B-lymphocytes, and T-lymphocytes (77). Altogether these tissues and cells are 
denoted as gut-associated lymphoid tissue (GALT). The epithelial cells, which 
can activate the pro-inflammatory signalling pathways, are as well as this special-
ized tissue also an essential component of innate immunity (48). All these cells 
involved in the immune response express pattern recognition receptors, such as 
TLR, that recognize different pathogen components. For example TLR5 recog-
nizes flagellin from a variety of flagellated pathogens, including Salmonella (78). 
The receptors are activated upon recognition of a threat and induce production 
of a range of cytokines and chemokines by both the enterocytes and immune 
cells. Cytokines communicate with the adaptive immune system and shape the 
response through either pro-inflammatory cytokine or anti-inflammatory cyto-
kine production. The chemokines are responsible for the recruitment of neutro-
phils, macrophages and DC to the site of infection.
The adaptive defence against foodborne infections
The Peyer’s patches in the small intestine are separated from the intestinal lumen 
by a single layer of columnar epithelium that includes microfold (M) cells. These 
M cells are specialized in antigen uptake. Absorbed antigens are transported to 
the basolateral cell membrane and delivered to the underlying lymphoid tissue 
(38). Antigen-presenting cells, like macrophages and DC which reside in the 
Peyer’s patches, couple antigens with major histocompatibility complex (MHC) 
class II receptors and activate T-helper cells (CD4) to secrete cytokines (38). 
These cytokines then stimulate B cells within the Peyer’s patches to produce 
immunoglobulins, specifically sIgA (79). sIgA plays an important role in anti-
gen exclusion and bacterial agglutination, which prevents microbial contact and 
uptake of the intestinal epithelium (80). 
DIET AND INTESTINAL INFECTIONS
Survival of pathogenic bacteria in the GI tract is directly influenced by intestinal 
content and thus by our diet. At the same time diet can indirectly affect pathogen 
survival by affecting the above described defence mechanisms of the intestinal 
tract. For example, when the habitual diet is deficient in one or more essential 
nutrients, normal functioning of all cells, including cells of the immune system, 
is impaired (81). Therefore diet may not only be a tool to reduce survival of the 
pathogen, but it may also reduce infection-associated symptoms (or sequelae). 
These latter events may even be reduced by dietary compounds without interfer-
ing with the survival of pathogens.
Currently, there is major interest in specific food ingredients that mod-
ulate the intestinal microbiota and subsequent infection resistance. This area is 
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divided into two classes, the so-called probiotics and prebiotics. Probiotics are 
classically defined as a viable microbial dietary supplement that beneficially 
affects the host through its effects in the intestinal tract (82). Prebiotics are 
non-digestible food ingredients, usually non-digestible carbohydrates, which 
are assumed to be beneficial for host health by stimulating the protective intes-
tinal microbiota (83). Furthermore there is another heterogeneous domain of 
dietary components that directly or indirectly influence the course of infec-
tion. This thesis has its focus on this domain of dietary components. This other 
domain of dietary components includes minerals, such as zinc and calcium, 
and polyphenols.
Nutrient deficiencies that increase infection risk 
Zinc
Zinc can play an important role as it is a cofactor of approximately 120 enzymes 
of mammals. Zinc deficiency affects nucleic acid metabolism and thereby protein 
synthesis and cell growth (84). Inadequate zinc intake is associated with impaired 
immune function (84,85), increased oxidative damage of intestinal tissue (86) 
and an increased risk of infection (85). Zinc supplementation, on the other hand, 
can reduce the incidence and prevalence of acute infectious diarrhoea (85,87) 
and has been shown to reverse the increase in intestinal permeability during Shi-
gella infection in children with a borderline or deficient zinc status (88). Zinc 
carnosine, a functional food ingredient, stimulates migration and proliferation 
of intestinal cells and stabilizes the gut mucosa (89). These results indicate that 
besides the restoration of immune-cell functioning, normalization of the epithe-
lial cell lining and strengthening of the epithelial barrier might be responsible for 
the observed beneficial effects of zinc supplementation.
Vitamin A
Vitamin A, or retinol, deficiency, which is an endemic nutritional problem 
throughout much of the developing world, increases susceptibility to severe 
infection (90). Supplementation of vitamin A in this population increases resis-
tance to infection (90,91). Although vitamin A was one of the first “accessory” 
factors to be identified by nutritional research, the understanding of its role 
in human health is still evolving. The existence and properties of cellular and 
nuclear receptors, the conversion of carotenes to retinol, and the role that vita-
min A plays in regulating gene function remain topics of continuing discovery 
and interest. Mechanistic studies of vitamin A deficiency in Salmonella-infected 
rats showed that the deficiency damaged both humoral and cellular immunity in 
the intestinal mucosa, resulting in aggravated damage to the intestinal mucosa 
(92). It is unclear whether increasing the vitamin A intake in a population that 
already has a sufficient intake increases intestinal defence to infection. This 
kind of research is limited because vitamin A can be toxic when taken in excess. 
Therefore the focus of vitamin A research is on the deficient population.
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Dietary compounds that increase intestinal resistance to infection
Calcium
Another beneficial mineral is dietary calcium. It enhances intestinal resistance to 
infectious disease and protects rats (93-96) and humans (96) against Salmonella 
and enterotoxigenic Escherichia coli (ETEC) associated diarrhoea. 
Absorption of ingested dietary calcium is generally less than 10% (97). 
Beneficial health effects, especially bone health, are ascribed to absorbed calcium 
and for a long time unabsorbed dietary calcium has been considered without 
physiological benefit. However, luminal calcium exerts various effects. It should 
be noted that systemic (serum) calcium concentrations are tightly regulated, and 
thus stable, and are not influenced by dietary calcium supplementation (98). The 
substantial amount of ingested calcium that escapes absorption forms an insolu-
ble complex with dietary phosphate in the upper small intestine (99). Protective 
effects of calcium phosphate against infection and infectious diarrhoea are asso-
ciated with an increase of lactobacilli in the indigenous microbiota and reduc-
tion of luminal cytotoxicity (93,95). Both these are suggested to be important 
for the protective effects of calcium. Studies in animals (94) and humans (97) 
have shown that calcium precipitates irritating bile acids and reduces cytotox-
icity of the luminal contents, which prevents epitheliolysis and may strengthen 
intestinal barrier function. It is also suggested that the decrease in cytotoxicity is 
responsible for the increase of lactobacilli (100). 
Anti-diarrhoeal effects found in rat and human infection studies were 
recently also shown in a transgenic rat model of IBD (101). Moreover these 
studies showed that colitis-related intestinal barrier defects were reduced by 
dietary calcium. Even in healthy rats it was shown that calcium decreases intes-
tinal permeability (Schepens et al 2010 Br J Nut, In Press). Moreover, calcium 
increases the intestinal barrier function in healthy rats. The protective mecha-
nism on the epithelial barrier function might be via direct effects of calcium on 
the TJ function, or indirectly e.g. via modulation of the microbiota. These are 
areas to be explored. 
Similar to the property of calcium phosphate to bind or precipitate bile 
acids and fatty acids, it also precipitates lipopolysaccharides (LPS) at least in in 
vitro binding experiments. LPS includes a hydrophobic fatty acid containing part 
and is present in the outer membrane of Gram-negative bacteria, including Sal-
monella. It was hypothesised that calcium can precipitate Gram-negative bacte-
ria and thus prevent their attachment to the intestinal epithelium (96). 
Polyphenols
Another group of dietary components which potentially can improve resistance 
to intestinal infections are polyphenols. Polyphenols are a group of chemical sub-
stances found in plants characterized by the presence of more than one phenol 
unit or building block per molecule. Polyphenols are widely distributed in veg-
etable foods (legumes, cereals, fruits) and beverages (tea, wine) (102). In many 
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cases, these substances serve as plant defence mechanisms against predation by 
microorganisms, insects and herbivores (103). Polyphenols have antimicrobial 
properties in vitro and could possibly inhibit intestinal Salmonella infections. 
For example, hydrolysable tannins, which are widespread in grapes, berries and 
wines (104), are suggested to have antimicrobial effects against Gram-negative 
bacteria (105). Their mode of antimicrobial action may be related to their abil-
ity to prevent microbial adhesion and to inactivate bacterial enzymes and cell 
envelope transport proteins (103). Tannic acid is a complex hydrolysable tan-
nin that is used as a preservative by the food industry (106). It is composed of 
six to nine gallic acid molecules esterified with glucose, derived from (Chinese) 
gallnuts (106,107), and may have protective effects against Salmonella infection. 
Despite the described anti-bacterial properties of polyphenols as mentioned 
above, their potentially beneficial effect for host resistance in vivo has not been 
demonstrated yet.
Amino acids and fatty acids
Sulphur-containing amino acids (such as cysteine and glutamine), n-3 fatty acids 
and the short chain fatty acid butyrate, are all suggested to ameliorate gastrointes-
tinal integrity and might ameliorate the gut barrier integrity in infection-related 
disease (108,109). Butyrate itself is not a dietary component but a fermenta-
tion product of the microbiota which increases in the intestinal lumen on high 
dietary fibre intake (109). In the healthy human colon butyrate was shown to 
beneficially affect oxidative stress (110) and thereby possibly be a candidate to 
improve the gut barrier function. 
A wide area of intestinal diseases has been investigated concerning pro-
tective effects of n-3 fatty acids. For example consumption of n-3 fatty acid supple-
ments reduces mucosal inflammation, diarrhoea and improved histological repair 
in rats with experimental colitis (109). In a study of endotoxin-induced intestinal 
ischaemia in rats, it was found that fish oil-supplemented parenteral diets, which 
contains n-3 fatty acids, improved killing of translocated bacteria (111).
Glutamine is a nonessential amino acid and is one of the most inten-
sively studied nutrients in gastrointestinal research. However, it appears to be 
required in greater quantities under certain catabolic conditions in the intestine. 
Glutamine is a substrate in many key metabolic processes, including inter-organ 
nitrogen transfer, protein synthesis, gluconeogenesis, acid-base homeostasis, 
and nucleic acid biosynthesis. Glutamine is also utilized as a major fuel/substrate 
by intestinal mucosal cells and by immune cells throughout the body, includ-
ing those of the gut-associated immune system (109). Therefore it must be a key 
player during intestinal infection. Numerous studies in animal models and an 
increasing number of clinical trials indicate that glutamine-supplemented nutri-
tion has beneficial effects in certain clinical situations (109).
Cysteine is essential for glutathione synthesis (112) and cysteine availabil-
ity is often the rate-limiting factor for intracellular glutathione synthesis (113). 
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Cysteine may also affect host defence by other mechanisms. Trefoil peptides, 
which stabilize the mucosal glycoproteins in the mucus network and thereby 
protect the mucosa from various insults, contain several cysteine-rich domains 
(35,114). In addition, defensins, which are antimicrobial peptides secreted by 
human and rodent ileal Paneth cells, contain 6 conserved cysteines (115) and 
are important for intestinal resistance to Salmonella infection (116). Although 
cysteine is not an essential amino acid and can be synthesised from methionine, 
it might be conditionally essential as suggested for glutamine (109,117). This 
means that under conditions of increased demand, e.g. during infectious disease, 
normal production of cysteine from methionine becomes limited and this amino 
acid has to be additionally and directly obtained from dietary sources. However, 
up to now this area has not been investigated in vivo.
INFECTION MODELS TO CONDUCT DIETARY INTERVENTIONS
The ultimate goal of the dietary interventions to improve intestinal resistance 
against infectious disease described in this thesis is to improve human health. 
However, it is ethically not so simple to infect humans to perform a standardized 
and well-monitored infection study. There are human models, such as an oral 
infection model with an attenuated ETEC strain (96). Another method to inves-
tigate dietary effects on the course of infection is to perform a well-monitored 
dietary intervention in a high-risk population. Currently, it is being investigated 
whether dietary calcium can reduce incidence of diarrhoea in Indonesian chil-
dren (Agustina & Bovee-Oudenhoven et al, NCT00512824 ClinicalTrials.gov), 
who are a group at high risk of foodborne infection and subsequent diarrhoea 
(118). It is important to first conduct research in appropriate animal models 
before starting such investigations in humans. Therefore intestinal infection 
studies are primarily performed in animals, generally in rodents, to screen the 
efficacy of potentially protective dietary components and to investigate their 
functional mechanism. Fundamental studies on dietary modulation of intestinal 
Salmonella infection are results from a Salmonella infection model in rats. In this 
model S. enteritidis is used, since this bacterium is invasive in rodents, which 
enables research on bacterial colonization as well as translocation, and it is an 
accepted animal model for gastroenteritis (119). Moreover this is the predomi-
nant strain in the Western hemisphere and in Europe (1).
To reveal the role and importance of specific innate defence mechanisms 
this Salmonella infection model can be sensitized. By depletion or interruption 
of specific host defence mechanisms the role of these mechanisms in infection 
and disease outcome can be specifically investigated. Using these sensitized 
models also enables us to identify specific defence mechanisms associated with 
dietary modulation of intestinal infection. By such investigations crucial host 
mechanisms are revealed and lay the foundation for improvement of gut health 
and disease. Furthermore, investigations in infection models are a tool to iden-
tify new potential biomarkers of intestinal disease. There is great scientific and 
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medical interest in identifying and validating new and especially non-invasive 
biomarkers of intestinal health and disease, such as gut infection and inflamma-
tion. Their implementation in clinical routine in humans is attractive because 
these markers yield valuable information on intestinal health status by a non-
invasive means. These markers could facilitate monitoring of intestinal disease 
activity with time, e.g. in response to therapeutic or dietary intervention, and 
may reduce the need for endoscopic investigations. Dependent on the sensitivity 
and specificity of e.g. faecal biomarkers, their analysis can be highly quantitative 
and even suitable for early detection of sub-clinical activity (120).
RATIONALE AND OUTLINE OF THESIS
Diet is likely a unique tool to improve intestinal defence against infection but, at 
present, its potential is far from fully explored. Growing resistance of bacterial 
pathogens, including Salmonella species, to generally applied antibiotics makes 
alternative methods to improve intestinal defence against these threats a neces-
sity. Building on one of the alternatives, this thesis contributes to the exploratory 
field of dietary modulation of gut infections. The first chapter elaborates on con-
temporary scientific knowledge of defence mechanisms of the intestine against 
foodborne infections. Furthermore dietary components that might improve 
resistance against Salmonella infection are highlighted.
Chapter 2 evaluates the new potential faecal biomarker, RegIII(β), to 
monitor infection severity in rats. The functional role of RegIIIβ in intestinal 
resistance to infection, which is explored by using RegIIIβ knock-out mice, is 
described in Chapter 3. Extrapolation to humans of the findings on the possible 
biomarker function of RegIIIβ in rodents is described in an exploratory study in 
healthy subjects, ETEC infected subjects and IBD patients (Chapter 4). 
Some of the intestinal defence mechanisms may be crucial for the course 
of Salmonella infection although in vivo evidence is often lacking. The effects of 
depletion of glutathione during Salmonella infection and its relevance for gut 
barrier function are reported in Chapter 5. In the same chapter, the efficacy of 
dietary cystine supplementation to increase glutathione levels aimed at enhanc-
ing resistance to infection is described. Intestinal permeability changes and the 
severity of infection in response to perturbation of the indigenous microbiota by 
antibiotic treatment are described in Chapter 6. In the same sensitized infection 
model it was investigated whether dietary calcium and tannic acid could coun-
teract some of the negative antibiotic side-effects and improve health outcomes 
related to infection resistance in this rat model.
The main findings, general discussion and recommendations for future 
studies are presented in the final Chapter 7
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ABSTRACT
Background: Microbial infections induce ileal pancreatitis associated protein/
regenerating gene III (PAP/RegIII) mRNA expression. Despite increasing interest, 
little is known on PAP/RegIII protein. Therefore, ileal mucosal PAP/RegIII protein 
expression, localization, and fecal excretion were studied in rats upon Salmonella 
infection.
Results: Salmonella infection increased ileal mucosal PAP/RegIII protein levels in 
enterocytes located at the crypt-villus junction. Increased colonization and trans-
location of Salmonella was associated with higher ileal mucosal PAP/RegIII levels 
and secretion of this protein in feces.
Conclusions: PAP/RegIII protein is increased in enterocytes of the ileal 
mucosa during Salmonella infection and is associated with infection severity. 
PAP/RegIII is excreted in feces and might be used as a new and non-invasive 
infection marker.
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INTRODUCTION
Pancreatitis associated protein (PAP) is a type III member of the regenerating 
(Reg) gene family and was originally identified as a lectin-related secretory pro-
tein present in rat pancreatic juice during experimental pancreatitis (1). Since 
then, considerable attention has been given to the Reg family and its structur-
ally related molecules. Recently, the complex terminology of the Reg family and 
its isoforms was elegantly reviewed (2) and a combined term of PAP/RegIII was 
coined, to foster a concerted effort in the investigation of PAP and the isoforms. 
In this study we focused on ileal PAP/RegIII in rats, represented by the genes 
PAP1 and PAP3. Both genes encode for a protein of similar size and these genes 
are paralogues, which means that they derive from the same ancestral gene. The 
rat PAP3 (alias RegIIIγ) and mouse RegIIIγ are orthologues, which means that 
they are on amino acid level the most identical genes between two species (bidi-
rectional best hit). The other isoform, the rat PAP1 (alias PAP) is the orthologue 
of the mouse PAP1 (alias RegIIIβ). 
Expression of PAP/RegIII mRNA has been shown in the pancreas of 
human (3), mouse (4) and rat (5). Moreover, PAP/RegIII was described as consti-
tutively expressed in the rat (6) and human (7) small intestine. Intestinal expres-
sion was not altered during acute pancreatitis (6), indicating that intestinal and 
pancreatic expression are differentially regulated. Interestingly, increased levels 
of intestinal PAP/RegIII mRNA have been detected during active inflammatory 
bowel disease (IBD), Crohn’s disease and ulcerative colitis in humans (8,9), and 
in animal models of IBD (9-11). We recently reported a time dependent increase 
in intestinal PAP/RegIII mRNA, represented by the genes PAP1 and PAP3, in 
Salmonella infected rats (12,13). These results are in line with studies showing 
increased PAP/RegIII mRNA upon bacterial colonization of the porcine small 
intestine with Salmonella (14) and enterotoxigenic Escherichia coli (ETEC) 
(15). Hence, it is suggested that PAP/RegIII expression is triggered by increased 
microbial-epithelial contact and reflects a state of enhanced host defense (16). 
Hitherto, few studies focused on PAP/RegIII protein levels and it was not inves-
tigated whether PAP/RegIII expression actually reflects infection severity or an 
improved host defense status.
Furthermore, data on localization of ileal PAP/RegIII is controversial. 
PAP/RegIII mRNA is reported to be present in epithelial cells of the lower vil-
lus part (6), whereas other studies limit expression to Paneth cells in the ileal 
crypt bottoms (16). 
To investigate intestinal localization and protein levels of PAP/RegIII we 
studied PAP/RegIII expression in the rat small intestine upon infection with Sal-
monella enteritidis, which is a common foodborne pathogen. Our study focused 
on the distal ileum, since this area is important in Salmonella infection pathol-
ogy and sensitive for infection-induced up-regulation of PAP/RegIII genes (12). 
In addition, we determined whether ileal PAP/RegIII expression relates to infec-
tion severity. Modulation of this infection severity can be achieved by inoculating 
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animals with different doses of the pathogen, but it has been shown that Salmo-
nella translocation to organs (17) and the magnitude of immune response can 
be irrespective of the inoculated dose (18). On the other hand, we have shown in 
previous studies that dietary calcium has profound resistance-enhancing effects 
and protects against Salmonella and ETEC infection in rats (19-22) and humans 
(22). Therefore, we performed a dietary calcium intervention in rats to modulate 
Salmonella infection severity and to relate well-established infection markers with 
intestinal PAP/RegIII protein expression. More importantly, we determined the 
presence of PAP/RegIII in feces and studied the proposed antimicrobial activity 
of PAP/RegIII in vitro using fecal water incubates. 
METHODS
Diets, infection and dissection of the rats
The experimental protocol was approved by the animal welfare committee of 
Wageningen University (Wageningen, the Netherlands). Specific pathogen-free 
male outbred Wistar rats (WU, Harlan, Horst, the Netherlands), 8 weeks old and 
with a mean body weight of 245 g, were housed individually in metabolic cages as 
described (23). Rats were fed purified diets containing per kg: 200 g acid casein, 
326 g cornstarch, 174 g glucose, 160 g palm oil, 40 g corn oil, 50 g cellulose and 
vitamin and mineral mix (without calcium) according to AIN-93 (24). To mimic 
the composition of a Western human diet, the prepared diets were relatively low 
in calcium and high in fat compared to standard rodent diets (24). Diets were 
supplemented with CaHPO4.2H2O (Merck, Darmstadt, Germany), at the expense 
of glucose, to a final concentration of 30 mmol/kg (control diet) or 120 mmol/
kg (calcium diet). Food, intake recorded daily, and demineralized drinking water 
were supplied ad libitum. Body weight was measured every two days before infec-
tion and daily after infection. Two groups were fed the control diet and another 
two groups were fed the calcium-supplemented diet (n=9 per group). In addi-
tion, five rats were fed the control (n=3) or calcium (n=2) diet and served as non-
infected controls.
Animals were acclimatized to housing and dietary conditions for 14 days, 
after which they were orally infected with 0.5 ml of saline containing 3.109 col-
ony-forming units of Salmonella enteritidis (clinical isolate, phage type 4; strain 
NIZO1241, NIZO food research, Ede, the Netherlands) as described elsewhere 
(23). Animals in the non-infected group orally received 0.5 ml saline only. 
On day 3 or 4 after oral infection, rats from one control and one calcium-
supplemented group were randomly selected and killed by carbon dioxide inhala-
tion. The non-infected control rats were also killed by this procedure. During the 
dissection, the distal 12 cm of the ileum was excised. A 2 cm piece, identical loca-
tion in each sample, was cut out and preserved in 10% formalin (Sigma-Aldrich, 
St Louis, Missouri, USA) and embedded in paraffin for histological analysis. The 
remaining parts were cut open longitudinally and, after flushing with saline, the 
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mucosa was scraped off and immediately frozen in liquid nitrogen for RNA isola-
tion and protein analyses, as described below.
The other infected control and calcium groups were followed until day 7 
after infection to collect fresh fecal samples with time for Salmonella quantifica-
tion, as described elsewhere (21). In addition, 24 h feces (pooled per animal per 2 
days) and urines were collected before infection and seven consecutive days after 
oral infection. All 24 h feces and urine samples were stored at –20°C until further 
analysis. Oxytetracycline (Sigma-Aldrich) was added to the urine collection vessels 
of the metabolic cages to prevent bacterial deterioration. Bacterial translocation 
was quantified by measuring urinary NOx (sum of nitrate and nitrite) excretion 
by using a colorimetric enzymatic kit (Roche Diagnostics, Basel, Switzerland), as 
described (25). Urinary NOx is a more sensitive and quantitative marker of intesti-
nal bacterial translocation than culturing of extra-intestinal organs (26,27)
Myeloperoxidase analysis in ileal mucosa
Frozen mucosal scrapings of the ileum were pulverized under liquid nitrogen. 
Approximately half of the pulverized tissue was suspended in a 0.2 M sucrose buf-
fer of pH 7.4 containing 20 mM trishydroxymethylaminomethane (Tris), 1 mM 
dithiothreitol (DTT) and a protease inhibitor cocktail (Complete, Roche Diagnos-
tics). After mixing and centrifugation at 14000 g for 20 min the pellet was resus-
pended in acetate-HETAB buffer (0.5% hexadecyltrimethylammonium bromide 
(HETAB) at pH 6.0, 50 mM sodium acetate, 10 mM ethylenediaminetetraacetic 
acid (EDTA) and 0.25 M sucrose) and sonicated on ice for 30 s at level 2-3 (Sonica-
tor XL2020, Heat Systems, Farmingdale, NY, USA). The protein concentration of 
the samples was determined using BC Assay (Omnilabo, Breda, the Netherlands) 
according to the manufacturer’s protocol. A mouse myeloperoxidase (MPO) 
ELISA test kit (Hycult biotechnology, Uden, the Netherlands), which is cross-reac-
tive with rat MPO, was used according to the manufacturer’s guidelines to deter-
mine the concentration of MPO in mucosal scrapings. 
Quantitative real-time PCR analysis of PAP/RegIII, represented
by PAP1 and PAP3 mRNA, in ileal mucosa
The other half of the pulverized ileal mucosal scrapings was dissolved in TRIzol 
reagent (Invitrogen, Carlsbad, California, USA) to isolate and purify total RNA 
as described before (12). By using TaqMan Reverse Transcription reagents 
(Applied Biosystems Inc., Foster City, California, USA) copy DNA was created 
from 1 µg of RNA on a Perkin Elmer DNA Thermal Cycler 480, followed by SYBR 
Green-based real-time PCR on a 7500 Fast Real-Time PCR system (Applied Bio-
systems). PCR conditions used were 95 °C for 10 min, followed by 40 amplifica-
tion cycles (95°C for 15 s, 60°C for 1 min). Data were normalized against β-actin 
and aldolase. Controls, methods and primer design were performed as described 
(12). The primer sequences are listed in Table 1.
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Analysis of PAP/RegIII protein in ileal mucosa
Ileum paraffin sections were immunostained with a goat polyclonal antibody 
against rat PAP/RegIII (1:50) (PAP/ RegIII #AF 1996; R&D Systems, Minneapo-
lis, MN, USA). This antibody can not discriminate between PAP1 and RegIII 
(PAP3), but since both PAP1 and PAP3 fall within the PAP/RegIII group, this 
discrimination is not essential for our investigation (2). Western blot analysis 
of total mucosal homogenates showed that the antibody bound to a single size 
protein band only, indicating specific binding of the antibody. Localization of 
Paneth cells was confirmed by immunostaining for lysozyme with ready to use 
anti-lysozyme (N1515; Dako). DAB peroxidase substrate kit (Dako) was used 
for signal detection of the horseradish peroxidase (HRP) labeled secondary anti-
body, according to the manufacturer’s protocol. 
PAP/RegIII protein expression in the ileal mucosa was semi-quantified 
by light microscopy as follows: total length of (bottom) crypt to villus (tip) and 
part of this length stained positive for PAP/RegIII were measured. The length 
stained positive for PAP/ RegIII was expressed as percentage of total crypt-vil-
lus length. For each tissue section three completely visible crypt-villus axes were 
analyzed, scored and averaged for that particular rat. All histological slides were 
recoded before microscopy to ensure blind scoring and to prevent observer’s bias.
Analysis of PAP/RegIII protein in feces
Total 24 h feces were lyophilized in a manifold freeze dryer (FD5515; Ilshin 
Laboratory Co Ltd, Seoul, South Korea) and pooled per treatment group on the 
basis of individual daily fecal dry weight excretion. Proteins were isolated from 
lyophilized feces pools as described elsewhere (28) with a few modifications. 
Briefly, 100 mg of feces was homogenized in 500 µl buffer containing 50 mmol/L 
Tris-HCl (pH7.5), 100 mmol/L NaCl, 1 mmol/L EDTA and Complete Protease 
Inhibitor Cocktail (Roche). After centrifugation (2 min at 15000 g), the super-
natant was taken and its protein concentration was determined using DC pro-
tein assay kit (Bio-rad Laboratories, Veenendaal, the Netherlands) according to 
1
Table 1 Primer sequences
Gene Acc. nr forward primer (5'→3') reverse primer (5'→3')
PAP1 NM_053289 GACTCCATGACCCCACTCTTG GCAGACGTAGGGCAACTT CAC
PAP3 NM_173097 GCTTCCTTTGTGTCCTCCTTGATT TACTCCACTCCCATCCACCTCTG
β-actin NM_031144 CTTTCTACAATGAGCTGCGTGTG GTCAGGATCTTCATGAGGTAGTCTGTC
aldolase NM_012495 ATGCCCCACCCATACCCAGCACT AGCAGCAGTTGGCGGTAGAAGCG
Sequences of primers used for quantitative real-time PCR analysis. Acc. nr describes the
accession number of the used sequence ID.
Table 2 Fecal Salmonella excretion, translocation-induced urinary
excretion of nitric oxide metabolites (NOx) a d mucosal myeloperoxidase.
InfectedNon-infected
Control Calci
Day after infection
Day 1 n.d. 7.2 ± 0.3a 6.3 ± 
Day 3 n.d. 6.2 ± 0.4a 4.9 ± Fecal Salmonella (log CFU/g)
Day 7 n.d. 4.7 ± 0.4 a 4.2 ± 
Infection-induced urinary NOx (µmol/ 7 days) Days 1-7 0 73 ± 14 a 25 ±
Ileal mucosal myeloperoxidase (ng/mg prot in) Day 3/4 11 ± 3a 127 ± 52 b 60 ± 
Values are means ± SE, n=8 per infected group and n=5 for the non-infected control group.
Differences between groups were tested for statistical significance using Student's t test (2-
sided). Except for myeloperoxidase data, which were tested by non-pa ametric Kruskall-
Wallis ANOVA followed by Mann-Whitney U test (2-sided).  Values in the same row not
sharing the same letter are significantly different (p<0.05). N.d. indicates not detected
Sequences of primers used for quantitative real-time PCR analysis. Acc. nr describes the accession 
number of the used sequence ID.
CHAPTER 2
35
the manufacturer’s protocol. 45 µg Protein was denatured at 100°C for 3 min in 
Tricine sample buffer (Bio-rad Laboratories), subjected to SDS- polyacrylamide 
gel electrophoresis (SDS-PAGE) gel (4% stacking-gel, 14% separation-gel) and 
transferred to a PVDF membrane (Bio-rad Laboratories). After blocking, the 
membranes were incubated with the PAP/RegIII antibody (1:100). The signal of 
the secondary HRP-conjugated antibody was detected using the ECL Plus che-
miluminescent detection kit (GE Healthcare, Den Bosch, the Netherlands).
To evaluate recovery of PAP/RegIII protein in feces, 3x 50 mg of the pre-
infection feces pool, from animals fed the control diet, was homogenized in PBS. 
One of these three samples was spiked with 1 µg recombinant rat PAP (recPAP 
alias PAP1; pre-release reagent from R&D Systems Inc.). The second sample was 
heat inactivated by incubation at 75°C for 10 min, then cooled down to room 
temperature and identically spiked with the recombinant protein. PBS was 
added to the third sample and used as negative control. Subsequently, the three 
samples were incubated at 37°C for 1 h and protein was isolated and analyzed by 
immunoblotting as described above.
Analysis of antimicrobial activity 
To assess antimicrobial activity of rat PAP/RegIII against Gram-negative S. 
enteritidis and Gram-positive Listeria monocytogenes (strain EGD-e, strain 
NIZO2364, NIZO food research, Ede, the Netherlands), analysis was performed 
exactly as described (16). Briefly, target organisms were grown in brain-heart 
infusion (BHI) broth and resuspended in 25 mM 2-(N-morpholino)ethane-
sulfonic acid (MES) (pH 6), containing 25 mM NaCl. The initial bacterial con-
centration of the incubates was 106 CFU/ml and recPAP was added to a final 
concentration of 4 and 10 µM. After incubation for 2 and 24 hours at 37 °C viable 
bacteria were quantified by plating 10-fold dilutions on BHI agar plates. 
To mimic the environment in which PAP/RegIII is proposed to function 
as antimicrobial peptide, we performed a similar antimicrobial activity assay but 
replaced the MES buffer by sterile fecal water extracts from non-infected animals 
fed the control diet. Fecal water was prepared as described (29). Purified recPAP 
was added to fecal water incubates to a final concentration of 4 and 10 µM and 
viable pathogens were quantified after 2 and 24 hours of incubation as described 
above. Experiments were performed in duplicate.
A control experiment was performed to check correct folding and thus 
binding activity of recPAP as described elsewhere (16). Briefly, 10 µg recPAP was 
added to 50 µg insoluble Bacillus subtilis peptidoglycan (Sigma-aldrich) and pel-
leted. Pellet and supernatant fractions were analyzed on recPAP content by SDS-
PAGE (as described above). 
Statistical analysis
Data from the non-infected rats fed the control or calcium diet were pooled as 
no diet-induced differences were observed. All data are expressed as means ± SE, 
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Table 2 Fecal Salmonella excretion, translocation-induced urinary excretion of nitric oxide metabolites (NOx)
and mucosal myeloperoxidase.
InfectedNon-infected
Control Calcium
Day after infection
Day 1 n.d. 7.2 ± 0.3a 6.3 ± 0.3b
Day 3 n.d. 6.2 ± 0.4a 4.9 ± 0.3 bFecal Salmonella (log CFU/g)
Day 7 n.d. 4.7 ± 0.4 a 4.2 ± 0.5 a
Infection-induced urinary NOx (µmol/ 7 days) Days 1-7 0 73 ± 14 a 25 ± 5 b
Ileal mucosal myeloperoxidase (ng/mg protein) Day 3/4 11 ± 3a 127 ± 52 b 60 ± 17 b
Values are means ± SE, n=8 per infected group and n=5 for the non-infected control group. Differences between
groups were tested for statistical significance using Student's t test (2-sided). Except for myeloperoxidase data,
which were tested by non-parametric Kruskall-Wallis ANOVA followed by Mann-Whitney U test (2-sided).
Values in the same row not sharing the same letter are significantly different (p<0.05). N.d. indicates not detected
Figure 1. Relative pancreatitis associated protein 1 (PAP1, panel A) and pancreatitis asso-
ciated protein 3 (PAP3, panel B) mRNA expression in ileal mucosa due to Salmonella 
infection in rats fed the control or calcium-supplemented diet. Individual values were first 
normalized to β-actin expression. These normalized data were used to calculate relative 
expression levels by setting the mean expression level of non-infected rats fed the identical 
diet at one. The mean of each diet group (n=9) is indicated by a line. Differences between 
the calcium and control group were tested for statistical significance using Student’s t test 
(2-sided). The asterisk indicates p<0.05. Identical results were found when signals were 
normalized to aldolase (data not shown).
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except for PCR results, which are individually plotted in addition to indication of 
groups’ mean. Data were tested for normality by the Kolmogorov-Smirnov test. 
If normally distributed, differences between means were tested for significance 
using one-way ANOVA and/or Student’s t test (two-tailed). For non-normally 
distributed data, differences between means were tested for their significance 
using the non-parametric Kruskall-Wallis ANOVA and/or Mann-Whitney U 
test (two-tailed). Statistical significance was set at p<0.05. 
RESULTS
Animals and food intake
All data from one animal in the calcium group (followed until day 7 or 8 after 
infection) were excluded from the study results because that rat suffered from 
pneumonia due to oropharyngeal reflux of the S. enteritidis suspension. At the 
start of the experiment, mean body weight of the animals was 245 g. Average 
body weight gain (mean before infection 5 g/d, after infection 3.3 g/d) and 
food intake (mean 17 g dry wt/d; not affected by Salmonella infection) were not 
affected by dietary treatment. 
Fecal excretion and translocation of Salmonella
As expected, no Salmonella could be detected in feces collected before infection 
of the animals. The first days after Salmonella infection, rats fed the calcium diet 
had approximately 10-fold less Salmonella in their feces than rats fed the control 
diet (p<0.05; table 2), reflecting reduced intestinal colonization of this pathogen. 
Furthermore, translocation of Salmonella was inhibited in rats on the calcium 
diet as measured by the infection-induced increase in urinary NOx excretion. 
Total infection-induced urinary NOx excretion (area under the curve) of the cal-
cium group was significantly lower than that of the control group (p<0.05; table 
2). Results are in accordance with previous infection studies of our lab (20,21,27). 
Ileal mucosal inflammation
Compared to non-infected animals, ileal MPO levels increased 12-fold in the 
Salmonella infected control group (p<0.05; table 2) and 5-fold in the calcium 
group on days 3-4 post-infection. Although post-infection MPO levels in the 
calcium-supplemented rats were less than half of those detected in the control 
group, the difference did not reach statistical significance. This was likely due to 
the relatively large inter-individual variation observed in the Salmonella-infected 
control group.
Effect of infection and dietary calcium intervention
on PAP/RegIII mRNA and protein expression in ileal mucosa
During infection, ileal PAP1 was 3 fold higher expressed than PAP3 (PAP1/actin 
was 0.8 and 0.7 and PAP3/actin was 0.29 and 0.27 in control and calcium groups, 
respectively). Salmonella infection of rats fed the control diet increased PAP1 
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mRNA 2.4-fold, whereas no up-regulation was observed in calcium-supple-
mented infected rats (p<0.05, Fig. 1A). Furthermore, compared to non-infected 
rats a 3.6-and 1.8-fold induction of PAP3 mRNA was observed in infected rats 
fed the control and calcium diet, respectively (Fig. 1B). 
Little PAP/RegIII protein was detected in the ileum mucosa of non-
infected rats, whereas Salmonella infected animals showed an increased num-
ber of cells staining positive for PAP/RegIII protein (Fig. 2). PAP/RegIII protein 
was detected specifically in enterocytes at the crypt-villus junction. The pro-
tein was not detected within Goblet cell thecae. After infection the number of 
PAP/RegIII-positive enterocytes increased towards both villus tips and crypts’ 
bottom. So, a larger area of the surface epithelium stained positive for PAP/
RegIII after infection. Semi-quantification showed that the percentage of total 
crypt-villus length stained positive for PAP/RegIII protein increased 34% after 
Figure 2. Pancreatitis associated protein/regenerating gene III (PAP/RegIII) protein expres-
sion in the ileal mucosa of non-infected and Salmonella infected rats fed either the control 
or calcium-supplemented diet. PAP/RegIII protein was present in enterocytes at the crypt-
villus junction (panel A, 12.5x; panel B, 40x). The number of PAP/RegIII positive cells 
increased after infection, especially in the direction of villus tips (panel A). Dietary calcium 
reduced PAP/RegIII expression in infected animals. No staining was observed in sections 
incubated without primary antibody (data not shown). All sections were counterstained 
with haematoxylin to visualize nuclei.
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Salmonella infection in the control group (p<0.05; Fig. 3). In contrast, no sig-
nificant increase in PAP/RegIII protein was observed in calcium-supplemented 
infected animals (Fig. 3). PAP/RegIII protein was not detected in the ileal Paneth 
cells located at the deep crypt bottom as confirmed by Paneth cells-specific stain-
ing of lysozyme (data not shown). 
Presence of PAP/RegIII in feces
Immunoblotting revealed the presence of PAP/RegIII protein in feces (Fig. 4A, 
lanes 1-10). Similar to the PAP/RegIII levels in the ileum mucosa, PAP/RegIII 
protein in feces of rats fed the control diet was considerably increased from 3-4 
days and remained steady until day 7 after infection. This infection-induced 
increase in fecal PAP/RegIII was less in calcium-supplemented infected ani-
mals. However, basal fecal PAP/RegIII levels in non-infected rats were slightly 
higher in the calcium group than in the control group.
Purified recPAP protein showed a single band of approximately 16 
kDa, which is identical to the size of PAP/RegIII detected in ileum mucosa 
(Fig. 4B, lanes 4 and 5). When recPAP was added to feces it was hydrolyzed 
into two smaller forms. RecPAP incubated with pre-infection feces formed 
identical sized bands to that seen in feces of infected rats (data not shown). 
Adding recPAP to heat-inactivated feces largely prevented subsequent hydro-
lysis and merely preserved the 16 kDa band (Fig. 4B, lanes 2 and 3). 
Figure 3. Pancreatitis associated protein/regenerating gene III (PAP/RegIII) protein expres-
sion in the ileum mucosa of non-infected (n=5) and Salmonella infected rats fed either the 
control (n=9) or calcium-supplemented (n=9) diet. Immunohistochemical slides (represen-
tative images are shown in Fig. 2) were used to quantify the percentage of total crypt-villus 
length stained positive for PAP/RegIII. Total crypt-villus length was not affected by infec-
tion or calcium supplementation. Slides were recoded before microscopy to guarantee blind 
scoring. Results are expressed as means ± SE. Differences between groups was tested by 
non-parametric Kruskall-Wallis ANOVA followed by Mann-Whitney U test (2-sided). Dif-
ferent letters indicate significant differences (p<0.05).
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Antimicrobial activity 
No antimicrobial activity could be detected when 4 or 10 µM recPAP was incu-
bated with L. monocytogenes or S. enteritidis in a MES buffer system (Fig. 5). 
Figure 5. Rat PAP lacks anti-bacterial activity against L. monocytogenes (black bars) and 
S. enteritidis (white bars) in vitro. Bacteria were incubated in MES buffer or fecal water 
extract (FW) with 0, 4 or 10 µM recombinant rat PAP (PAP). Pathogens were also grown in 
brain-heart infusion (BHI) broth as positive control. The initial bacterial concentration in 
the incubates was 106 colony-forming units per ml (CFU/ml). After incubation for 2 hours 
at 37°C, viable bacteria were quantified by plating serial dilutions. The increase (positive 
values) or decrease (negative values) in viable pathogen counts in comparison with t=0 is 
expressed as Δ log CFU/ml. Elongation of the incubation time to 24 hrs resulted in similar 
results (data not shown). The assays were performed in duplicate. 
Figure 4. Effect of Salmonella infection and dietary calcium on pancreatitis associated pro-
tein/regenerating gene III (PAP/RegIII) secretion in feces with time. Lyophilized feces were 
pooled per group (n=9 and n=8 for control and calcium group, respectively) and per two 
days. SDS-PAGE gels were loaded with equal quantities of fecal protein and analyzed for 
PAP/RegIII (panel A, lanes 1-10) by using PAP/RegIII anti-serum. Recombinant rat pan-
creatitis associated protein (recPAP) showed a single band (panel B, lane 5), similar to PAP/
RegIII detected in the ileum mucosa of animals fed the control diet (panel B, lane 4). Rec-
PAP incubated with pre-infection feces from rats fed the control diet was hydrolyzed into 
two smaller fragments (panel B, lane 2). When run on one gel, these fragments were of 
identical size as those found in fecal extracts of infected rats (data not shown). Heat inacti-
vation of feces before addition of recPAP largely prevented hydrolysis of the protein (panel 
B, lane 3). Non-spiked feces (from non-infected rats) was added to lane 1 and served as 
negative control. No signal was detected when immunoblots were incubated without pri-
mary antibody (data not shown).
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Also, no bactericidal or bacteriostatic activity of rat PAP was noticed against 
these pathogens when fecal water was used (Fig. 5). When the incubation time 
was prolonged from 2 to 24 hrs, results similar to that in Fig. 5 were obtained. To 
investigate whether absence of antibacterial activity was due to potential incor-
rect folding of the recombinant protein, binding activity was tested as described 
by Cash et al (16). The recPAP used in the present study bound to bacterial pep-
tidoglycan (data not shown). 
DISCUSSION
This study shows that upregulation of PAP/RegIII protein expression by Salmo-
nella infection parallels infection severity as quantified by intestinal Salmonella 
colonization and translocation. Interestingly, PAP/RegIII protein is also present 
in feces and these fecal levels reflect the concentration of this protein in infected 
ileal mucosa.
In support of findings reported (6,9,30), our experiments clearly showed 
that PAP/RegIII protein was present in enterocytes at the crypt-villus junction 
of the ileal mucosa. The protein was not detected in the Goblet cells, Goblet cell 
thecae or Paneth cells. Others have reported expression of RegIIIγ in mouse ileal 
Paneth cells isolated by laser capture microdissection before mRNA analysis (16). 
In that study possible production of RegIIIγ by other mucosal cell types was not 
described. Moreover, the latter study was performed in (ex-)germ-free mice, 
whereas, our and other (6) studies were performed in animals with a conven-
tional flora. First time exposure of germ-free animals to micro-organisms initi-
ates a period of intense contact between microbes and the gut mucosa, until their 
naïve immune system has matured and e.g. secretion of sIgA is normalized (31). 
Therefore, results obtained in germ-free animals should be extrapolated with cau-
tion, as those might not be relevant for the normal host with a conventional flora. 
Furthermore, differences between animal species and the various RegIII isoforms 
should be considered. However, the ileal PAP/RegIII localization results of the 
present study are in line with those reported in mice (9), so there is no evidence 
that mice behave differently from rats in this respect. Other studies reporting 
Paneth cells as expression site mostly concerned so-called metaplastic Paneth 
cells in the colon of IBD patients (8,10). As Paneth cells are absent in the healthy 
colon, it can be questioned whether these cells are identical to ileal Paneth cells. 
Increased mRNA levels of PAP or Reg in the intestinal mucosal after 
bacterial infection has been reported by our and other groups (12,14,15). We 
now confirmed that this increase actually occurs at the protein level. The for-
mer and our results indicate that PAP/RegIII expression is triggered by increased 
microbial-epithelial contact at mucosal surfaces. In order to establish infection, 
foodborne pathogens like S. enteritidis and ETEC bind to the small intestinal 
mucosa by using adhesins or colonization factors which are known virulence 
factors (32-34). Situations of increased host epithelium-microbial contact 
often coincide with gut mucosal inflammation, especially when pathogenic 
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bacteria are involved (35). Inflammation in general, is also suggested as trigger 
for PAP/RegIII upregulation, as increased mRNA levels have been documented 
in inflamed colonic mucosa from patients with active IBD (8,9) as well as in 
experimental models of colitis (9,11). It should be realized that during active 
inflammation the mucosa might be damaged, its barrier function impaired, and 
mucosal cells are likely more exposed to micro-organisms from the gut lumen in 
comparison to a healthy non-inflamed mucosa (36-38). Hence, it is very difficult 
to point out whether it is the inflammation or the microbe-host contact only 
that induces PAP/RegIII upregulation. In a previous study we have shown that 
PAP/RegIII mRNA is not upregulated till day 3 after oral Salmonella administra-
tion (12). This is in line with the time-dependent fecal PAP/RegIII excretion pat-
tern of the present study (Fig. 4A). As translocation of Salmonella already takes 
place on day 1-2 (12,20), initial bacterial contact is less likely the main driver 
for PAP/RegIII upregulation. From day 3 after oral Salmonella administration, 
infection-induced mucosal inflammation is starting and many genes of immune 
function are upregulated (12). Together these results suggest inflammation as 
trigger for PAP/RegIII increase. It is becoming increasingly recognized that epi-
thelial cells, besides being crucial for absorption of nutrients and maintenance 
of the gut barrier, function through an interactive process with components of 
the underlying immune system. Intestinal epithelial cells play an important role 
in both innate and adaptive immune responses. Intraepithelial lymphocytes, 
triggered by bacterial translocation, exist in direct contact with epithelial cells 
and their interaction can lead to epithelial expression of a variety of regulatory 
molecules e.g. involved in adhesion, bacterial recognition and antigen presenta-
tion, chemotaxis, and mucosal inflammation (32). Follow-up infection studies, 
for instance in immuno-deficient animal models can reveal whether this inter-
play is important for PAP expression and functionality. Furthermore, a study 
in which SPF animals are inoculated with an organism known to adhere to the 
gut mucosa without causing inflammation can show whether inflammation is 
indeed required for PAP/RegIII upregulation. 
The function of intestinal PAP/RegIII is of most interest. Studies sug-
gesting antimicrobial activity of PAP/RegIII have shown that mouse RegIIIγ was 
able to bind to Gram-positive bacteria in vitro (16). Analogous to defensins, PAP/
RegIII is a small protein (± 16 kDa), it consists of a secretion signal and a carbo-
hydrate-binding motif. Carbohydrates are present in the gut mucosa (for example 
mucins) and on the surface of Gram-positive bacteria. Up to now, actual secretion 
of PAP/RegIII to the gut lumen has only been briefly mentioned without showing 
data (6). The results of our infection study clearly show that PAP/RegIII is pres-
ent in feces and is upregulated within the same timeframe as the mucosal levels 
of this protein. This suggests that fecal PAP/RegIII originates from ileal mucosa 
and the gut lumen might be the functional site. Our recovery experiments identi-
fied hydrolysis of PAP/RegIII in intestinal contents (Fig. 4B). RecPAP incubated 
with pre-infection feces formed identical sized bands to that seen in the feces 
CHAPTER 2
43
of infected mice. The hydrolysis of PAP might activate its function like shown 
for pancreatic derived PAP/RegIII (39). Therefore, the proposed antimicrobial 
properties of PAP/RegIII reported by others (16) were further explored. Besides 
repetition of the bactericidal activity assay in MES buffer as performed (16), we 
also included incubates of L. monocytogenes and S. enteritidis in fecal water in the 
presence or absence of PAP/RegIII. Fecal water, containing intestinal enzymatic 
activity and gut surfactants like bile acids and fatty acids, better represents the 
natural (in vivo) environment than a clean MES buffer system. The concentration 
of recPAP used in our experiments was 4 µM, as this was the estimated concen-
tration in feces after Salmonella infection as detected by immunoblotting. More-
over, this concentration fits well in the range applied and found active in reported 
experiments (16). In addition, a higher PAP concentration (10 µM) and a longer 
incubation time were included. Remarkably, we found no evidence for any bacte-
ricidal or bacteriostatic activity against L. monocytogenes or S. enteritidis. These 
results are in line with unpublished results from another research group, who also 
failed to confirm the antimicrobial activities of rat PAP as well as human PAP (J.L. 
Iovanna, personal communications). In view of the suggested exclusive antimi-
crobial function against Gram-positive bacteria (16), it also remains unexplained 
why Gram-negative bacterial pathogens, like S. enteritidis in our present and 
previous (12) studies and ETEC (15), are the most potent inducers of intestinal 
PAP/RegIII, whereas this mucosal protein has no anti-bacterial effect against its 
inducers. It might indicate that PAP/RegIII functions only at the mucosal inter-
face, where most of the protein would be unhydrolyzed still containing its signal 
sequence. On the other hand, it cannot be excluded that hydrolysis of PAP/RegIII 
in the intestinal lumen reflects activation, as is suggested for pancreatic derived 
PAP/RegIII (39), rather than inactivation of a function yet to be discovered. 
Furthermore, PAP/RegIII will face a myriad of carbohydrates associated with 
the mucosa upon epithelial secretion. In that respect, binding of PAP/RegIII to 
mucins and effects on gut barrier function are areas to be investigated in the near 
future. It should be noticed that PAP1, or RegIIIβ, applied in our in vitro experi-
ments is a homologue but not the orthologue of mouse RegIIIγ which was used in 
published in-vitro experiments on bactericidal activity. It might well be that PAP1 
(RegIIIβ) and RegIIIγ have different functions. Binding assays showed that the 
recombinant-rat-PAP protein we used was able to bind peptidoglycan, indicating 
proper folding of the protein. 
Diet is known to modulate gene and protein expression in the gut. As we 
used a calcium intervention to modulate severity of Salmonella infection in rats, 
we can not exclude a direct effect of dietary calcium on intestinal PAP expression. 
In fact, the Western blots seemed to indicate that PAP protein in feces of non-
infected rats fed the calcium diet was higher than that of non-infected rats fed the 
control diet (Fig. 4A, lanes 1 and 4). Despite a possible difference in basal excre-
tion, the situation was totally reversed after infection showing the highest ileal 
and fecal PAP/RegIII protein levels in the low-calcium control group. 
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In conclusion, this study demonstrates that PAP/RegIII protein lev-
els present in the ileal mucosa and feces reflect infection severity. As fecal PAP/
RegIII levels can be monitored non-invasively and with time, its use as new infec-
tion and/or inflammation marker in animal and in human studies is worthwhile 
to be further explored. Considering the growing interest in intestinal PAP/RegIII, 
elucidation of its functionality is scientifically important and might be achieved 
by generation of PAP/RegIII knock-out animals. Recently a PAP/HIP knock-out 
mice study on experimentally induced pancreatitis was published (40). Investiga-
tion of the reaction of these mice to intestinal infection and inflammation would 
be very interesting.
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ABSTRACT
Background: The RegIII protein family, including the human member des-
ignated pancreatitis-associated protein, are secreted proteins that contain a 
C-type lectin domain involved in carbohydrate binding. They are expressed by 
intestinal epithelial cells. Colonization of germ-free mice and intestinal infec-
tion with pathogens increases the expression of RegIIIγ and RegIIIβ in the 
murine ileum. RegIIIγ is directly bactericidal for Gram-positive bacteria but 
the exact role of RegIIIβ in bacterial infections is unknown.
Methods: To investigate the possible protective role of RegIIIβ in 
intestinal infection RegIIIβ-knockout(-/-) mice and wild-type (wt) mice were 
orally infected with the Gram-negative Salmonella enteritidis or the Gram-
positive Listeria monocytogenes. At day 2 (Listeria infection) and at day 4 (Sal-
monella infection) after oral infection mice were sacrificed to collect intestinal 
and other tissues for pathogen quantification. Protein expression of RegIIIβ 
and RegIIIγ was determined in intestinal mucosal scrapings of infected and 
non-infected mice. In addition, binding of faecal derived RegIIIβ to Listeria 
and Salmonella was investigated.
Results: Whereas recovery of Salmonella or Listeria from faeces of 
RegIIIβ-/- and wt mice was not different, significantly higher numbers of viable 
Salmonella, but not Listeria, were recovered from the colon, mesenteric lymph 
nodes, spleen and liver of the RegIIIβ-/- mice than from those of wt mice. Pro-
tective effects of RegIIIβ were associated with direct binding of the protein to 
Salmonella and to a lesser extent to Listeria. 
Conclusion: RegIIIβ protects mice against intestinal translocation of the 
Gram-negative bacterium S. enteritidis, but not against the Gram-positive bacte-
rium L. monocytogenes.
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INTRODUCTION 
In many countries in the industrialized world, foodborne intestinal infections 
are continuing to increase (1). For example, outbreaks of salmonellosis and 
listeriosis have been reported for decades, but within the past 25 years their 
incidence has increased on many continents (2). To inhibit the colonization 
(adhesion to the intestinal epithelium) and translocation (invasion of host tis-
sues) of foodborne pathogens and commensals the intestinal mucosal surfaces 
are armed with an array of physical and chemical defence mechanisms. The 
low pH of the gastric compartment, and bile acids secreted in the proximal 
intestine, reduce the number of bacteria that will survive within the gut (3,4). 
Other important defence mechanisms against pathogens include competition 
for nutrients and adhesion sites from commensal bacteria, a thick mucus layer 
on the luminal side of the epithelium and the rapid innate response of the 
intestinal epithelium (5,6).
Studies in rodents indicate that innate recognition of bacteria or bacte-
rial components triggers epithelial expression of secreted C-type lectins RegIIIγ 
and RegIIIβ (7-10). In rodents mucosal and faecal levels of RegIII protein are 
associated with the severity of infection (9). The human paralogue of this pro-
tein, pancreatitis-associated protein (PAP), is also detectable in faeces and its use 
as biomarker to monitor or discriminate human intestinal disease is the subject 
of ongoing studies.
Currently, the role and function of the RegIII family members is of 
much interest. The murine RegIIIγ and human PAP have been shown to have 
antimicrobial activity against Gram-positive bacteria but not the Gram-nega-
tive Escherichia coli (8). PAP and RegIIIγ were shown to bind peptidoglycan 
carbohydrate, which is critical for bacterial killing (11). Expression of RegIIIγ 
is greatly reduced in mice deficient in MyD88, an intracellular adaptor pro-
tein involved in most Toll-like receptor (TLR)-mediated signaling. MyD88-
deficient mice have been shown to be more susceptible to L. monocytogenes 
infection compared with wild-type (wt) mice (12). Injection of recombinant 
RegIIIγ into the lumen of MyD88-deficient ligated ileal loops before inocula-
tion with L. monocytogenes was shown to reduce L. monocytogenes survival in 
the gut. Other in vivo studies showed that genetic ablation of RegIIIβ, which is 
another RegIII murine isoform, resulted in impaired clearance of the bacterial 
load in ileal Peyer’s patches during Yersinia pseudotuberculosis infection with-
out affecting luminal bacterial levels (13). It remains unclear, however, how 
RegIIIβ protects against bacterial translocation and whether this is specific for 
Gram-negative pathogens. 
In this study we used RegIIIβ-knockout(-/-) mice and their wt litter-
mates to investigate the protective role of RegIIIβ following oral challenge with 
Gram-negative Salmonella enteritidis or Gram-positive L. monocytogenes. Addi-
tional in-vitro experiments were performed to gain insights into the mechanisms 
involved in the protective function of RegIIIβ.
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MATERIALS AND METHODS
Animals and diet
The experimental protocol was approved by the animal welfare committee of 
Wageningen University (Wageningen, the Netherlands). RegIIIβ-/- mice with 
a Bl6/129SV background were generated as described (14). Genotyping of the 
mice was performed as described previously (14). Mice were fed a semi-purified 
AIN93-G (15) diet (Abdiets, Woerden, The Netherlands). At 7-9 weeks of age 
mice with an average body weight of 22 g (range 16 – 31 g) were housed indi-
vidually. They received a purified diet containing per kg: 200 g acid casein, 326 
g cornstarch, 174 g glucose, 160 g palm oil, 40 g corn oil, 50 g cellulose, and 
vitamin and mineral mix (without calcium) according to AIN93 (15). Diets were 
supplemented with CaHPO4.2H2O (Merck, Darmstadt, Germany) to a final con-
centration of 30 mmol/kg. To mimic the composition of a Western human diet, 
the prepared diets were relatively low in calcium and high in fat compared to 
standard rodent diets (15). Food and demineralized drinking water were sup-
plied ad libitum. Mice were separated into groups and age and gender were ran-
domized over all groups as much as possible. In total 3 RegIIIβ-/- and 3 wt groups 
were formed. From each mouse strain one group was orally infected with Salmo-
nella (-/-: n=10, wt: n=12), a second group of each strain was orally infected with 
Listeria (-/-: n=7, wt: n=8) and a final group was sham treated (-/-: n=5, wt: n=6). 
The power analysis used to calculate the minimal number of animals needed 
per group was based on previously performed infection studies in this model 
(unpublished results). Body weight was measured every two days before infec-
tion and daily after infection. 
Infection
After adaptation to individual housing and diet for 8 days, mice were orally 
infected by gavage with 0.2 mL saline containing 5*108 colony-forming units 
(CFU) of S. enteritidis (clinical isolate, phage type 4; strain NIZO1241, NIZO 
food research, Ede, the Netherlands) or L. monocytogenes (animal isolate, EGD-
e, serotype 1/2a, NIZO food research). The virulence of each strain was sustained 
by routine oral passage in RegIIIβ+/- mice and subsequent isolation of the patho-
gen from extra-intestinal organs. S. enteritidis was grown on BGAM agar plus 
Sulphamandalate supplement (Oxoid, Basingstoke, United Kingdom) and quan-
tified as described (16). L. monocytogenes was grown and determined by simi-
lar culturing methods but by using PALCAM agar (17) plus PALCAM selective 
supplement (Oxoid). 
Collection of biological samples and bacterial quantification
A pilot study indicated that determination of the number of L. monocytogenes 
and S. enteritidis in organs of mice was optimal, which means that Listeria and 
Salmonella CFUs could be detected in organs, at 2 and 4 days after oral infec-
tion, respectively (unpublished results). Non-infected mice were sacrificed 3 
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days after oral sham treatment. Mice were anaesthetized by isoflurane and blood 
was collected via an orbital puncture to isolate heparin plasma. After cervical 
dislocation the colon and the distal 1/3 of the small intestine, representing the 
ileum, were excised. Approximately 1 cm was cut from the middle of each intes-
tinal segment to quantify the number of viable Salmonella or Listeria present in 
colonic and ileal tissue. This piece was cut open longitudinally, briefly flushed in 
sterile saline, homogenized in 250 μL of saline and 10-fold dilutions were plated 
for bacterial growth on selective agar for Salmonella or Listeria (as described 
above). The remaining parts of the ileum and colon were cut open longitudi-
nally, flushed with saline and the mucosa was isolated by scraping with a spatula. 
Mucosal samples were immediately frozen in liquid nitrogen for protein anal-
ysis. Furthermore, the mesenteric lymph nodes (MLN), spleen and liver were 
removed, and after homogenization in sterile saline, directly used for Salmonella 
or Listeria quantification as described above. Bacterial counts were expressed as 
the total log10 CFU per gram tissue.
RegIIIβ and RegIIIγ protein analysis in the ileal mucosa 
RegIIIγ and RegIIIβ expression were determined in the ileum because this is the 
area where expression is upregulated during infection of rats (9,10) and upon 
microbial colonization of germ-free mice (8). Frozen mucosal scrapings of the 
ileum were pulverized under liquid nitrogen. Approximately 2/3 of the pulver-
ized tissue was suspended in a 0.2 mol/L sucrose buffer of pH 7.4 containing 
20 mmol/L trishydroxymethylaminomethane (Tris) and a protease inhibitor 
cocktail (Complete, Roche Diagnostics). To homogenize the samples they were 
sonicated on ice for 30 s at level 4 (Sonicator XL2020, Heat Systems, Farming-
dale, NY, USA) and protein concentrations were determined using the BC Assay 
(Omnilabo, Breda, the Netherlands) according to the manufacturer’s protocol. 
One hundred µg protein was denatured at 95°C for 10 min in sample buffer 
(4x buffer: 160mM Tris, pH 6.8, 8% SDS, 40% glycerol, 0.05% w/v bromophe-
nol blue), subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
(4.8% stacking-gel, pH 6.8, 12.5% separation-gel, pH 8.8) and transferred to a 
PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA). After blocking, 
the membranes were incubated with polyclonal anti-RegIIIβ (1:50000) or anti-
RegIIIγ (1:10000) antibodies (custom made by Eurogentec, Seraing, Belgium). 
These antibodies were generated in rabbits against synthetically produced pep-
tides, using the peptide sequences GEDSLKNIPSARISC (RegIIIβ) and EVAK-
KDAPSSRSSC (RegIIIγ). The chosen peptide sequences correspond to unique 
sequences within the REGIII protein and allow differentiation between the 
RegIIIβ and RegIIIγ proteins. Serum from immunized rabbits was affinity puri-
fied using the same peptides. The signal of the secondary HRP-conjugated anti-
body (Goat-anti-Rabbit HRP, 1:100000, Jackson ImmunoResearch, Suffolk, UK) 
was detected by using the ECL Plus chemiluminescent detection kit (GE Health-
care, Den Bosch, the Netherlands). 
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Myeloperoxidase analysis in ileal mucosa and
serum amyloid A detection in plasma
A mouse myeloperoxidase (MPO) ELISA test kit (Hycult biotechnology, Uden, 
the Netherlands), was used according to the manufacturer’s guidelines to deter-
mine the concentration of MPO in ileal mucosal scrapings.
Serum amyloid A (SAA) 2, an acute phase apolipoprotein present in 
plasma (18), was determined to investigate systemic inflammation. A mouse 
SAA2 ELISA kit (Life Diagnostics, Inc. West Chester, Pennsylvania, USA) was 
used according to the guidelines of the manufacturer. 
Pull-down assay
In order to investigate whether RegIIIβ present in the luminal content of mice 
was able to bind Salmonella or Listeria a pull-down assay was performed. First 
faecal-water extracts were prepared from faeces of infected RegIIIβ-/- and wt 
mice as described previously (9). Briefly, faeces from day 4 or day 2 post Salmo-
nella or Listeria infection, respectively, were pooled per group. One hundred mg 
of each pool was homogenized in 1 mL buffer containing 50 mmol/L Tris-HCl 
(pH7.5), 100 mmol/L NaCl, 1 mmol/L EDTA and Complete Protease Inhibitor 
Cocktail (Roche). After incubation at 37 °C for 1 h and centrifugation at 15 000 
g for 2 min, the supernatant was taken and used as faecal-water extract. Pres-
ence of bacteria in the faecal-water extracts was investigated by plating undiluted 
extracts on Luria-Bertani (LB) agar.
S. enteritidis and L. monocytogenes, identical to the strains used in the 
infection study, were grown overnight (37°C in a horizontal shaker at 250 rpm) in 
LB and BHI broth, respectively. Overnight grown bacteria were spun down (6 min 
at 5000 g) and 4.3*106 bacteria were resuspended in 30 µL faecal water extracts 
from RegIIIβ-/- or wt mice. The bacteria were incubated for 1 h at 37°C in faecal-
water extracts or in the buffer that was used to prepare extracts as described above. 
After spinning down the bacteria presence of RegIIIβ was investigated in the pellet 
(resuspended in 20 µL PBS), supernatant (20 µL), and original faecal extracts (20 
µL) by SDS-PAGE as described above. Proteins were transferred to an Immobilon-
FL membrane (Millipore) and after blocking exposed to rat anti-mouse RegIIIβ 
antibodies (MAB5110; R&D systems, Minneapolis, USA, 1:2000). The secondary 
antibody used was Goat-anti-Rat IRDye® 680CW (Li-Cor, Nebraska, USA, 1:20 
000) and the blots were scanned by using the Odyssey scanner (Li-Cor). 
Statistics
All data are expressed as mean ± SEM and statistical analysis was performed by 
using Prism 5.0 Software (GraphPad, San Diego, California, USA). Our aim was 
to investigate the role of RegIIIβ in infection. Therefore the pre-defined compari-
sons were RegIIIβ-/- versus wt. Except for in vitro investigations to evaluate bind-
ing of RegIIIβ to Salmonella and Listeria when binding to these pathogens are 
compared. Data were tested for normality by Kolmogorov-Smirnov normality 
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test and Shapiro-Wilk normality test. If normally distributed, differences were 
tested for significance using Student’s t test (two-tailed). Data with unequal vari-
ances were tested by using the Mann-Whitney U test. Salmonella output in faeces 
was determined at multiple time points and therefore these data were analysed 
by repeated-measures two-way ANOVA (mixed-model). Differences were con-
sidered statistically significant when P<0.05.
RESULTS
Body weight
To monitor the general condition of the mice, body weight was determined dur-
ing the experiment. At the start of the experiment average body weight was 22 
± 0.7 g. During the study there was no significant difference between the body 
weight of RegIIIβ-/- and wt mice (data not shown). Average body weight before 
infection (average weight of 2 weeks prior to infection) was 23.0 ± 1.4 g and 
post-infection (average of the post infection period) 23.2 ± 1.5 g.
Bacterial infection increases RegIIIβ and RegIIIγ in the ileum mucosa 
To evaluate presence of RegIIIβ and RegIIIγ protein in the ileal mucosa of wt and 
RegIIIβ-/- mice, and subsequent levels upon oral infection, mucosal scrapings were 
evaluated by immunoblotting using antibodies specific for RegIIIβ and RegIIIγ. 
As expected, RegIIIβ was not detected in the ileal mucosa of RegIIIβ-/- animals 
(Fig 1). After Salmonella and Listeria infection the protein level was higher in the 
mucosal samples of wt mice than before infection (Fig 1). The isoform RegIIIγ was 
not detectable in mucosal scrapings of non-infected RegIIIβ-/- mice (Fig 1). In con-
trast, the wt mice had detectable levels of this RegIII isoform and levels increased 
during Salmonella and Listeria infection in wt and RegIIIβ-/- mice.
RegIIIβ-/- mice are more susceptible to Salmonellosis but 
not to Listeriosis than wt mice.
To investigate the role of RegIIIβ in intestinal colonization, the numbers of viable 
Salmonella were investigated in fresh faecal samples of infected wt and RegIIIβ-/- 
mice. Colonization of Salmonella in RegIIIβ-/- mice was not different from that of 
wt mice (Fig 2). In the colonic tissue, which was first flushed with saline to remove 
intestinal content, higher numbers of Salmonella were recovered in RegIIIβ-/- mice 
than in wt mice (Fig 3A; P<0.05). In the ileal tissue Salmonella levels were identical 
in RegIIIβ-/- and wt mice. Furthermore, in MLN, spleen and liver these levels were 
higher in RegIIIβ-/- mice than in their wt counterparts (Fig 3B; P<0.05). 
Intestinal colonization of Listeria was identical in RegIIIβ-/- and wt mice 
as found for Salmonella (Fig 2). To further investigate effects of RegIIIβ on Liste-
ria translocation the CFU in ileal and colonic tissue and extra-intestinal organs 
were determined. The number of Listeria recovered from wt did not differ from 
RegIIIβ-/- mice in ileal and colonic tissues, (Fig 4A) and in MLN, spleen, and 
liver (Fig 4B). 
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Figure 2. Salmonella (p, r) and Listeria (l, ○) excretion in faeces. Individually housed 
mice were orally infected at day 0. RegIIIβ-/- mice (closed symbols) were infected with 
5*108 colony-forming units (CFU) of S. enteritidis (n=10) or L. monocytogenes (n=7) and 
wt littermates (open symbols) with identical CFU of S. enteritidis (n=12) or L. monocyto-
genes (n=8). Values are means ± SEM.
Β-actin
S   L    S   L KO Wt
KO
RegIIIβ
Wt Non
infected
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RegIIIγ15 kDa
Figure 1. Western blot analysis of RegIIIβ and RegIIIγ in the ileal mucosa of RegIIIβ-/- 
mice (KO) or wt mice (Wt). RegIIIβ-/- mice (n=10) and wt mice (n=12) were orally 
infected with S. enteritidis (S) or RegIIIβ-/- mice (n=7) and wt mice (n=8) were orally 
infected with L. monocytogenes (L). Non-infected mice (n=5) received saline as control 
treatment. Equal amounts of protein from mucosal pools were separated by SDS-PAGE and 
subsequently transferred to PVDF membranes. Proteins on the membranes were detected 
with anti-RegIIIβ, anti-RegIIIγ and anti-β-actin.
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Mucosal and systemic inflammation
The role of RegIIIβ in inflammation was investigated by measuring the levels of 
the inflammation marker myeloperoxidase (MPO) in the ileum mucosa. MPO 
levels of all infected groups did not differ significantly from the non-infected 
groups (0.35 ± 0.05 ng/mg protein; data not shown). To study systemic inflam-
mation SAA levels in plasma were determined. The levels were elevated from 
0.1±0.001 µg/ml (non-infected mice) to 1164±186 and 502±174 µg/ml upon Sal-
monella and Listeria infection, respectively (P<0.05; data not shown). However, 
there were no significant differences between wt and RegIIIβ-/- mice.
Figure 4. Number of Listeria in intestinal and extra-intestinal tissues. CFU of Listeria in 
(A) the ileal and colonic mucosa and in (B) mesenteric lymph nodes (MLN), spleen and 
liver of RegIIIβ-/-mice (n=7; black bars) or wt mice (n=8; white bars) two days after oral L. 
monocytogenes infection. Values are means + SEM.
Figure 3. Salmonella in intestinal and extra-intestinal tissues. CFU of Salmonella in (A) 
the ileal and colonic mucosa and in (B) mesenteric lymph nodes (MLN), spleen and liver 
of RegIIIβ-/- mice (n=10; black bars) or wt mice (n=12; white bars) four days after oral S. 
enteritidis infection. Values are means + SEM. *Different from wt, P<0.05.
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RegIIIβ aggregates preferentially with Salmonella than with Listeria
To investigate whether RegIIIβ present in the faecal-water extracts is able to 
bind S. enteritidis or L. monocytogenes, pull-down assays were performed. Faecal 
water extracted from faeces of infected wt mice showed a band of approximately 
15 kDa and a slightly lower molecular weight band (Fig 5). Faecal-water extracts 
were negative for presence of microbiota-derived bacteria. Upon incubation of 
the extract with Salmonella most of the RegIIIβ protein was found in the pel-
let that contained the Salmonella bacteria. A minor part of the protein was 
detected in the supernatant (Fig 5 panel A). In contrast, lower levels of RegIIIβ 
were detected in the pellet than in the supernatant when this assay was per-
formed with Listeria (Fig 5 panel B). Previous experiments of protein isolation 
from faeces including microbiota indicated that the protein is normally present 
in the supernatant, even when centrifuged at 15 000 g (9). Therefore the results 
presented here indicated that secreted RegIIIβ recovered from faeces is able to 
directly bind Salmonella and binds to a lower level to Listeria.
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Figure 5. Listeria and Salmonella pull-down assays. Presence of RegIIIβ, detected by West-
ern blot analysis, in pellet and supernatant fractions of faecal-water extracts from S. enter-
itidis (panel A) or L. monocytogenes (panel B) infected wt (Wt) or RegIIIβ-/- (KO) mice 
incubated with Salmonella or Listeria. Bacteria that were incubated with the faecal-water 
extraction buffer served as negative control (-) and bacterial culture alone was also loaded 
as control. The pre-stained marker is indicated by M.
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DISCUSSION 
Both microbial infections of conventional mice and intestinal colonization of 
germ-free mice by commensals increases ileal expression of the secreted C-type 
lectins RegIIIγ and RegIIIβ (7-10) . While RegIIIγ has been shown to have a bac-
tericidal activity against Gram-positive bacteria (8), the physiological function 
of RegIIIβ remains unknown . This study now shows an essential role of RegIIIβ 
in protecting the intestine against infection with the Gram-negative S. enteritidis. 
Despite similar levels of viable Salmonella recovered from faeces an increased 
number was recovered from MLN, spleen and liver from infected RegIIIβ-/- mice 
compared to wt mice, indicating that the translocation and dissemination of Sal-
monella in host tissues is increased in the absence of RegIIIβ. 
In colonic tissue Salmonella levels were also increased in RegIIIβ-/- mice 
compared with wt mice. The MLN drain the small intestine, which is a main site 
of Salmonella invasion (18). Therefore reduced levels of Salmonella in the MLN 
of wt mice suggest protective effects of RegIIIβ on Salmonella translocation in 
the ileum. Although we did not observe differences in Salmonella counts in the 
ileal tissues of wt and RegIIIβ-/- mice, this may be due to lack of statistical power 
in this assay, as SEM levels are higher in ileal tissue than those in colonic tis-
sue. Moreover the investigated ileal tissue did not contain Peyer’s patches and M 
cells, which are considered, in addition to absorptive enterocytes, to be impor-
tant sites of Salmonella translocation (19,20). Together the experimental infec-
tion data strongly suggest that RegIIIβ inhibits Salmonella translocation from 
the gut lumen into intestinal tissues and further extra-intestinal tissues but does 
not kill Salmonella in the gut lumen. These results are supported by recent find-
ings of Dessein et al., who showed that genetic ablation of RegIIIβ did not affect 
the bacterial load of the Gram-negative pathogen Yersinia pseudotuberculosis 
in the intestinal lumen (13) but significantly increased bacterial burden in the 
Peyer’s patches, which are the main route of entry for this pathogen. In contrast, 
RegIIIβ did not to influence resistance to infection with the Gram-positive Lis-
teria monocytogenes, as identical numbers of this pathogen were recovered from 
intestinal and extra-intestinal tissues in RegIIIβ-/- and wt mice in our study. 
As murine RegIIIγ and human PAP are directly bactericidal for Gram-
positive bacteria in vitro (8,21) it seemed possible that RegIIIβ would have simi-
lar antimicrobial activity. However, in this study there was no effect of RegIIIβ 
on the colonization and translocation of L. monocytogenes. The strain of L. 
monocytogenes used in our infection study was identical to that used previously 
for in vitro antibacterial assays with RegIIIγ (8). Previous investigations with rat 
PAP1, which is the orthologue of the murine RegIIIβ, also showed no direct bac-
tericidal effect against L. monocytogenes in vitro (9). Others also report a lack of 
bactericidal effect of this protein (13). The co-existence of the two closely related 
RegIII proteins in the mouse strongly suggests a different function for each 
of these proteins. Here we provide evidence that RegIIIβ has a protective role 
against Gram-negative Salmonella translocation but not Listeria infection. The 
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exact mechanism by which RegIIIβ inhibits Salmonella translocation into host 
tissues is unclear. 
The observed difference of RegIIIβ functionality between Listeriosis and 
Salmonellosis might be due to differences in physical appearance and host inva-
sion tactics between the two pathogens but might also be related to differences 
in host responses induced by these pathogens. We can only speculate about the 
latter as we did not monitor the exact (immune) response of the mice. Previ-
ous studies by Brandl et al. indicated that the innate immune defence against L. 
monocytogenes, which requires Toll-like receptor (TLR)-mediated signals, plays 
a crucial role in RegIIIγ related protection against this pathogen. As S. enteriti-
dis and L. monocytogenes may trigger different (TLR-mediated) innate immune 
signals (22), this might be a cause a differential regulation of RegIIIβ expression 
and thus regulate its subsequent protective effects. On the other hand, it might 
be that RegIIIβ modulates the immune response directed against Salmonella but 
not the response against Listeria. Although measured at a single time point in 
the current study, RegIIIβ did not affect the systemic inflammatory response as 
measured by SAA levels in serum. The local inflammatory response in our infec-
tion models was relatively low, as MPO levels did not increase upon infection in 
the ileal mucosa. This was likely due to the relatively short period that mice were 
exposed to the orally administered pathogens because our focus was on patho-
gen colonization and translocation which normally precedes inflammation. Thus 
based on our study design, we can not fully exclude absence of effects of RegIIIβ 
on the inflammatory response. However, previous investigations in our lab with 
a similar Salmonella infection model in rats indicated that mucosal inflamma-
tion in this infection model is relatively low at day 4 post infection (23). Fur-
ther analysis of the collected intestinal tissues from the current study might give 
insight on the role of the innate (immune) response in RegIIIβ related protec-
tive effects. For example, micro-array analysis of intestinal tissues may identify 
whether and which host defence pathways are associated with protective effects 
of RegIIIβ. Performing additional Listeria and Salmonella infection experiments 
in mice deficient in specific TLRs might reveal the involvement of specific innate 
immune signaling in RegIIIβ mediated protection against intestinal infection. 
Besides the proposed association of the host response with RegIIIβ 
related protection of intestinal infection, this lectin might also directly and differ-
entially affect Listeria and Salmonella. The outer membrane of these pathogens is 
different, for example Salmonella contains immuno-reactive lipopolysaccharides 
(LPS) which are absent in Gram-positive bacteria like Listeria. This influences 
host signaling pathways, e.g. TLR recognition. Our biochemical analysis revealed 
that faecal RegIIIβ showed increased affinity to Salmonella than to Listeria, pro-
viding a mechanism whereby RegIIIß-deficient mice showed increased suscep-
tibility to salmonellosis but not to listeriosis. Bactericidal activities of RegIIIγ 
depend on binding to cell wall peptidoglycan, a molecule exposed on the Gram-
positive bacterial surface (8). This peptidoglycan recognition is determined by 
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the so called Loop1 EPN tripeptide motif, which is also present in RegIIIβ (11). 
This motif is involved in peptidoglycan binding, and binding affinity for carbo-
hydrate ligands depends on carbohydrate chain length (11). Moreover RegIIIβ 
binds to the Gram-positive Bacillus subtilis peptidoglycan, mannose polysaccha-
rides and chitin, which is a long-chain polymer of N-acetylglucosamine (11). 
Our results suggest that Regβ possibly recognizes carbohydrate structures on 
the Gram-negative bacterial surface. Currently we do not know what the spe-
cific target of RegIIIβ is on the outer membrane of Gram-negative bacteria. It 
may be related to LPS, which are large molecules consisting of a lipid and a 
polymeric carbohydrate structure (24). The latter may be a binding target for 
the EPN motif in RegIIIβ. The molecular mechanism by which RegIIIβ may 
recognize (the peptidoglycan of) Salmonella remains to be determined. Studies 
with purified RegIIIβ are needed to determine what ligands specifically bind to 
this protein. To address this question it will be necessary to have purified bio-
logically active RegIIIβ protein, and efforts are under way to produce and purify 
this protein in active form. 
Another important difference between the pathogens is that Listeria and 
Salmonella use complex and very different mechanisms of cellular attachment 
and invasion (25,26). Listeria can invade the human intestinal epithelium via 
the epithelial receptor E-cadherin. A single amino acid change in the murine 
E-cadherin, however, makes mice relatively resistant to intestinal infection (27). 
As also shown in the present study, relatively high doses of Listeria, do achieve a 
significant invasive infection in rodents (27). This probably involves a second but 
less well characterized surface protein of L. monocytogenes Internalin B, which 
enables Listeria to enter and survive within epithelial cells via interaction with 
three different epithelial membrane receptors (25,26). In the case of Salmonella 
the bacteria are not highly adherent, but their invasion machinery is particu-
larly efficient (26). Salmonella has another mechanism to invade cells which 
involves binding to epithelial cells by its type III secretory system (TTSS) 
(20,28). The TTSS allows direct activation of components of the host-cell cyto-
skeleton by intracellular delivery of dedicated bacterial effectors, resulting 
in membrane ruffling and endocytosis. By this event Salmonella invade and 
reside in an atypical acidic compartment called the SCV (Salmonella contain-
ing vacuole) and survive inside the cell (25). It might be possible that RegIIIβ 
interferes with the expression or function of Salmonella pathogenicity island 1 
(SPI-1) TTSS invasion machinery. 
In conclusion, RegIIIβ inhibits intestinal bacterial translocation upon 
oral infection with the Gram-negative Salmonella. In contrast, this protein does 
not protect against intestinal infection with the Gram-positive Listeria. Inhibi-
tory effects of RegIIIβ on bacterial infection may be linked to its observed pref-
erential binding to Salmonella. The protective mechanism of RegIIIβ is not 
associated with direct bactericidal affects but may interfere with Salmonella viru-
lence mechanisms or host responses to the pathogen. 
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ABSTRACT
Objective Pancreatitis-associated protein (PAP), also denoted regenerating pro-
tein III (RegIII), is highly expressed in the intestinal mucosa and detected in 
feces during intestinal infection and inflammation in rodents. The aim of the 
present study was to explore the human relevance of these findings and to com-
pare PAP concentrations with calprotectin, a fecal biomarker of mucosal inflam-
mation.
Methods PAP and calprotectin concentrations were determined by ELISA in feces 
of healthy subjects (n=31) before and at various time points after oral infection 
with a live but attenuated enterotoxigenic Eschericia coli (ETEC) and in feces of 
patients with ulcerative colitis (UC; n=36) or Crohn’s disease (CD; n=22). 
Results Fecal PAP was present at low levels, 59±20 ng/g in healthy subjects, 
whereas calprotectin concentrations were 5±1 μg/g. Oral ETEC infection was 
associated with increased PAP (by 76±31 ng/g; p<0.05) from 3 days post infec-
tion. In contrast, fecal calprotectin increased instantaneously from the first day 
after infection. Both fecal PAP (87±18 ng/g) and calprotectin (120±24 μg/g) 
were significantly higher in UC patients in clinical remission than in healthy 
subjects (p<0.05). In CD patients, either with active disease or in remission, 
fecal PAP was not elevated despite significantly increased fecal calprotectin 
concentrations.
Conclusions This exploratory study indicates that PAP is detectable in human 
feces and levels increase upon intestinal infection and in UC but, interestingly, 
not in CD. The output kinetics of fecal PAP and calprotectin are not similar. Fur-
ther studies are needed for validation of fecal PAP as a potential new biomarker 
to monitor or discriminate human intestinal disease.
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INTRODUCTION
There is great interest in identifying and validating new fecal biomarkers of 
intestinal health and disease, like gut infection and inflammation. Their imple-
mentation in clinical routine is attractive because these markers yield valuable 
information on intestinal health status by a non-invasive means. These markers 
could facilitate monitoring of intestinal disease activity with time, e.g. in 
response to therapeutic intervention, and may reduce the need for endoscopic 
investigations. At present a widely applied fecal marker for intestinal inflamma-
tion is the protein complex S100A8/S100A9 denoted ‘calprotectin’ (1). Applica-
tion of these kinds of markers can also be considered in patients with mild 
symptoms of abdominal pain or diarrhea. Dependent on the sensitivity and 
specificity of fecal biomarkers, their analysis can be highly quantitative and even 
suitable for early detection of subclinical activity (2).
Recently, we have shown that the expression of pancreatitis associated 
protein (PAP), also known as regenerating protein III (RegIII), is increased in 
enterocytes of the ileal mucosa during Salmonella infection in rodents (3). 
Increased colonization and translocation of Salmonella coincided with higher 
ileal mucosal PAP/RegIII levels. The protein was shown to be excreted in rat 
feces at levels similar to mucosal levels and it was proposed as a potential new 
intestinal infection marker (3). Stimulated intestinal PAP expression is not spe-
cific for Salmonella infection as increased PAP transcript levels are found in the 
small intestine of pigs in a small intestinal perfusion model with Escherichia coli 
(4). The cellular origin of intestinal PAP and especially its functionality is still 
under investigation (5-8). Dessein et al. recently showed that the murine ortho-
logue of PAP, alias RegIIIβ, plays a role in clearance of invasive Yersinia pseudo-
tuberculosis in Peyer’s patches of mice through a Toll-like receptor 2-mediated 
interaction (7). This suggests that PAP functions in a more complex manner than 
via the proposed direct antimicrobial activity (6). Concomitantly the above men-
tioned studies indicate that microbe-host interaction plays a crucial role in PAP 
expression and functionality.
Chronic inflammatory bowel disorders (IBD), such as ulcerative colitis 
(UC) and Crohn’s disease (CD), are characterized by disturbed microbe-host 
interactions and an impaired gut barrier function (9). As many as 1.4 million 
subjects in the US and 2.2 million subjects in Europe suffer from these debilitat-
ing disorders (10). Most patients are subjected to invasive methods for diagnos-
tics and monitoring disease activity and new non-invasive (fecal) surrogate 
markers of mucosal condition are needed. Several studies have reported that in 
IBD microbe-host interactions are crucial and PAP mRNA levels are increased 
in the intestinal mucosa of these IBD patients (11,12). This suggests that fecal 
PAP levels could be used as a potential new biomarker.
To address human relevance of PAP as potential new biomarker of intes-
tinal infectious disease and/or mucosal inflammation we first established its 
presence in human feces and subsequently studied whether levels changed upon 
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intestinal bacterial infection and in established IBD. Fecal calprotectin was mea-
sured to quantify intestinal mucosal inflammation in the studied patient groups 
and to determine its association, if any, with fecal PAP. Our results indicate that 
fecal PAP is a marker dissimilar to the mucosal inflammation marker calprotec-
tin and might aid in discriminating UC from CD.
METHODS
Healthy and enterotoxigenic Escherichia coli infected subjects
Post-hoc analyses was performed in stools collected in a human infection 
study, published previously (13). Feces from this healthy population, collected 
on two different but consecutive days per individual, were used as healthy sub-
ject samples in the present study. Briefly, thirty-one healthy men with the fol-
lowing characteristics were included: aged between 20-55 years, without 
reported use of antibiotics, immunosuppressive drugs, antacids, laxatives, or 
anti-diarrheal drugs in the last 3 months before the study, and no gastrointesti-
nal illness or surgical operations in the past (13). All subjects gave their written 
informed consent before participation. The study was performed in accordance 
with the principles of the Helsinki Declaration and was approved by the Medi-
cal Ethics Committee of Wageningen University, the Netherlands. Before 
inclusion, serum and feces were screened for absence of enterotoxigenic Esch-
erichia coli (ETEC) specific antibodies (CFAII epitope) and the presence of 
streptomycin resistant E. coli, respectively. The subjects ingested a live but 
attenuated ETEC strain as described (13). On several days after oral ETEC 
infection and on the above-mentioned pre-infection days 24 h stool was col-
lected as described previously (13). These lyophilized-stool samples were used 
to determine baseline and infection-induced fecal PAP and calprotectin excre-
tion as described below. 
Ulcerative colitis patients
UC patients in remission were recruited from the South Limburg IBD registry 
(14). Thirty-six patients had a well-defined diagnosis of UC established by 
clinical, endoscopic, histological and/or radiological criteria. All patients were 
clinically in remission and had an Endoscopic Grading System (EGS) score 
below 5 at the first endoscopy (15). Disease location and medication at the 
time of fecal sampling are presented in Table 1. The left-sided colitis group 
included 15 patients with distal colitis. Patients were between 31 and 65 years 
of age and consumed a stable Western diet. Exclusion criteria comprised: proc-
titis only, pregnancy, lactation, changes in medication and/or prebiotic and 
probiotic intake less than two weeks prior to endoscopy, use of corticosteroids, 
enemas and suppositories within two weeks prior to endoscopy, use of antibi-
otics within the 3 months prior to or during endoscopy, other clinically signifi-
cant systemic diseases, and previous radiotherapy or chemotherapy. All 
patients gave their written informed consent before participation. The study 
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was performed in accordance with the principles of the Helsinki Declaration 
and was approved by the Medical Ethics Committee of the University Hospital 
Maastricht, the Netherlands. Prior to endoscopy each patient collected 24 h 
stool, which was homogenized and lyophilized.
Crohn’s disease patients
CD patients, aged 19-96 years, were either in remission (n=14) or had active dis-
ease (n=8). Remission was clinically determined by a physician global assess-
ment (PGA), serum C-reactive protein <5 mg/L and fecal calprotectin <60 mg/
kg (60 μg/g). Further subject characteristics are presented in Table 1. All patients 
gave their written informed consent before participation. The study was per-
formed in accordance with the principles of the Helsinki Declaration and 
approved by the Medical Ethics Committee of the University Medical Centre 
Groningen, the Netherlands. From each patient stool was collected, homoge-
nized and stored at -80ºC.
Fecal calprotectin analysis
Fecal calprotectin was determined by a commercially available ELISA (Calpro 
AS, Oslo, Norway) following the manufacturer’s instructions (16). Briefly, feces 
Table 1. Patient characteristics.
Ulcerative Colitis Crohn’s disease
Remission Active Remission
Age (years): Mean (range) 53 (31-65) 28 (19-39) 45 (20-69)
Number of patients 36 8 14
Gender: Male 21 5 4
Localization of disease Left-sided colitis 27
Pancolitis 7
Unknown 2
Ileum 4
Ileocolonic 4
Ileum 8
Ileocolonic 3
Ileorectal 1
Colon 2
Medication :
Biologicals
Immunomodulators
Oral 5-ASAs
Topical corticosteroids
None
0
3
18
0
15
0
3
1
1
4
3
8
6
3
1
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from healthy or infected subjects (13) or IBD patients were suspended and incu-
bated at RT in the extraction buffer provided for 30 min. After vigorous shaking 
the extracts were centrifuged for 20 min at 10,000 g at 4 °C. The clear superna-
tants were diluted to fit the standard curve range and calprotectin levels were 
expressed as µg per g fecal wet weight. To monitor assay quality in each assay 
standard recovery and duplicates were included. 
Fecal PAP analysis
A commercially available ELISA (Dynabio S.A., Marseille, France) for assaying 
human PAP in serum was used to determine PAP in feces. Fecal extracts were 
prepared as previously described (3). Control experiments on fecal extract resi-
dues showed that the method used extracted all PAP protein from (lyophilized) 
human feces. In each assay standard recovery was checked and duplicates were 
included to monitor assay quality. PAP output was expressed as ng per g fecal 
wet weight. From the two baseline samples intra-individual variation was calcu-
lated. To evaluate fecal PAP and calprotectin excretion kinetics during ETEC 
infection, the infection-induced change in these markers was calculated by sub-
tracting the individuals’ baseline (pre-infection) concentration from their post-
infection concentrations.
In a separate control experiment, the stability of this protein in stool was 
investigated. For that purpose, fresh fecal samples from healthy subjects were 
homogenized and aliquots were stored either at RT or 4°C or at -20°C for 24 h 
and 48 h and PAP levels were measured and compared with that of fresh feces. In 
addition, the effect of repeated freeze-thaw cycles and lyophillization on PAP 
stability was investigated. 
Statistics
Statistical analysis was performed by using Prism 5.0 Software (GraphPad, San 
Diego, California, USA). All data was tested for normality by Kolmogorov-
Smirnov normality test and Shapiro-Wilk normality test. 
Absolute data from PAP and calprotectin excretion during ETEC infec-
tion were compared per time point to basal levels by Wilcoxon matched pairs 
test. Individual data from IBD patients versus healthy controls were tested by the 
nonparametric Kruskal-Wallis test, followed by Dunn’s post-test for multiple 
comparisons. Statistical significance was set at p<0.05. Numerical data are pre-
sented as mean ± SE or median as indicated.
RESULTS
Stability of fecal PAP
To determine stability of fecal PAP various preservation methods were investi-
gated. Fecal PAP was stable at -20ºC, 4ºC and room temperature for at least 48 
hrs and after repeated freeze-thaw cycles, as concentrations were similar to those 
observed in the fresh fecal samples (data not shown). In addition, fresh fecal 
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samples stored at -20ºC or the same samples lyophilized and stored at room tem-
perature resulted in similar concentrations (data not shown). This indicated that 
lyophilization had no effect on fecal PAP concentrations.
Fecal PAP and calprotectin in healthy subjects
before and after ETEC infection
To investigate fecal PAP and calprotectin levels in healthy subjects and after 
ETEC infection both proteins were analyzed in feces. In healthy subjects there 
was large variation in fecal PAP. The mean was 59±20 ng/g concentration 
(median 12 ng/g). Five subjects had a high basal PAP excretion (>100 ng/g; Fig. 1 
and 3B) in comparison with other healthy subjects. Standard additions and iden-
tical results from multiple assays indicated that an analytical error was unlikely. 
As far as we know, these subjects had no other discriminating characteristic in 
common. Their fecal calprotectin concentration was as low as observed in other 
healthy subjects (total group mean 5±1 μg/g; data not shown), total fecal output 
and relative fecal dry weight were also in the same range as those of other sub-
jects. Also, fecal characteristics like pH, cytotoxicity, ammonia levels, phosphate 
levels and the number of lactobacilli did not differ from other healthy subjects. 
Characteristics of the subjects such as age, BMI, habitual dietary intake, smoking 
Figure 1. Fecal PAP excretion pattern in healthy subjects orally exposed to enterotoxi-
genic Escherichia coli (ETEC). Pancreatitis associated protein (PAP) concentrations in feces 
before (day 0) and after (days 1, 2, 3, 5 and 7) ingestion of a live but attenuated ETEC strain. 
Each line represents a categorical group based on basal PAP concentration: group 0-50 ng/g 
(¢; n=26), and those with basal levels >100 ng/g (p; n=5). Basal (pre-infection) levels were 
based on two fecal samples of each subject, collected on different days. Fecal calprotectin was 
identical in both subgroups (data not shown). Data are expressed as mean ± SE.
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habits, and previous appendectomy were compared but revealed no differences 
between the five subjects and other healthy subjects. Aside from these five high-
PAP excretors, all other subjects had low basal PAP levels (≤50 ng/g; Fig. 1). Fol-
low-up of these two subgroups after oral ETEC infection showed that the 
infection-induced response in fecal PAP excretion was similar, although in the 
>100 ng/g-group an initial decrease of fecal PAP was shown on the first day after 
ETEC ingestion (Fig. 1). Overall the PAP output showed the same kinetics 
between the subgroups. 
The absolute intra-individual variation was determined by analysis of 
two fecal samples collected prior to infection. As expected the intra-individual 
variation in PAP excretion including the five extreme subjects was much higher 
than without those subjects, namely 100 ng/g and 16 ng/g, respectively.
On the first day after oral infection fecal PAP was significantly lower 
than baseline level (Fig. 2; by 44±17 ng/g; p<0.05), which was mainly caused by a 
decrease in fecal PAP in the five high-excretors as mentioned above. In contrast, 
at the same time fecal calprotectin was significantly elevated (by 53±11 μg/g; 
p<0.05). On the second day after infection, calprotectin increased even more (by 
104±20 μg/g; p<0.05). Only from day three did fecal PAP increase significantly, 
by 76±31 ng/g, and concentrations returned to baseline levels at day seven post 
infection, whereas calprotectin levels were still elevated at that time (Fig. 2). 
Overall, fecal PAP and calprotectin were both increased by ETEC infection but 
their kinetics were different.
Figure 2. ETEC-induced excretion kinetics of PAP is not similar to calprotectin. Fecal 
PAP and calprotectin after ingestion of a live but attenuated ETEC strain on day 0 by 
healthy subjects (n=31). ΔConcentration was calculated by correcting for baseline pre-
infection levels. Baseline levels were calculated from two fecal samples from each subject, 
collected on different days. Data are expressed as mean ± SE per gram wet weight (g ww). 
Per time point absolute data were compared to basal levels by Wilcoxon matched pairs test 
for nonparametric paired data. * <0.05; # p<0.01
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Stool analysis of IBD patients
PAP en calprotectin were determined in feces from IBD patients to investigate 
and compare levels in UC and CD. Fecal calprotectin was higher in CD patients 
(432±123 µg/g) and in UC patients (120±24 μg/g; Fig. 3A) than in healthy sub-
jects (5±1 μg/g). UC patients in remission had a significantly higher fecal PAP 
concentration (87±18 ng/g) than healthy subjects (59±20 ng/g; p<0.05). In con-
trast, fecal PAP was not elevated in patients with active or non-active CD (20±6 
ng/g; Fig. 3B). Interestingly, PAP was significantly lower in feces from this patient 
group compared to levels detected in feces from UC patients (p<0.05; Fig. 3B). 
PAP levels were not associated with disease location or with medication (Table 
1). In addition E2 and E3 location in UC patients, presented as one group termed 
“left-sided colitis”, was not associated with PAP levels. Similarly, fecal calprotec-
tin was not related to PAP levels.
DISCUSSION
This exploratory study shows that fecal PAP concentrations were associated with 
intestinal infection induced by oral ETEC infection in healthy volunteers. Fur-
thermore, fecal PAP was increased in patients with UC in clinical remission, 
while in CD patients fecal PAP concentrations were not elevated despite signifi-
cantly increased fecal calprotectin levels.
Figure 3. Fecal PAP and calprotectin in IBD patients. Calprotectin (A) and PAP (B) con-
centrations from healthy individuals (n=31), ulcerative colitis (UC; n=36) and patients with 
Crohn’s disease (CD; n=22). Inflammatory bowel disease patients were in remission (l) 
or had active disease (○). Each individual is represented by a single dot and lines indicate 
the group’s median. Data were tested by the nonparametric Kruskal-Wallis test, followed by 
Dunn’s post test for multiple comparisons. Statistical significance was set at *p<0.05.
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Fecal biomarkers of intestinal inflammation are attractive in the clinical 
routine as they provide a non-invasive examination that can help the investiga-
tion of patients with mild symptoms such as abdominal pain and diarrhea. Mea-
surement of such biomarkers can easily be repeated and enables non-invasive 
follow-up of mucosal inflammation, e.g. to monitor therapeutic efficacy (2). The 
most intensively investigated and currently applied fecal marker is the protein 
complex S100A8/S100A9 termed ‘calprotectin’. This protein complex is mainly 
expressed by infiltrating granulocytes as well as monocytes and it is, to some 
extent, also inducible in epithelial cells (1,17). The observed increase of fecal cal-
protectin in IBD patients we investigated is in concordance with results reported 
by others (18-20). High calprotectin levels are observed in active UC and CD 
(18-20), but even during a phase of (clinical) remission levels generally exceed 
those of healthy controls (20). The latter probably reflects the chronic nature of 
this disease. 
To our knowledge, this is the first study showing that PAP is readily 
detectable in feces from healthy subjects. The protein is stable in feces for at least 
48 hr even at room temperature. Repeated measurements in multiple subjects 
indicated a rather high inter-individual variation but a relatively low intra-indi-
vidual variation in fecal PAP. In most subjects, basal levels were below 50 ng/g, 
but in a small subgroup relatively high levels were detected without any other 
discriminating health characteristic, including diet. Since there is no clear expla-
nation for the higher levels identified in these subjects, we feel that there is no 
reason to exclude their data from the control group. The mechanism behind this 
high excretion of PAP requires further investigation. 
The variation between individuals implies that PAP would not be suit-
able as a solitary biomarker, but more as a differentiating marker in addition to 
e.g. calprotectin. Irrespective of the basal level, fecal PAP increased with time 
after exposure of healthy subjects to an attenuated ETEC. Strikingly, similar to 
previous studies in rats, increased levels were not detected until day 3 post infec-
tion (3,21). The course of an infection is characterized by different phases, from 
initial mucosal adherence and colonization of the pathogen, followed by activa-
tion of host defense and an inflammatory response, eventually resulting in 
inflammation suppression with mucosal repair and epithelial cell differentiation. 
Considering the delayed fecal PAP output in response to oral ETEC infection, a 
role for PAP in initial mucosa-pathogen contact seems less likely as intestinal 
ETEC colonization takes place within the first day after gastrointestinal entrance 
of this pathogen (13). Our results suggest that PAP plays a role in a more second-
ary defense or repair of the intestinal mucosa. Some studies indicate an anti-
inflammatory role of PAP in the immune response. Blocking of PAP in an animal 
model of acute pancreatitis increased pancreatic inflammation (22) and in 
human colonic HT29 cells PAP reduced inflammation by inhibiting TNF-α 
induced NFκB activation (23). 
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The difference in excretion kinetics of PAP and calprotectin is not that 
surprising since the cellular origin of these proteins is different. Although still 
debated, human PAP and the rodent orthologue RegIIIβ are predominantly 
present in intestinal epithelial cells (3,5,24) whereas calprotectin is mainly pres-
ent in infiltrating neutrophils (1). 
We show that fecal PAP was elevated in UC patients in remission but not 
in CD patients (either active or in remission), suggesting increased intestinal 
mucosal levels of this protein in UC only. The latter seems in contrast with ear-
lier studies describing increased PAP mRNA levels in inflamed colonic tissue of 
both UC and CD patients (11,12). However, it was also reported that despite 
detectable RNA levels along all segments of the intestinal tract (25), in the 
healthy mucosa PAP protein detection was limited to the small intestine and the 
proximal colon (26). Studies on non-proximal parts of the colon failed to detect 
PAP protein (27), indicating that results depend on which part of the large intes-
tine is investigated. It is not fully clear what part of the intestine is responsible for 
the increase in fecal PAP levels we observed. ETEC, used in our infection study, 
is known to attach mainly in the small intestine (28). This suggests that in this 
group the small intestine is mainly responsible for the fecal PAP elevation. Thor-
ough investigation of the different disease locations of the IBD subjects and indi-
vidual PAP levels did not indicate that a specific area was responsible for the 
increase in fecal PAP. UC patients with pancolitis or left-sided colitis (also E2 or 
E3) were represented in the complete range of fecal PAP concentrations. Simi-
larly CD patients with active or inactive disease did not show relatively high or 
low levels of fecal PAP excretion but levels were equally distributed along the 
range. Therefore, we cannot state which part of the intestine is responsible for 
the increase of fecal PAP or whether disease activity plays a role. Further investi-
gations using feces and biopsies from larger subgroups of UC and CD patients 
are needed to provide better insight. Monitoring PAP levels in feces from UC 
patients in active state also need to be investigated. This will tell us whether the 
increase of fecal PAP is specific for UC patients in remission or that levels are 
elevated further during active disease. These results will also provide a better 
insight in the possible function of this protein. 
Our healthy population consisted of males only whereas the IBD groups 
were represented by males and females. However, the results from the IBD 
groups do not indicate that gender plays a role in fecal excretion of PAP and 
could have interfered with our results. 
Our previous animal experiments (3,21) and the present human infec-
tion study indicate that increased mucosal PAP excretion is a normal response 
to adherent Gram-negative enteropathogens, such as Salmonella and E. coli. 
An important role for E.coli in the pathogenesis of CD is suggested by clinical, 
experimental, and therapeutic studies (9). Functional alterations in the micro-
biota are most evident in adherent E. coli that colonizes the ileum of CD 
patients (29,30). However, fecal PAP levels in CD patients in our study were 
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low and not increased as in healthy subjects after E. coli infection. We speculate 
that CD patients have an impaired PAP response to enteropathogens and 
therefore lack a mucosal defense or repair which may contribute to CD pathol-
ogy. Functionality studies of the mucosal response to enteropathogens in PAP 
knock-out mice are ongoing. These studies will tell us more about the role of 
PAP in mucosal defense or repair, and whether absence of PAP in the mucosa 
could contribute to CD pathology. Clarity on that point is highly essential for 
further validation of PAP as potential fecal biomarker to identify or monitor 
intestinal disease activity or recovery either induced by therapeutics or occur-
ring spontaneously. 
In conclusion, PAP is detectable in human feces and is increased upon 
intestinal bacterial infection. Moreover this protein is increased during UC in 
remission but not in CD patients, either in remission or with active disease. Fecal 
PAP excretion kinetics differs from that of the inflammation marker calprotec-
tin, reflecting their different cellular origin and function. Neutrophil-derived 
proteins like calprotectin have already proved their value as biological markers 
to determine intestinal inflammation by non-invasive procedures. Markers 
derived from intestinal epithelial cells are far less well-developed but can be of 
high potential. This exploratory study in humans is an initial step and definitely 
needs confirmation and further investigation to determine the value of PAP to 
monitor intestinal disease activity and to discriminate between UC and CD.
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ABSTRACT
Background: Glutathione, the main antioxidant of intestinal epithelial cells, is 
suggested to play an important role in gut barrier function and prevention of 
inflammation-related oxidative damage as induced by acute bacterial infection. 
Most studies on intestinal glutathione focus on oxidative stress reduction with-
out considering functional disease outcome. Our aim was to determine whether 
depletion or maintenance of intestinal glutathione changes susceptibility of rats 
to Salmonella infection and associated inflammation.
Methods: Rats were fed a control diet or the same diet supplemented with buthi-
onine sulfoximine (BSO; glutathione depletion) or cystine (glutathione mainte-
nance). Inert chromium ethylenediamine-tetraacetic acid (CrEDTA) was added 
to the diets to quantify intestinal permeability. At day 4 after oral gavage with 
Salmonella enteritidis (or saline for non-infected controls), Salmonella transloca-
tion was determined by culturing extra-intestinal organs. Liver and ileal mucosa 
were collected for analyses of glutathione, inflammation markers and oxidative 
damage. Faeces was collected to quantify diarrhoea.
Results: Glutathione depletion aggravated ileal inflammation after infection as 
indicated by increased levels of mucosal myeloperoxidase and interleukin-1β. 
Remarkably, intestinal permeability and Salmonella translocation were not 
increased. Cystine supplementation maintained glutathione in the intestinal 
mucosa but inflammation and oxidative damage were not diminished. Neverthe-
less, cystine reduced intestinal permeability and Salmonella translocation.
Conclusions: Despite increased infection-induced mucosal inflammation upon 
glutathione depletion, this tripeptide does not play a role in intestinal permeabil-
ity, bacterial translocation and diarrhoea. On the other hand, cystine enhances 
gut barrier function by a mechanism unlikely to be related to glutathione.
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BACKGROUND
During foodborne Salmonella enteritidis infection pathogens can pass the gut 
epithelial cell lining and translocate to extra-intestinal organs like the spleen and 
liver (1). In response to mucosal invasion of pathogens, epithelial cells and mac-
rophages express pro-inflammatory cytokines, e.g. interleukin-1β (IL-1β), to 
recruit neutrophils(2,3). These efficient killers of translocating microbes (4) con-
tain high concentrations of the enzyme myeloperoxidase (MPO) (4,5), which 
participates in the innate immune defence through formation of powerful reac-
tive oxidants (4,5). An unfortunate side-effect of this defence machinery is that 
the anti-bacterial reactive oxygen species produced also react with cellular 
organic molecules and have the potential to induce oxidative tissue damage 
(4-6). For example, MPO is associated with oxidative stress-related damage (pro-
tein nitration) in the inflamed mucosa of ulcerative colitis patients (7). To reduce 
this damage, inhibition of MPO has even become a possible target of new drug 
development (8).
Glutathione, a tripeptide composed of γ-glutamic acid, cysteine and gly-
cine is quantitatively the most important low-molecular-weight (non-protein) 
thiol in tissues (6,9,10). Glutathione, synthesised by most mammalian cells but 
mainly in the liver (9,11), is an active free-radical-scavenging compound found 
in virtually all animal cells (6,9,11). In comparison with a number of other tis-
sues the liver has a particularly high content of glutathione (9). A relatively high 
concentration of glutathione is also detected in the intestinal epithelium (12). 
Here glutathione has been shown to play an important role in the protection of 
the intestinal mucosa against oxidative stress both in vitro (13,14) and in vivo 
(12,15). For example, glutathione depletion in newborn rats leads to increased 
nitrosative stress during necrotising enterocolitis (15). Furthermore, Salmonella 
infection decreases enterocyte glutathione levels in mouse ileal loops and this 
reduction increases the susceptibility of epithelial cells to oxidative damage (16). 
This oxidative damage in its turn might impair barrier function. As well as the 
gut microbiota (17), mucus (18) and the immune system (19,20), intestinal glu-
tathione is suggested to be important for intestinal barrier function (15). Many 
studies on the role of glutathione in prevention of oxidative damage in the intes-
tinal mucosa have been performed (13-15). However, actual in vivo proof that 
intestinal glutathione is important for gut barrier function is lacking. We there-
fore investigated the role of glutathione in intestinal barrier function and infec-
tion-induced mucosal inflammation. 
Buthionine sulfoximine (BSO) is a specific inhibitor of γ-glutamyl-
cysteine synthetase (gamma-GCS), which is the rate-limiting enzyme of gluta-
thione synthesis (21). This chemical causes glutathione-deficiency in animals 
(22) and enables us to investigate the role of this tripeptide in animal models. 
Besides glutathione depletion, stimulation of synthesis is interesting for that 
purpose as well. Cysteine is known to stimulate glutathione synthesis (23), and 
cysteine availability is often the limiting factor for intracellular glutathione 
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synthesis (24). For example, intraperitoneally administered N-acetylcysteine was 
shown to increase hepatic and intestinal glutathione levels in bile-duct ligated 
rats (25). Therefore, dietary supplementation with cysteine, or the more stable 
variant cystine, can potentially maintain or increase hepatic and intestinal gluta-
thione levels during oxidative stress.
Our aim was to determine whether depletion of glutathione by BSO 
affects gut barrier function and increases susceptibility of rats to Salmonella 
infection and the associated inflammation. In addition, the effect of dietary cys-
tine on glutathione levels in the intestinal mucosa and consequences for the 
resistance to infection were investigated.
METHODS
Diets, infection and dissection of the rats
The animal experiments were approved by the animal welfare committee of 
Wageningen University (Wageningen, the Netherlands). Specific-pathogen-free 
male Wistar rats (WU, Harlan, Horst, the Netherlands), 8 weeks old at the start 
of the dietary intervention, were housed individually in metabolic cages. Rooms 
were temperature (20-21°C) and humidity-controlled (50-60%) with a 12:12-
hour light/dark cycle. Rats were fed purified diets containing per kg: 200 g acid 
casein, 326 g cornstarch, 174 g glucose, 160 g palm oil, 40 g corn oil, 50 g cellu-
lose and vitamin and mineral mix (without calcium) according to AIN-93 (26). 
To mimic the composition of a Western human diet, the prepared diets were rel-
atively low in calcium (30 mmol/kg) and high in fat content (200 g/kg) in com-
parison with recommendations for rodent diets by AIN-93. This control diet was 
supplemented with DL-buthionine (S,R)-sulfoximine (BSO) or L-cystine (both 
purchased from Sigma-Aldrich, St. Louis, Missouri, USA), at the expense of glu-
cose, to a final concentration of 7.5 mmol/kg and 12.3 mmol/kg, respectively. 
Nitrogen correction of the diets was considered unnecessary, since the contribu-
tion of cystine was marginal (0.035%). In addition, the inert intestinal permea-
bility marker CrEDTA was added to the diets (27,28). Preparation and purity 
control of CrEDTA was performed as described (29-31). The CrEDTA solution 
was lyophilised in a manifold freeze dryer (FD5515; Ilshin Laboratory Co Ltd, 
Seoul, South Korea) and the dry material obtained was added to the diets to a 
final concentration of 2 g/kg.
 Food and demineralised drinking water were supplied ad libitum. Body 
weight and food intake were recorded twice a week before infection and daily after 
infection. One group was fed the control diet and another group was fed the cys-
tine-supplemented diet (n=14 per diet). The third group (n=14) was fed the con-
trol diet for one week, followed by the BSO diet for the remaining study period.
Animals were acclimatised to housing and dietary conditions for 21 
days, after which 8 animals per diet group were orally infected with 1 ml of saline 
containing 1.109 CFU of Salmonella enteritidis (clinical isolate, phage type 4; 
strain B1214 NIZO food research, Ede, the Netherlands) as described elsewhere 
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(32). The other 6 animals per diet group were not infected and received 1 ml 
saline orally.
In previous Salmonella infection studies in rats we have found that levels 
of ileal mucosal glutathione change with time (unpublished). After an initial 
decrease, total glutathione levels start to recover at day 4 post infection. Further-
more, for monitoring functional infection outcomes like Salmonella colonization, 
translocation and infection-induced permeability changes, follow-up of infected 
rats for at least 3 to 4 days is needed. Therefore section was performed at day 4 after 
infection (or sham treatment). Rats were randomly selected and killed by carbon 
dioxide inhalation. During the dissection, the distal 12 cm of the ileum was excised 
and cut open longitudinally. After flushing rapidly with saline, the mucosa was 
scraped off with a spatula and immediately frozen in liquid nitrogen for protein 
analyses. Furthermore, the spleen and liver were aseptically excised and after 
homogenisation in sterile saline directly used for Salmonella quantification, as 
described elsewhere (33). Another part of the liver was immediately frozen in liq-
uid nitrogen for further preparation and analyses as described below.
Fresh faecal samples were collected to quantify Salmonella colonization 
prior to infection and 1 and 3 days post infection, as described elsewhere (34). In 
addition, 24 h faeces (pooled per animal in both the pre-infection and post-infec-
tion period) and urines were collected from 2 days before infection until 4 days 
after oral Salmonella administration. All faeces and urine samples were stored at 
-20°C until further analysis. Oxytetracycline (Sigma-Aldrich) was added to the 
urine collection vessels of the metabolic cages to prevent bacterial deterioration.
Salmonella colonization and diarrhoea
Faecal Salmonella was determined in fresh faecal samples collected with time as 
described elsewhere (34). Total 24 h faeces were lyophilized in a manifold freeze 
dryer (FD5515; Ilshin Laboratory Co Ltd). Faecal water was prepared as 
described previously and osmolarity was measured (Osmomat 030-D, Gonotec, 
Berlin, Germany) to calculate the percentage wet weight (35). Direct determina-
tion of faecal wet weight by lyophilisation was considered inappropriate because 
this underestimates relative faecal wet weight due to evaporation of water from 
the faecal pellets in the collection vessels of the metabolic cages.
Intestinal permeability analysis
CrEDTA excreted in 24 h urine samples was determined by inductively coupled 
plasma atomic emission spectroscopy (ICP-AES; Varian, Mulgrave, Australia) as 
described elsewhere (30). Urinary CrEDTA output was expressed as percentage 
of dietary intake. Infection-induced urinary excretion of CrEDTA was corrected 
for baseline (pre-infection) levels. Urine was tested negative for faecal contami-
nation by checking the absorption spectrum 400-600 nm for bile pigments. 
These pigments are present in faeces but absent in urine. 
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Tissue sample preparation
Frozen liver tissue and ileal mucosa were pulverised under liquid nitrogen. Fro-
zen pulverised tissue was suspended in a 0.2 M sucrose buffer of pH 7.4 contain-
ing 20 mM trishydroxymethylaminomethane (Tris), 1 mM dithiothreitol (DTT; 
Sigma Aldrich) and Complete Protease Inhibitor Cocktail (Roche Diagnostics, 
Basel, Switzerland) and sonicated on ice for 20-30 s at level 2-3 (Sonicator 
XL2020, Heat Systems, Farmingdale, NY, USA). The protein concentration of the 
samples was determined using biocinchoninic acid (BC) Assay (Omnilabo, 
Veenendaal, the Netherlands).
Total glutathione and cysteine analyses
Total glutathione in liver and ileum was measured using a slightly modified assay 
described by Mansoor et al. (36). This method determines the total of reduced, 
oxidized, and protein-bound forms of glutathione by HPLC without discrimina-
tion of the individual forms. As a result, total glutathione levels are presented 
and indicated in the text by ‘glutathione’. Compared to the original method, 
twice the sample volumes and reagents were used. Briefly, samples of 25 µl were 
injected into a 150 x 4.6 mm, 3 µm PLRP-S column, equipped with a PLRP-S 
guard column (Polymer Laboratories, Amherst, MA, USA). Flow rate was 1 ml/
min at 30º C with elution solvent A (0.1% trifluoric acid (TFA), 5% acetonitrile) 
and solvent B (0.1% TFA, 80% acetonitrile), both diluted with distilled water. 
Chemicals were purchased from Sigma-Aldrich. The elution profile was as fol-
lows: 0-20 min, 0% B; 20-25 min, 16% B; 25-30min 50% B, with retention time of 
bimane derivatives of glutathione of 23 min. A Spectra Systems FL2000 fluorom-
eter (Spectra Physics, Mountain View, CA, USA) was used for detection, with 
excitation and emission at 394 and 480 nm, respectively. Plotting and integration 
of peaks were performed by Chromeleon software 6.6 (Dionex, Sunnyvale, CA, 
USA). Total glutathione results are expressed as µmol/g tissue protein.
In the samples described above cysteine, identified as a separated peak 
in chromatograms, was determined identically and simultaneously with the glu-
tathione analysis.
Mucosal antioxidant capacity
Mucosal antioxidant capacity of non-thiols, thus excluding glutathione, was deter-
mined using the ferric reducing ability method as described for plasma (37). 
Briefly, to 33 µl ileum sample 1 ml of ferric reducing ability reagent was added (37). 
Antioxidant capacity is expressed as nmol Fe2+ formed per mg protein.
Mucosal inflammation and oxidative damage
A mouse MPO ELISA test kit (Hycult biotechnology, Uden, the Netherlands), 
which is cross-reactive with rat MPO, was used to determine the concentration 
of MPO in mucosal scrapings. IL-1β levels were determined using an ELISA kit 
(Biosource, Nivilles, Belgium).
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To evaluate lipid peroxidation, TBARS in the mucosal samples were 
determined according to Ohkawa (38), using 100 µl of undiluted sample (35). 
Control experiments with reference samples, known to have TBARS, were anal-
ysed positive. In addition, spiking of ileal mucosal samples of the present study 
with the reference material showed good recovery of TBARS.
Ileal protein carbonyls, as marker of protein oxidation, were measured 
by an ELISA according to the method of Buss et al. (39). Briefly, standards and 
samples were diluted in phosphate-buffered saline to a protein concentration of 
4 mg/ml. Carbonyls were derivatised with 2,4-dinitrophenyl hydrazine (Sigma-
Aldrich) and coated on an ELISA plate (Nunc-Immuno plate maxisorp, Nunc, 
Roskilde, Denmark). After probing with biotinylated anti-2,4-dinitrophenyl 
hydrazine antibody (Molecular Probes Inc, Eugene, OR, USA), streptavidin-bio-
tinylated horseradish peroxidase (Amersham Biosciences, Piscataway, NJ, USA) 
was incubated in the wells. Staining was performed with o-phenylenediamine 
(Sigma-Aldrich). Absorbance was read at 490 nm in a ThermoMax microplate 
reader (Molecular Devices Corp, Sunnyvale, CA, USA).
S. enteritidis lipopolysaccharide experiment
To study the effect of dietary cystine on the capacity of rats to generate NO in 
response to systemic bacterial stimuli, rats (n=8 per group) fed the control or 
cystine diet (dietary acclimatisation of 14 days) were intraperitoneally injected 
with 0.5 mg/kg LPS, as described elsewhere (33). The LPS used was derived from 
S. enterica Serovar enteritidis, which is identical to the strain used in the oral 
infection study. Animals were monitored until 3 days after challenge and 24 h 
urines were collected. The NO response was quantified by measuring urinary 
NOx (sum of nitrate and nitrite) excretion by using a colorimetric enzymatic kit 
(Roche Diagnostics), as described elsewhere (40).
Statistical analysis
All data are expressed as means ± SE. Data were tested for normality by the Kol-
mogorov-Smirnov test. If normally distributed, differences between the control 
and dietary intervention groups (cystine or BSO) were tested for significance 
using one-way ANOVA, followed by Bonferroni’s multiple-comparison test. Our 
aim was to investigate dietary effects in the non-infection and the infection 
period separately. Therefore, differences between non-infected and infected 
groups were not tested. When data of groups showed unequal variances, the 
Kruskal-Wallis test was used, followed by Dunn’s post test for multiple compari-
sons. Statistical significance was set at p<0.05.
RESULTS
Animals and food intake
At the start of the study, mean body weight of the animals was 243 g. Average 
food intake before infection was 19 g/d in the control and cystine group, and 17 
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g/d in the BSO group (p<0.05). Post infection, food intake was 16 g/d in all 
groups. Mean body weight gain prior to infection was 5 g/d. After infection, 
average body weight gain was 3 g/d in all groups. 
 
BSO decreases the glutathione content in liver and ileum mucosa
BSO decreased hepatic glutathione by 48% in the infected animals in compari-
son with the control group (Figure 1A; p<0.05). Cystine supplementation did 
not significantly affect liver glutathione of non-infected rats. Post-infection lev-
els were 21% higher in cystine-fed animals, although this increase did not reach 
statistical significance. BSO decreased ileal mucosal glutathione by ≥98% in 
non-infected and infected rats (Figure 1B; p<0.05). Dietary cystine did not 
increase ileal glutathione in non-infected or infected rats. 
BSO is a competitive inhibitor of gamma-GCS and could possibly cause 
an accumulation of cysteine in the ileum mucosa. However, mucosal cysteine 
levels were decreased in BSO treated animals (data not shown).
Diarrhoea, faecal excretion and translocation of Salmonella
Glutathione depletion increased relative faecal wet weight in non-infected ani-
mals whereas cystine had no effect (Figure 2A). After infection, there was no 
difference in diarrhoea between the control and BSO group or between the con-
trol and cystine group. 
Faecal Salmonella excretion was similar in all diet groups on the first 
and third day after Salmonella infection (107 and 106 colony-forming units 
(CFU)/g faeces, respectively), indicating identical intestinal colonization levels 
in all groups. Furthermore, depletion of mucosal glutathione did not affect 
Figure 1. Total glutathione in liver and ileum mucosa. Total glutathione in liver (A) and 
ileum mucosa (B) of rats fed the control diet (white bars) or the same diet supplemented 
with buthionine sulfoximine (BSO; grey bars) or cystine (black bars). Rats were orally 
infected with 1.109 colony-forming units S. enteritidis (n=8 per diet) or received saline only 
(non-infected animals; n=6 per diet). Results are expressed as means ± SE. An asterisk indi-
cates a significant difference from the control diet group (either non-infected or infected 
rats; p<0.05).
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Salmonella translocation to liver and spleen (Figure 2B). In contrast, cystine 
decreased the number of Salmonella in both tissues (Figure 2B), pointing to a 
protective effect of cystine on Salmonella translocation to extra-intestinal organs.
Mucosal antioxidant capacity
In response to a serious decrease of glutathione, the body could compensate by 
increasing other (non-thiol) antioxidants. Therefore we investigated the total 
mucosal antioxidant capacity of non-thiols by determining the ferric reducing 
ability of mucosal tissue. Neither BSO nor cystine changed the mucosal non-
thiol antioxidant capacity before infection. The same results were found in 
infected rats (Figure 3).
Mucosal inflammation and oxidative damage
Despite identical colonization levels, the glutathione-depleted rats, presumably 
with lower antioxidant capacity, had increased ileal mucosal IL-1β levels (Fig-
ure 4A). This coincided with a more intensive inflammatory response in this 
group as measured by ileal MPO (Figure 4B). However, this did not increase 
oxidative-stress related mucosal damage like protein carbonyls (Figure 4C) 
and mucosal lipid peroxidation, measured by thiobarbituric acid reactive sub-
stances (TBARS; results not shown). Despite protective effects of cystine on 
Salmonella translocation and maintenance of glutathione levels, intestinal 
inflammation and oxidative damage markers were not decreased in this group 
(Figure 4).
Figure 2. Relative faecal wet weight and Salmonella translocation. Relative faecal wet 
weight (A) before (n=6 per diet group) and after oral S. enteritidis infection (n=8 per diet 
group) of rats fed the control diet (white bars) or the same diet supplemented with BSO 
(grey bars) or cystine (black bars). Translocation of S. enteritidis as determined by viable 
pathogen counts (B) in liver and spleen. Results are expressed as means ± SE. CFU means 
colony-forming units. An asterisk indicates a significant difference from the control diet 
group (either non-infected or infected rats; p<0.05). 
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Intestinal permeability
In general, the Salmonella infection increased paracellular intestinal permea-
bility with time (Figure 5). Despite increased mucosal inflammation in BSO 
treated animals, intestinal permeability was not aggravated. In contrast, the 
results suggest a decrease in comparison with the control group (Figure 5). 
Moreover, cystine partially restored infection-induced intestinal permeability 
to basal (pre-infection) levels, suggesting a beneficial effect of cystine on gut 
Figure 4. Inflammation and oxidative damage in the ileum mucosa. BSO increased 
inflammation in the ileum mucosa of S. enteritidis infected rats. S. enteritidis infected (n=8 
per diet) and non-infected (n=6 per diet) rats were fed the control diet (white bars) or the 
same diet supplemented with BSO (grey bars) or cystine (black bars). Mucosal levels of 
the pro-inflammatory cytokine interleukin-1β (IL-1β) and myeloperoxidase (MPO) are 
shown in panels A and B, respectively. Recovery experiments with purified IL-1β and MPO, 
added to the mucosal samples, were included in each assay and confirmed the absence of 
inhibiting factors in the ileal samples. Oxidative damage to ileal proteins was determined by 
measurement of protein carbonyls (C). All results are expressed as means ± SE. An aster-
isk indicates a significant difference from the control diet group (either non-infected or 
infected rats; p<0.05).
Figure 3. Ferric reducing ability of non-thiols in the ileum mucosa. Ferric reducing abil-
ity of non-thiols in the ileum mucosa of non-infected rats (n=6 per diet) and S. enteritidis 
infected rats (n=8 per diet) fed the control diet (white bars) or the same diet supplemented 
with BSO (grey bars) or cystine (black bars). All results are expressed as means ± SE. No 
significant differences were detected between the control diet group and the BSO or cys-
tine-supplemented group.
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barrier function. Neither BSO nor cystine supplementation affected intestinal 
permeability in non-infected rats (data not shown).
Nitric oxide response is not affected by the cystine diet
Since diet composition can affect the inducible nitric oxide (NO) production 
capacity in response to microbial stimuli, the effect of dietary cystine was inves-
tigated in an LPS experiment. Urinary NOx (sum of nitrate and nitrite) excretion 
in response to intraperitoneally administered lipopolysaccharide (LPS) was 
identical in the control and cystine group (data not shown), demonstrating equal 
host capacity to produce NO.
DISCUSSION
The present study shows that depletion of glutathione during Salmonella infection 
results in increased mucosal inflammation. However, as Salmonella translocation 
was not affected by BSO treatment, glutathione depletion obviously does not affect 
mucosal barrier function. Also, urinary excretion of the paracellular permeability 
marker chromium ethylenediamine-tetraacetic acid (CrEDTA) was not increased 
in comparison with infected rats fed the control diet. On the other hand, cystine 
supplementation resulted in improved barrier function and decreased Salmonella 
counts in extra-intestinal organs. However, the subsequent ileal inflammation was 
not reduced. Since cystine did not significantly increase glutathione and inflam-
mation was not reduced the results suggest that the protective mechanism of cys-
tine supplementation is not related to mucosal glutathione levels. Most likely other 
host defences than glutathione are strengthened by cystine.
Figure 5. Infection-induced urinary excretion of dietary CrEDTA. Infection-induced uri-
nary excretion of dietary CrEDTA after oral S. enteritidis infection (n=8 per diet) in rats 
fed the control diet or the same diet supplemented with BSO or cystine. Results, expressed 
as means ± SE, were corrected for baseline (pre infection) permeability. Baseline CrEDTA 
output was identical in all groups. The asterisk indicates a significant difference from the 
control group (p<0.05).
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In line with other studies, oral administration of BSO, a selective inhibitor 
of glutathione synthesis, decreased hepatic glutathione levels (41,42). Nearly com-
plete depletion was observed in ileal mucosa of both infected and non-infected 
animals. A decrease of intestinal glutathione is shown during necrotising entero-
colitis in rats (15) and in mouse ileal loops exposed to Salmonella typhimurium 
(16). This decrease is suggested to contribute to pathogenesis of disease and subse-
quent failure of barrier integrity (15,16). Our results now show that depletion of 
glutathione does not necessarily lead to impaired intestinal barrier function. A 
study with mice indicated that glutathione-depletion by BSO caused mucosal 
damage in the jejunum and colon (43). However, a much higher dose of BSO was 
applied, increasing the risk of pharmacological side-effects of BSO in that study. 
The lower dose used in our study, nearly depleted intestinal mucosal glutathione 
but hardly affected body weight gain and did not result in histological mucosal 
damage in haematoxylin- and eosin-stained ileum sections (data not shown).
The oral Salmonella infection in our experiment had no or little effect on 
liver and ileal mucosal glutathione at 4 days post infection, indicating that the 
organ-specific capacity to synthesise glutathione was adequate or that infection-
induced oxidative stress was absent in normally fed rats (diet adequate in antioxi-
dants). In previous studies we (unpublished results) and others (15) detected a 
temporarily decrease of intestinal glutathione after an intestinal insult. So, intesti-
nal glutathione levels may differ depending on the time point studied, which may 
result in seemingly contrasting results. For example, in our in-vivo study, glutathi-
one was determined at 4 days after infection and levels were not (or no longer) 
decreased. However, a reduction in glutathione was reported in an ileal loop study 
at 18 hrs after Salmonella introduction (16). Furthermore, studies limited to spe-
cific cell types, for example enterocytes isolated from infected animals (16), may 
show different results from in vivo studies investigating complete mucosa. Specifi-
cally, during infection T lymphocytes and macrophages migrate into the intestinal 
mucosa and these cells are also able to synthesise glutathione and thus contribute 
to mucosal glutathione (23,44). In our study, oxidative damage in the form of 
intestinal protein carbonyls or TBARS was not detected when intestinal glutathi-
one was depleted (BSO treated rats). Oxidative damage induced by glutathione 
depletion has been shown in plasma lipids (45) and liver (DNA adducts) (41), 
however those studies did not investigate the intestine.
Supplementation of cystine maintained intestinal glutathione levels simi-
lar to the control diet group. Surprisingly, inflammation was not reduced despite a 
decrease in intestinal permeability and significant inhibition of Salmonella translo-
cation. Improvement of gut barrier function has also been described for intraperi-
toneally administered N-acetylcysteine in partially hepatectomised rats (46). The 
reduced viable Salmonella counts in liver and spleen of the cystine-fed rats in our 
study may have resulted from decreased Salmonella translocation from the gut or 
from enhanced killing of translocated pathogens by the innate immune system, 
e.g. by increased production of nitric oxide (NO) (47,48). N-acetylcysteine can 
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enhance this NO defence (49), but the effect of cystine was unknown. Our LPS 
experiment revealed that rats fed the control and cystine diet responded identically 
to an intraperitoneal LPS challenge, excluding differences in the NO-based capac-
ity of the host to kill bacterial invaders. Therefore, the lower Salmonella counts in 
liver and spleen observed here probably reflect reduced translocation of this patho-
gen from the gut lumen. 
Surprisingly, infection-induced intestinal permeability of BSO-treated 
animals seemed lower than that of the control group (Figure 5) but the effect was 
not significant. One could hypothesize that competitive inhibition of gamma-GCS 
may cause accumulation of cysteine in the mucosa, resulting in protective effects as 
seen on the cystine diet. However, mucosal cysteine levels were decreased in BSO 
treated animals. Furthermore, in contrast to the cystine fed rats, no protective 
effect against Salmonella translocation was observed in these animals. 
The mucosal barrier enhancing effect of cystine requires further investiga-
tion. Results need to be reproduced and the mechanism behind the protective 
effect should be explored. Cysteine can play a role in various host defences. For 
instance, trefoil peptides, which stabilise mucosal glycoproteins and protect the 
mucosa from various insults, e g bacterial toxins (50), contain several cysteine-rich 
domains (50,51). In addition, defensins, which are antimicrobial peptides secreted 
by human and rodent ileal Paneth cells, contain 6 conserved cysteines (52) and are 
important for intestinal resistance to Salmonella infection (53). Although, cysteine 
is not an essential amino acid and can be synthesised from methionine, it might be 
conditionally essential like suggested for glutamine (54,55).
In conclusion, intestinal depletion of glutathione is not as detrimental for 
maintenance of the gut barrier as often presumed. Neither paracellular intestinal 
permeability nor Salmonella translocation were promoted at very low mucosal glu-
tathione levels, despite increased infection-induced ileal inflammation. On the 
other hand, dietary cystine did not reduce infection-associated inflammation but 
decreased intestinal permeability and Salmonella translocation to extra-intestinal 
organs by a mechanism unlikely related to glutathione. Follow-up studies are 
needed to elucidate the molecular mechanism(s) underlying the protective effect of 
cystine supplementation on gut barrier function and to address human relevance.
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ABSTRACT
Perturbation of the intestinal microbiota by antibiotics predisposes the host to 
foodborne pathogens like Salmonella. Effects of antibiotic treatment on intesti-
nal permeability during infection and the efficacy of dietary components to 
improve resistance to infection have not been studied. Therefore, we investigated 
the effect of clindamycin on intestinal barrier function in Salmonella-infected 
rats. We also studied the ability of dietary calcium and tannic acid to protect 
against infection and concomitant diarrhea and we assessed intestinal barrier 
function. Rats were fed a purified control diet including the permeability marker 
CrEDTA (2 g/kg), or the same diet supplemented with calcium (4.8 g/kg) or tan-
nic acid (3.75 g/kg). After adaptation, rats were orally treated with clindamycin 
for 4 d, followed by oral infection with Salmonella enteritidis. Two additional 
control groups were not treated with antibiotics and received either saline or Sal-
monella. Urine and feces were collected to quantify intestinal permeability, diar-
rhea, cytotoxicity of fecal water, and Salmonella excretion. In addition, 
Salmonella translocation was determined. Diarrhea, CrEDTA excretion, and 
cytotoxicity of fecal water were higher in the clindamycin-treated infected rats 
compared with the non-clindamycin treated infected control group. Intestinal 
barrier function was less in Salmonella-infected rats pretreated with antibiotics 
compared with non-clindamycin treated rats. Both calcium and tannic acid 
reduced infection-associated diarrhea and inhibited the adverse intestinal per-
meability changes, but did not decrease Salmonella colonization and transloca-
tion. Our results indicate that calcium protects against intestinal changes due to 
Salmonella infection by reducing luminal cytotoxicity whereas tannic acid offers 
protection by improving the mucosal resistance. 
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INTRODUCTION 
The use of antibiotics is ubiquitous in our present society. The use of broad-spec-
trum antibiotics like clindamycin disturbs the indigenous microbiota in the 
intestine. This perturbation of the intestinal microbiota predisposes the host to 
enteric pathogens such as Salmonella (1). Eradication or suppression of parts of 
the indigenous microbiota can decrease the colonization resistance of the host 
(2). For example, competition for mucosal adhesion sites (3) and growth sub-
strates (4) can decrease and thus facilitate intestinal colonization of bacterial 
pathogens. Invasive species, like certain types of Salmonella, are able to translo-
cate from the intestinal lumen to extra-intestinal organs (5,6), a phenomenon 
which is often accompanied by increased mucosal paracellular permeability and 
diarrhea (7). The magnitude of these latter events not only depends on the 
amount of pathogens present, but is also strongly determined by the intestinal 
defense status of the host (7). 
Diet may be a tool to strengthen this intestinal defense or resistance to 
infection and infectious diarrhea. We have shown earlier that dietary calcium 
enhances intestinal resistance to infectious disease and protects rats (8-11) and 
humans (11) against Salmonella and enterotoxigenic Escherichia coli (ETEC) 
associated disease. The protective effects of calcium are associated with an 
increase of lactobacilli in the microbiota (8,10). Whether this increase is causally 
related to the protective effect of calcium is not known yet, but can be studied by 
using antibiotics that lower indigenous lactobacilli. 
A group of dietary compounds with potential to inhibit intestinal infec-
tions are the polyphenols. For example, complex (hydrolysable) tannins, which 
are widespread in some vegetable foods, e.g. grapes, berries and wines produced 
from them (12), have antimicrobial effects against Gram-negative bacteria (13). 
The polyphenol tannic acid is a complex hydrolysable tannin. It is composed of 
six to nine gallic acid molecules esterified with glucose, and is used as a preserva-
tive by the food industry (14,15). 
In this study we investigated the effect of clindamycin on Salmonella 
infection, translocation and intestinal permeability using a rat model. Second, 
we examined whether dietary calcium is still able to protect against intestinal 
infection when the indigenous microbiota is temporarily crippled. Third, protec-
tive effects of tannic acid were investigated in the same model. 
METHODS
Experiment approval and rats 
The animal experiment was approved by the animal welfare committee of 
Wageningen University (Wageningen, the Netherlands). Specific pathogen-free 
male Wistar rats (WU, Harlan, Horst, the Netherlands), 8 wk old at the start of 
the dietary intervention, were housed individually in metabolic cages. The ani-
mal room was temperature (20-21°C) and humidity-controlled (50-60%) with a 
12:12-hour light/dark cycle.
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Diets, clindamycin treatment and infection
Rats were fed a purified control diet as described previously (7), containing, per 
kg, 200 g acid casein, 326 g cornstarch, 174 g glucose, 160 g palm oil, 40 g corn 
oil, 50 g cellulose, and vitamin and mineral mix according to AIN-93 (except for 
calcium) (16). To mimic the composition of a Western human diet the calcium 
concentration was lowered (to 1.2 g/kg) and the fat concentration increased (to 
200 g/kg) in comparison with the AIN-93 recommendations. The control diet 
was supplemented with either calcium phosphate (CaHPO4.2H2O) or tannic 
acid (both purchased from Sigma-Aldrich, St. Louis, Missouri, USA), at the 
expense of glucose. The final concentrations of calcium and tannic acid were 4.8 
g/kg and 3.75 g/kg, respectively. In addition, the inert intestinal permeability 
marker chromium ethylenediamine-tetraacetic acid (CrEDTA) was added to the 
diets (2 g/kg). Preparation, purity control and addition of lyophilized CrEDTA 
to the diets was performed as described previously (7). Rats consumed food and 
demineralized drinking water ad libitum. Body weight and food intake were 
recorded twice a week before clindamycin treatment. Body weight and food 
intake were measured daily after the clindamycin treatment to record possible 
day-to-day fluctuation in intake. Three groups were fed the control diet; one of 
these groups (n=5) served as a non-clindamycin treated, uninfected control (UC, 
uninfected rats fed the control diet). The second control-diet group (n=8) was 
not pre-treated with clindamycin and received Salmonella (IC, infected rats fed 
the control diet). The third control-diet group (n=8) was pre-treated with 
clindamycin and received Salmonella (AIC, antibiotic-treated infected rats fed 
the control diet). Two additional groups (n=8 per diet) that received clindamycin 
plus Salmonella were fed either the calcium (AICa, antibiotic-treated infected 
rats fed the calcium diet) or tannic acid (AITa, antibiotic-treated infected rats fed 
the tannic acid diet) supplemented diet (Table 1). 
Rats were acclimatized to housing and dietary conditions for 12 d, after 
which they received 15 mg/kg clindamycin or saline, the latter as sham treat-
ment, by oral gavage for four consecutive days depending on treatment group. 
After a day of rest, the rats were orally infected with 109 colony-forming units 
(CFU) of Salmonella enteritidis (clinical isolate, phage type 4; strain B1214 NIZO 
Table 1. Overview of different treatment groups of Wistar rats used in the study.
Group UC IC AIC AICa AITa
Diet Control Control Control Calcium Tannic acid
Antibiotic - - + + +
Infection - + + + +
n 5 8 8 8 8
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food research, Ede, the Netherlands) suspended in 1 mL saline as described else-
where (10) or received 1 mL saline only.
Collection of biological samples and bacterial quantification
On d 7 after oral infection or sham treatment, rats were randomly selected and 
killed by carbon dioxide inhalation. Blood was obtained by orbital puncture for 
the preparation of serum. Mesenteric lymph nodes (MLN), spleen and liver were 
aseptically excised and after homogenization in sterile saline directly used for 
Salmonella quantification, as described elsewhere (17). 
Fresh fecal samples were collected to quantify Salmonella colonization 
pre- and at various days post-infection, as described elsewhere (10). The num-
bers of lactobacilli and enterobacteria were determined only in feces collected 
prior to infection both pre- and post-clindamycin treatment, as described else-
where (10), with the slight modification that Rogosa plates, to quantify lactoba-
cilli, were incubated at 37 °C in anaerobic jars (Anoxomat™-system, MART 
Microbiology, Drachten, The Netherlands) for 2 days. 
In addition, feces were collected for 24 h and pooled per rat in the fol-
lowing periods: post-clindamycin but pre-infection, and post-infection d 4-7. 
Urine was collected each 24 h from d 2 before clindamycin treatment until d 7 
after oral Salmonella administration. All feces and urine samples were stored at 
-20°C until further analysis. Oxytetracycline (Sigma-Aldrich) was added to the 
urine collection vessels of the metabolic cages to prevent bacterial deterioration. 
Salmonella translocation was quantified by measuring urinary NOx (sum of 
nitrate and nitrite) excretion by using a colorimetric enzymatic kit (Roche Diag-
nostics, Basel, Switzerland), as described and validated earlier (17,18). The area 
under the curve (AUC) for infection-induced urinary NOx excretion was calcu-
lated and corrected for baseline (pre-infection) levels.
Quantification of diarrhea and cytotoxicity of fecal water
Total 24 h feces were lyophilized in a manifold freeze-dryer (FD5515; Ilshin Lab-
oratory Co Ltd). Fecal water was prepared as described previously and osmolar-
ity was measured (Osmomat 030-D, Gonotec, Berlin, Germany) to calculate the 
percentage wet weight (19). Direct determination of relative fecal wet weight by 
lyophilization was considered inappropriate because it underestimates the true 
water content of feces due to evaporation of water from the fecal pellets in the 
collection vessels of the metabolic cages of the rats.
Cytotoxicity of fecal water was determined by using an erythrocyte assay 
as described previously (20). Results were calculated as described (20) and are 
expressed as AUC of % lysis from a 40 µL and 80 µL sample of each fecal water.
CrEDTA excretion in urine
CrEDTA excreted in 24 h urine samples was determined by inductively coupled 
plasma atomic emission spectroscopy (Varian, Mulgrave, Australia), as described 
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previously (7). The output was expressed as percentage of dietary intake to cor-
rect for day-to-day and inter-individual variability in intake of this marker.
Serum immunoglobulin M (IgM) to Salmonella and core endotoxin
Detection of IgM instead of IgG was preferred because sera were obtained at d 7 
post infection. In general, full development of a serum IgG response takes almost 
2 wk, whereas IgM already peaks at earlier time points, as these are the earliest 
antibodies in the humoral immune response (21). The determination of serum 
IgM to core endotoxin, present in most Gram-negative microorganisms, was 
performed using the EndoCab ELISA kit (Hycult biotechnology b.v., Uden, The 
Netherlands) according to the manufacturer’s protocol. The IgM tracer was 
replaced by 1:1000 diluted horseradish peroxidase (HRP) conjugated mouse 
anti-rat IgM (Invitrogen, Carlsbad, USA).
To investigate serum IgM specific to Salmonella a maxisorp 96 well plate 
(Nunc, Roskilde, Denmark) was coated with 135 μL of a heat-killed S. enteriditis 
suspension. This suspension originally contained 1010 CFU/L S. enteritidis, iden-
tical to the strain used in the infection study, in PBS (pH 7.4), which had been 
incubated at 60°C for 90 min. After incubating the plates for 20 h at 4°C the wells 
were blocked with 4% Protifar plus (Nutricia, Cuijk, The Netherlands) in PBS for 
1 h. Plates were incubated with 100 µL of diluted serum for 2 h and with 100 µL 
HRP-Mouse Anti-Rat IgM (Invitrogen, Carlsbad, USA) for 1.5 h at room tem-
perature. Between all incubations the plates were washed thoroughly with PBS-
0.05% Tween-20. Finally, 100 µL of a reaction mixture containing hydrogen 
peroxide and o-phenylenediamine was added. The reaction was discontinued 
after 20 min by adding 100 µL 1 mol/L H2SO4 and the absorbance was read at 
490 nm on an automated ELISA plate reader (Dynatech MR7000; Trade Tek, 
Rotterdam, The Netherlands). Negative controls showed that the HRP-Mouse 
Anti-Rat IgM did not bind to wells coated with the blocking-solution only.
Statistical analysis
All data are expressed as means ± SEM and statistics were performed using 
Graphpad Prism 5 software (GraphPad Software, Inc. La Jolla, CA, USA). Our 
aim was to investigate 1) the effect of clindamycin on infection 2) the dietary 
effects in clindamycin pre-treated infected rats. Therefore, the pre-defined com-
parisons of interest were: UC and IC versus AIC, and AICa and AITa versus AIC. 
In addition, the effect of clindamycin on the fecal microbiota in rats on the dif-
ferent diets was investigated prior to infection.
Data were tested for normality by Kolmogorov-Smirnov and Shapiro-
Wilk tests. If normally distributed, differences were tested for significance using 
one-way ANOVA, and when needed followed by Dunett’s test for comparisons to 
the AIC group. Data with unequal variances were tested by using the Kruskal-
Wallis test, and when appropriate, followed by Dunn’s post hoc test for compari-
sons to the AIC group. Within group comparison of the microbiota data before 
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and after clindamycin treatment was tested by a paired t-test or Wilcoxon 
matched paired test for data with equal and unequal variances, respectively. Sal-
monella output in feces was determined at multiple time points and therefore 
these data were analyzed by repeated-measures two-way ANOVA (mixed-
model) followed by Bonferroni post testing for comparisons to the AIC group. 
Differences were considered statistically significant when P<0.05.
RESULTS
Growth and food intake
At the start of the study, body weight of the rats was 279±1.3 g. Food intake prior 
to clindamycin treatment was 20±0.3 g/d in all groups (data not shown). Daily 
food intake post-infection or sham treatment was higher in the IC and UC 
groups (17±0.3 g/d) than in the AIC group (14±0.3 g/d; P<0.05). Daily food 
intake did not differ from the AIC group in the AICa, and AITa groups (data not 
shown).
Prior to infection, body weight gain was 4±0.1 g/d in all groups. Post-
infection, body weight gain in all clindamycin-treated groups was 1±0.3 g/d 
whereas non-clindamycin-treated rats gained more weight (3±0.2 g/d; P<0.05). 
Body weight gain did not differ from the AIC group in either the AICa or the 
AITa group (data not shown).
Lactobacilli and enterobacteria in feces. 
The effects of clindamycin and the diets on the intestinal microbiota were deter-
mined prior to infection. In line with our earlier studies (10), fecal lactobacilli 
Table 2. Effect of dietary calcium, tannic acid and clindamycin on viable lactobacilli and
enterobacteria in the indigenous microbiota of rats before and after clindamycin treatment
and prior to infection1
Before After
Lactobacilli Enterobacteria Lactobacilli Enterobacteria
Group log CFU/g feces
AIC 7.40 ± 0.13 8.58 ± 0.28 4.28 ± 0.47# 9.15 ± 0.05
AICa 8.05 ± 0.09* 6.82 ± 0.15* 5.51 ± 0.28*# 9.12 ± 0.16#
AITa 7.79 ± 0.16 7.67 ± 0.27* 4.63 ± 0.28# 9.38 ± 0.15#
1 Values are means ± SEM, n=8.
*Different from AIC, P<0.05.
#Different from the before-clindamycin period, P<0.05.
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were higher and enterobacteria were lower in the AICa group than in the AIC 
group (Table 2; P<0.05). The enterobacteria were also lower in the AITa group 
than in the AIC group prior to clindamycin treatment (Table 2; P<0.05). 
Clindamycin drastically reduced the number of lactobacilli in all groups 
(Table 2; P<0.05) whereas enterobacteria increased in AICa and AITa groups 
compared with pre-clindamycin levels, resulting in levels that were identical to 
the AIC group. This showed that dietary effects on the gut microbiota were abol-
ished after clindamycin treatment, except for slightly more lactobacilli in the 
AICa group compared with the AIC group (Table 2; P<0.05). 
Salmonella colonization
Clindamycin treatment clearly decreased colonization resistance of the intestine, 
as fecal Salmonella excretion was 100-fold higher in the AIC group than in the 
IC group (Fig 1; P<0.05). Fecal Salmonella excretion was higher in the AIC com-
pared to the IC group at each day after infection. Colonization levels were not 
lower in the AICa and AITa groups compared with the AIC group. At d 3 the 
AITa group was higher than the AIC group (Fig 1; P<0.05). 
Salmonella translocation
Salmonella translocation to MLN, liver and spleen was lower in the IC group 
than in the AIC group (Table 3; P<0.05) and neither the AICa group nor the 
AITa group was different from the AIC group. Results of Salmonella culture of 
extra-intestinal organs were confirmed by analysis of urinary NOx excretion. 
Figure 1. Fecal S. enteritidis excretion in orally infected rats pre-treated with clindamycin. 
Values are means ± SEM, n=8. All error bars are shown, however, some error bars are smaller 
than figure symbols and therefore not visible. *Different from AIC, P<0.05.
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The AUC for infection induced urinary NOx was higher in the AIC group than 
in the UC and IC groups (Table 3; P<0.05). The levels in the AICa and AITa 
groups did not differ from the AIC group. Urinary NOx did not differ among 
the 5 groups before or after clindamycin treatment (data not shown), indicat-
ing that neither the diets nor a drastic change in the microbiota by clindamy-
cin treatment affected NOx excretion.
Diarrhea
Fecal relative wet weight was determined to quantify possible treatment effects 
on diarrhea. Clindamycin did not significantly affect fecal wet weight in the 
period prior to infection (data not shown). In contrast, fecal wet weight was 
greater in the AIC group than the IC group (Table 4; P<0.05). Infection-
induced diarrhea was less in the AICa and AITa groups than the AIC group 
(Table 4). This indicated that despite similar Salmonella-colonization and 
translocation levels, the normal functioning of the surface epithelium was bet-
ter maintained in the rats fed the calcium or tannic acid diet. Cytotoxicity of 
fecal water, which can affect the surface epithelium, was significantly higher in 
the AIC group than in the UC and IC groups (Table 4; P<0.05). This cytotoxic-
ity in the AITa group did not differ from the AIC group, but was much lower in 
the AICa group compared with the AIC group (Table 4; P<0.05). 
Table 3. Effect of dietary calcium, tannic acid or antibiotic on infection-induced urinary NOx excretion
and viable Salmonella counts in extra-intestinal organs in rats1
Salmonella Urinary NOx
MLN Spleen Liver AUC3
Group log CFU/g tissue µmol*7d
UC nd2 nd nd 0 ± 2*
IC 4.66 ± 0.11* 3.20 ± 0.10 2.13 ± 0.12* 61 ± 11*
AIC 5.01 ± 0.09 3.28 ± 0.14 3.23 ± 0.19 350 ± 36
AICa 5.05 ± 0.13 3.37 ± 0.13 2.85 ± 0.15 300 ± 34
AITa 4.97 ± 0.11 3.39 ± 0.11 3.00 ± 0.16 295 ± 35
1Values are means ± SEM, n=8 except UC n=5.
*Different from AIC, P<0.05.
2Not determined.
3Data were corrected for baseline values.
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Intestinal permeability
The barrier function of the epithelial monolayer was investigated by measuring 
urinary recovery of oral CrEDTA, which is a marker of paracellular permeability 
in gut epithelium (7). CrEDTA recovery almost doubled in the AIC group com-
pared with the UC and IC group (Table 4). However, this permeability was sig-
nificantly lower in the AICa and AITa groups compared with the AIC group 
(Table 4; P<0.05). 
Whether differences in intestinal permeability affected the leakage of nox-
ious luminal compounds was studied by measuring the antibody response to core 
endotoxin. The IgM response to core endotoxin was significantly higher in the AIC 
group compared to the IC group (Table 4; P<0.05). Both AICa and AITa groups 
had less of an IgM response compared with the AIC group (P<0.05). The difference 
in these IgM levels could be caused by modulation of the immune response by cal-
cium and tannic acid. Therefore, we also measured serum levels of IgM directed 
against Salmonella. This IgM response did not differ significantly among the AICa 
and AITa groups compared with the AIC group (data not shown), a result in line 
with the comparable translocation levels of this bacterium. Thus, these results 
indicated that the effects of calcium and tannic acid on core endotoxin IgM levels 
(Table 4) were not due to a generic modulation of the immune response.
DISCUSSION
This study corroborates earlier findings that antibiotic treatment predisposes the 
host to Salmonella infection (1,2). We now show that this phenomenon is accom-
panied by diarrhea, increased intestinal permeability and an increased IgM 
response to core endotoxin in serum. These symptoms are associated with a 
major increase in the cytotoxicity of fecal water, indicating increased irritating 
effects of the luminal content on the surface epithelium. 
Table 4. Effect of dietary calcium, tannic acid or antibiotic on fecal wet weight, luminal cytotoxicity, urinary CrEDTA excretion,
and the serum IgM response to core endotoxin in rats1
Group
Relative fecal wet weight
g/100 g feces
Cytotoxicity
% lysis
Urinary CrEDTA
% of intake
IgM to core endotoxin
A450
UC 68.5±2.2* 22.2±4.2* 3.6±0.3* 0.37±0.11*
IC 72.7±1.8* 27.6±2.9* 4.2±0.4* 0.33±0.04*
AIC 78.5±0.7 81.9±5.7 7.2±0.9 1.05±0.13
AICa 71.9±1.0* 40.7±7.8* 4.1±0.4* 0.60±0.10*
AITa 71.2±1.0* 93.9±3.5 3.8±0.4* 0.67±0.07*
1Values are means ± SEM, n=8 except UC n=5.
*Different from AIC, P<0.05.
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The present study indicates that Salmonella colonization levels were not 
lower in the AICa group than in the AIC group. This is in contrast to results in a 
conventional infection model, in which reduced colonization by dietary calcium 
is associated with an increase in fecal lactobacilli and a decrease in the number 
of enterobacteria (10). These effects of dietary calcium were present in the AICa 
group compared with the AIC group prior to clindamycin treatment. After 
clindamycin treatment these presumed beneficial changes of the intestinal 
microbiota were almost completely abrogated. Except for slightly more lactoba-
cilli in the AICa group, levels from all groups were identical to the AIC group. 
The suppression of enterobacteria in the AICa group compared with the AIC 
group was abolished by clindamycin, which can be explained by the fact that 
clindamycin favors growth of these bacteria (22). These results support our 
hypothesis (10) that calcium improves the resistance to Salmonella via stimula-
tion of the competitive microbiota. They falsify, however, our alternative hypoth-
esis (11) that protection is due to binding of Salmonella to amorphous calcium 
phosphate in the intestinal lumen. This proposed binding should not be affected 
by the clindamycin treatment and then colonization levels in the AICa group 
would have been lower than in the AIC group. 
Despite the absence of an inhibitory effect on Salmonella colonization 
and translocation, the infection-related diarrhea was less in the AICa group than 
in the AIC group. This indicated that, despite similar Salmonella colonization 
and translocation levels, the normal functioning of the surface epithelium was 
better maintained in AICa group than in the AIC group. The surface epithelium 
is highly affected by the cytotoxicity of fecal water (23). The present study pro-
vides evidence that clindamycin greatly increased the cytotoxicity of fecal water, 
as levels were much higher in the AIC group than in the IC group. Previous ani-
mal (9) and human (20,24) studies have shown that calcium precipitates irritat-
ing bile acids and other cytotoxic surfactants and thus reduces cytotoxicity of 
luminal contents, which prevents epitheliolysis and likely preserves intestinal 
barrier function. These human studies used a dietary calcium dosage within the 
same concentration range as in the present study. Therefore the proposed protec-
tive mechanism of calcium in rats is likely to be of relevance to humans.
Here we present the novel finding that dietary calcium preserved the 
barrier function in a sensitized Salmonella-infection model as leakage of 
CrEDTA from the intestinal lumen was lower in the AICa group compared with 
the AIC group. Increased paracellular permeability can facilitate translocation of 
noxious bacterial components such as (lipopolysaccharide) LPS, the outer-mem-
brane component of Gram-negative bacteria. Bacterial translocation of Salmo-
nella bacteria itself occurs via a transcellular route. This transport is facilitated by 
a mechanism which involves binding to epithelial cells by the type III secretory 
system (TTSS), which is present on the bacterium (25,26). This TTSS allows 
direct activation of components of the host cytoskeleton by dedicated bacterial 
effectors (5). Translocation of Salmonella is not affected by the difference in 
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cytotoxicity. Colonization levels were identical in the AIC and AICa groups, but 
cytotoxicity was clearly higher in the AIC group. Despite the difference in cyto-
toxicity translocation levels of Salmonella were identical in both groups. This 
shows that increased luminal cytotoxicity did not affect Salmonella translocation 
in our study. Furthermore, we investigated the antibody response directed to 
core endotoxin, which is the conserved part of bacterial LPS. Increased serum 
LPS is associated with increased paracellular permeability, for example induced 
by non-steroidal anti-inflammatory compounds (27,28). The IgM response to 
core endotoxin was significantly lower in the AICa group than in the AIC group, 
a result in line with intestinal permeability differences between these groups. 
This indicated that dietary calcium inhibited the leakage of LPS. We speculate 
that this is due to the observed inhibition of luminal cytotoxicity (Table 4). Thus 
calcium lowers the concentration of cytotoxic surfactants to which the mucosa is 
exposed and this may inhibit paracellular permeability, as discussed above. This 
protective effect of calcium on leakage of noxious luminal components is further 
supported by our recent finding that dietary calcium ameliorates colitis in a 
transgenic rat model of inflammatory bowel disease (29). 
On the other hand, the observed difference in the luminal calcium con-
centration due to our dietary intervention might affect gut barrier function 
more directly. Obviously, alterations in tight junction proteins as the primary 
regulators of intestinal permeability are expected. Recent studies indicate that 
calcium did not induce changes in gene expression of tight junction proteins 
(e.g. claudins, occludin, zona occludens, and myosin IXb) (29), although mor-
phological and structural alterations in tight junctions might exist. For exam-
ple, internalization into the cellular cytoplasm and phosphorylation of tight 
junction proteins are suggested to be important for leakiness of the mucosal 
barrier (30). Extracellular (luminal) calcium is crucial for maintenance of intes-
tinal tight junction function in cell studies. However, these effects seem to occur 
at free calcium concentrations up to 0.1 mmol/L (31), which is at least 50 times 
lower than the luminal calcium levels of rats fed the control or calcium diet 
(29). Therefore direct effects of luminal calcium on tight junction proteins in 
vivo seem less likely. 
Despite antimicrobial effects of (hydrolysable) tannins like tannic acid 
in vitro (13,15), neither intestinal Salmonella colonization nor translocation was 
lower in the AITa group than in the AIC group. This indicated that possible anti-
microbial effects of tannic acid were overruled by the clindamycin pretreatment, 
as shown by our culture data (Table 2 and Fig 1). Notwithstanding that, tannic 
acid, although chemically unrelated to calcium, had similar effects on diarrhea 
and epithelial permeability in the AITa group compared with the AIC group. As 
cytotoxicity of fecal water was not lower in the AITa group than in the AIC 
group, this polyphenol apparently maintained the proper functioning of the 
mucosa by increasing its resistance to luminal cytotoxicity. 
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At present, we can only speculate about the mechanism of this unex-
pected barrier-strengthening effect of tannic acid. As a first hypothesis we pro-
pose that protection is due to direct binding of tannic acid to the outer leaflet of 
the apical membrane of the surface epithelium, as is shown for ligated intestinal 
segments of rats (32). We conjecture that a surface layer of bound tannic acid 
polymers prevents the interaction of hydrophobic, and thus cytotoxic, surfac-
tants with the apical membrane. This is supported by the finding that topically 
applied tannic acid protects human skin epithelium against hydrophobic surfac-
tants such as lauryl sulfate (33). As an additional mechanism, we propose that 
gallic acid, taken up by enterocytes, may have additional protective effects. This 
phenolic monomer is released from the polymeric tannic acid by hydrolysis and 
fermentation by intestinal bacteria (34). A recent in-vitro study (35) shows that 
gallic acid, taken up by mast cells, lowers cytosolic calcium and inhibits stress 
signaling via protein kinases by preventing NF-kB activation. This is in line with 
another study (36), which shows that gallic acid inhibits several protein kinases 
by competitive inhibition of the ATP binding site. Decreasing cytosolic calcium 
and protein kinase activity lowers fluid and ion secretion, such as chloride secre-
tion regulated by the cystic fibrosis transmembrane conductance regulator 
(CFTR), by enterocytes (37). As activation of myosin light-chain kinase increases 
tight-junction permeability (38), we speculate that this can be counteracted by 
gallic acid. These two hypothetical mechanisms are difficult, if not impossible, to 
study in vivo. Therefore, we plan further in-vitro studies in which enterocytes, 
cultured in a Transwell system, are apically exposed to cytotoxic surfactants in 
the absence and presence of tannic acid or gallic acid. It should be noted that the 
suggested mechanism by changes in cytosolic calcium is not relevant to our cal-
cium intervention. A diet high in calcium does increase luminal calcium levels 
but it does not increase intracellular calcium levels. Systemic (serum) calcium 
concentrations are tightly regulated, and thus stable, and are not influenced by 
dietary calcium supplementation (39). Therefore, the effects of an increase of 
intracellular calcium differ from effects of increased luminal calcium.
It is important to extrapolate our dietary interventions to the human 
situation. The calcium content of the calcium-supplemented diet was 4.8 g/kg 
dry food, which corresponds to a daily calcium intake of 2.4 g in humans, assum-
ing that humans have a daily dry food intake of approximately 500 g. In general, 
human dietary calcium intake in the Western world is approximately 1.4 g daily 
(24). This indicates that the calcium-supplemented diet provided more than the 
general habitual dietary calcium intake. However, this is not an unrealistic intake 
when using calcium supplements. Similarly, it can be calculated that the used 
tannic acid diet of 3.75 g/kg dry food corresponds to a daily tannic acid intake of 
1.9 g in humans. The estimated daily tannic acid intake in humans (in the US) is 
1 g (40). Therefore, the applied tannic acid diet can also be extrapolated to 
humans using tannic acid supplements.
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In conclusion, clindamycin resulted in increased diarrhea, intestinal 
permeability and elevated IgM levels to core endotoxin in a Salmonella-infection 
model. These symptoms were associated with increased cytotoxicity of fecal 
water. Both calcium and tannic acid lessened these effects, but without decreas-
ing Salmonella colonization and translocation. Further investigations should 
focus on the mechanisms by which these dietary components maintain proper 
barrier function of the surface epithelium in this mucosal-stress model. Our 
results indicate that calcium protects by reducing luminal cytotoxicity and that 
tannic acid functions by improving the mucosal resistance to luminal cytotoxic-
ity. Verification of the human relevance of our findings in exploratory studies, 
e.g. in antibiotic-treated humans, are also needed.
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INTRODUCTION
Gastrointestinal infections are a major health problem and growing resistance of 
bacterial pathogens, including Salmonella species, to generally applied antibiotics 
is a concern (1-5). Therefore alternative methods to increase host resistance to 
intestinal infection are crucial for society in general and specifically those sub-
populations prone to intestinal infections and its complications, like young chil-
dren and the elderly. 
This thesis focuses on dietary modulation of intestinal Salmonella infec-
tion and its sequelae. The over-arching question of this thesis is “How can diet 
modulate intestinal Salmonella infection?”. The studies contributing to the thesis 
aimed to answer more specific questions like “Which host defence mechanisms 
are important during Salmonella infection?” and “What dietary components can 
modulate intestinal Salmonella infection?”. This final chapter summarizes and 
discusses the main findings of our research (schematically depicted in Fig 1 and 
summarized in Table 1) in the perspective of the current state-of-the-art knowl-
edge in this area. Attention is paid to extrapolating findings of the rat studies to 
the human situation. In addition, suggestions for future research are addressed.
Figure 1. Cascade of Salmonella infection in rats (stages shown in boxes). Pathophysi-
ological consequences known to occur or increase upon infection are depicted in random 
order and involved host defence mechanisms in italics. Grey arrows indicate specific host 
mechanisms or pathophysiological consequences that are directly or indirectly modulated 
by dietary components in regular infected (*) or antibiotic-pretreated infected (#) rats 
described in this thesis.
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The acute Salmonella infection model in rats, which is the basis of the 
investigations presented in this thesis, can be used as a model for gastro-intesti-
nal infections in general. Findings can be extrapolated depending on the affected 
host defence mechanisms and (patho)physiological consequences. When these 
defence mechanisms or sequelae are known to be relevant for other infec-
tions, such as e.g. diarrhoea during non-invasive enterotoxigenic Eschericia coli 
(ETEC) infection, dietary components might also affect resistance to these other 
pathogens.
MODELS TO INVESTIGATE DEFENCE MECHANISMS DURING 
SALMONELLA INFECTION
The necessity to identify and select appropriate models is a pivotal issue in inves-
tigating dietary modulation of intestinal infection and finding new dietary com-
ponents to improve intestinal defence. Traditionally, dietary interventions are 
initially performed in animal models. The Salmonella enteritidis infection model 
in rats, which was used in the studies presented in this thesis, is a relatively mild 
infection model associated with relatively low mucosal inflammation, infectious 
diarrhoea, and undetectable mucosal oxidative protein or lipid damage. More-
over, S. enteritidis is a highly relevant human bacterial pathogen based on its 
incidence rates (1). The mild infection symptoms make the model appropriate 
for elucidating the presumably subtle protective effects of dietary components. 
The putative action of nutritional modulation should be aligned with the specific 
characteristics of the model applied. For example, this model is not suitable for 
investigating antioxidative properties of dietary components because oxidative 
damage is not detectable.
The rats in all our studies were fed “Western” purified diets in order to 
mimic the human situation. It is known that diet affects the composition, gene 
abundance, and gene expression of the intestinal microbiota in rodents and a 
humanized diet results in a more human-like microbiota than a standard rodent 
diet (6). In this way we optimized our studies for extrapolating results to the 
human situation. It should be kept in mind, however, that S. enteritidis might 
behave differently in humans compared with rats. Especially the occurrence of 
microbial translocation is much more frequent and severe in animal models 
than in the healthy human. In humans, especially in infants and in immunocom-
promised adults, the infection can become systemic, which is associated with 
substantial morbidity and even mortality (7,8).
This thesis describes, in addition to the above mentioned regular Sal-
monella infection model in rats, other animal models that can be used in this 
field of research. These models concern compromised host defence mechanisms 
in order to reveal the role of a specific nutrient-gut interaction in the course 
of infection and enable us to: 1) identify what pathophysiological mechanisms 
could be improved during infection, 2) deliver proof-of-concept that a specific 
dietary compound has beneficial effects, and 3) identify specific host defence 
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mechanisms involved in protective effects of a specific dietary component, and 
therefore indicate if the component can be used to combat also other disorders 
than Salmonella infection. In addition, the compromised host defence mecha-
nism, or more sensitive, infection model can be used for development of new 
biomarkers that can be used in intervention research.
Clindamycin model
This host compromised model concerns a situation in which the intestinal 
microbiota is temporarily disturbed by clindamycin administration before the 
rats receive the oral Salmonella infection (Chapter 6). Such a disturbance 
increases susceptibility to infection and increases bacterial colonization, translo-
cation and mucosal inflammation (9,10). Our studies showed that the epithelial 
barrier was negatively affected by clindamycin administration prior to infection, 
and that luminal lipopolysaccharide (LPS), possibly microbiota-derived, leaked 
to the systemic circulation. This phenomenon was associated with increased 
luminal cytotoxicity, which showed that the epithelial lining was exposed to 
more noxious compounds. 
A future area of research is to establish human relevance, thus whether 
the results found in this animal model would have been similar in the human 
situation. This would include non-invasive studies, such as monitoring gut 
permeability by urinary CrEDTA excretion in humans that receive antibiotics. 
It is necessary to know whether this gut barrier impairment generally occurs 
during (oral) antibiotic treatments and whether non-infected individuals also 
show these symptoms. This could be investigated for example in relatively 
healthy humans that receive oral clindamycin for acne treatment. Investiga-
tion of serum LPS or antibodies against LPS can be used to determine whether 
LPS increases systemically upon antibiotic treatment, even in non-infected 
humans. Appropriate (dietary) measures against these symptoms then might 
reduce the antibiotic treatment related symptoms such as diarrhoea and may 
reduce secondary infection risks.
Glutathione depletion model
The glutathione depletion model (Chapter 5) is a second compromised host 
defence model presented in this thesis. Glutathione is an important compound 
in the natural antioxidant defence of the host. Our study showed that this 
defence mechanism was not substantially involved in colonization and translo-
cation of Salmonella. It did, however, play an important role in the magnitude of 
the immune response. Mucosal myeloperoxidase (MPO) levels were extremely 
high in glutathione-depleted rats during infection. This highly increased muco-
sal inflammatory activity was, however, not associated with paracellular perme-
ability defects. 
The role of glutathione in infection has been studied mainly in ex-vivo 
models. Salmonella infection, for example, decreases enterocyte glutathione 
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levels in mouse ileal loops and this reduction increases the susceptibility of epi-
thelial cells to oxidative damage (11). Studies in this thesis clearly showed that 
decreased glutathione levels in the intestinal mucosa of ‘healthy’ or infected rats 
fed an adequate diet did not result in oxidative damage and subsequent intestinal 
barrier defects. This underlines that one should be cautious to extrapolate con-
clusions from ex-vivo experiments to in vivo situations. Apparently, during rela-
tively mild intestinal inflammation, such as in the Salmonella infection model, 
glutathione is not such an important antioxidant as often presumed. The study 
described in Chapter 5 actually showed that the healthy gut has a good antioxi-
dant defence system, even when one player is eliminated. This may indicate the 
importance of studying antioxidative networking rather than that of specific 
anti-oxidative compounds. In situations in which the gut is chronically compro-
mised, as seen in inflammatory bowel disease (IBD), glutathione depletion could 
have different outcomes and might have detrimental effects. In fact, in animal 
models (Schepens et al. submitted for publication) and in humans (12,13) IBD 
has been associated with extremely low glutathione levels. IBD is a chronic disor-
der and the inflammatory process there cannot simply be compared with inflam-
mation in an acute infection model as used in the studies of this thesis. However, 
the hyper-immune response of the intestinal epithelium that was observed in the 
acute situation might resemble the situation that occurs chronically during IBD. 
Some studies have suggested that thiol-mediated redox regulation of intestinal 
lamina propria T lymphocytes is involved in the pathogenesis of IBD (14,15). 
Our study might support this hypothesis. 
Several questions remain to be answered. What is the pathophysiology 
of the increased inflammatory activity of the intestinal mucosa in glutathione-
depleted rats? What is the role of the above mentioned hyperresponse of propria 
T lymphocytes? Do these phenomena also occur in chronic intestinal disorders 
like IBD? Answers revealing these pathophysiologic mechanisms may offer solu-
tions to disorders associated with glutathione deficiency. 
BIOMARKERS 
There is great scientific and medical interest in identifying and validating new 
and non-invasive biomarkers of intestinal health and disease, such as gut infec-
tion and inflammation. Their implementation in clinical routine in humans is 
attractive because these markers yield valuable information on intestinal health 
status by non-invasive means, reducing the need for invasive endoscopy. There-
fore, and besides studying nutritional effects on host defence against intestinal 
infectious disease, there was keen interest in new potential biomarker identifica-
tion using the Salmonella infection model.
Expression of rat pancreatitis-associated protein 1 (PAP) and its murine 
homologue RegIIIβ protein increased in the ileal mucosa as well as faeces of 
infected rodents (Chapters 2 and 3). The amount of protein found in faeces 
well reflected the infection severity in rats (Chapter 2). Moreover, the human 
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homologue, designated PAP, was also detected in human faeces (Chapter 4) and 
its levels were higher after ETEC infection. Faecal PAP levels were also elevated 
in faeces from ulcerative colitis (UC) patients, but not in those from Crohn’s 
disease (CD) patients (Chapter 4). Human faecal PAP concentrations were 
not proportional to those of calprotectin, a commonly used faecal biomarker 
of intestinal inflammation. Our data suggested that faecal PAP levels possibly 
provide information about the defence status of intestinal epithelial cells, rather 
than being an inflammation marker. Mechanistic studies in mice revealed that 
RegIIIβ protein plays a protective role against infection with the Gram-negative 
S. enteritidis but not against the Gram-postive Listeria moncytogenes (Chapter 3). 
Its function was associated with binding of RegIIIβ to this Gram-negative bacte-
rium and thereby possibly inhibiting bacterial translocation. 
Faecal PAP might be a new non-invasive biomarker for intestinal epthe-
lial defence status in humans, and might have added value in combination with 
calprotectin measurement, which reflects the mucosal inflammatory response. 
Currently, we can not describe the specific properties of the biomarker. Increased 
faecal PAP concentrations in UC patients (Chapter 4), do not support PAP as a 
biomarker of intestinal infection.
This family of RegIII proteins exists in many species and the mice and 
human isoforms are very similar at the amino acid level, which indicates that this 
protein is well preserved during evolution. This underlines that RegIII function 
might be crucial for host survival. The murine isoform RegIIIγ and human PAP 
have antimicrobial activity against Gram-positive bacteria but not the Gram-
negative E. coli. (16). Studies published in this thesis contribute to elucidating 
the biological function of RegIIIβ.
The exploratory study in humans described in this thesis (Chapter 
4) is an initial step and definitely needs confirmation and further investiga-
tion to determine the value of PAP for monitoring intestinal disease activity 
and discriminating between UC and CD. Larger follow-up studies including 
well-defined IBD patients and healthy volunteers are needed. Investigations con-
cerning faecal PAP concentrations in healthy volunteers are needed to address 
our questions concerning a small group of ‘outliers’ at baseline level (Chapter 
4). If the range of faecal PAP concentrations in healthy individuals really is that 
wide, a clinical application of the biomarker might not be feasible. Biopsies of 
IBD patients are needed to indicate whether ileal or colonic tissues (or both) are 
the specific source areas causing an increase of faecal PAP. Also PAP concentra-
tions in serum should be investigated, as studies describe elevated serum PAP in 
IBD patients with active disease (17). Although those studies suggest intestinal 
epithelial expression as the cause of increased serum levels, the question how 
this protein is secreted to the serosal side remains to be answered. It would be 
remarkable that an epithelial expressed protein is secreted into the systemic cir-
culation as well as into the intestinal lumen. Therefore a more comprehensive 
investigation in epithelial tissues, faeces and serum is needed to address all these 
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issues simultaneously. Ultimately, faecal PAP levels should be correlated with 
severity of disease or recovery in order to fine-tune the function of this protein 
as biomarker or even to separate CD from UC. 
Further studies to reveal the exact function of murine RegIIIβ (PAP) 
can tell us whether this protein is involved in all Gram-negative infections. It 
might also have impact on bacteria from the indigenous microbiota and thereby 
modulate its composition or functionality. Binding competition experiments, for 
example with anti-RegIIIβ antibodies, may reveal whether binding of the protein 
to bacteria is crucial for its protective function.
DIETARY MODULATION OF INTESTINAL INFECTION 
Cystine
Dietary cystine supplementation preserved (paracellular) gut barrier function 
and inhibited Salmonella translocation in infected rats (Chapter 5). Studies on 
the protective function of this dietary component have mainly focussed on glu-
tathione-related aspects. Our study showed that a cystine supplemented diet did 
not increase hepatic or ileal glutathione levels compared to rats fed a control diet 
adequate in sulphur-containing amino acids. This indicated that dietary cystine 
has protective properties on the intestinal barrier function due to mechanisms 
unrelated to glutathione. 
Further studies are needed to reveal the mechanism by which cystine 
supplementation affects the intestinal barrier and how it may inhibit Salmonella 
translocation. It still remains unsolved whether the cystine-associated effects are 
due to its absorbtion by the intestinal mucosa and whether subsequent circula-
tion of cystine is required. Amino acids like cystine are absorbed in the small 
intestine and, as has been shown for glutamine, cystine probably affects the epi-
thelial barrier via systemic effects. Depending on the results of future studies, 
cystine might be a suitable nutritional supplement in enteral and/or parenteral 
nutrition in other application areas and more chronic disorders than investi-
gated in this thesis. 
Calcium
Dietary calcium supplementation was shown to have protective properties with 
regard to intestinal Salmonella infection as it decreased Salmonella colonization 
and translocation (Chapter 2). This thesis presents results which showed that dis-
turbance of the composition of the endogenous microbiota, by antibiotic treat-
ment before Salmonella infection, influenced these protective effects of calcium. 
In this compromised host model calcium beneficially affected the epithelial bar-
rier function (urinary CrEDTA excretion and LPS antibody response in serum) 
and diarrhoea. Both functional effects were associated with lowered cytotoxicity 
of faecal water. In the same infection model, however, calcium supplementation 
was not able to inhibit colonization and translocation of Salmonella in contrast 
to the regular infection situation when rats were not pretreated with antibiotics 
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(Chapters 6 and 1, respectively). This suggests that the microbiota play a pivotal 
role in some, but not all of the protective effects of calcium against intestinal 
infectious disease. 
Animal (18) and human (19,20) studies have shown that calcium pre-
cipitates irritating bile acids and other cytotoxic surfactants and thus reduces 
cytotoxicity of luminal contents, preventing epitheliolysis. This seems to be a 
prominent mechanism in calcium-associated protection of epithelial function. 
Other protective mechanisms, such as shown in the regular infection model 
including reduced colonization and translocation of Salmonella, probably act 
via stimulation of competitive microbiota (lactobacilli) (21). Previous studies 
suggested an alternative hypothesis of epithelial protection by dietary calcium. 
Calcium binds to phosphate in the intestinal lumen and this complex has been 
suggested to bind Salmonella and thereby inhibiting epithelial binding and trans-
location of this bacterium (22). Calcium should still have these properties in 
the calcium intervention in antibiotic-pretreated infected rats (Chapters 6) and 
consequently colonization and translocation should be reduced. However, these 
protective effects were not shown in the antibiotic-pretreated infection model. 
Hence, this hypothesis is ruled out by the data presented in this thesis.
The study presented in this thesis (Chapter 6) underlined the usefulness 
of the clindamycin-pretreated infection model in dietary interventions. It pro-
vided better insight into how calcium may enforce the intestinal barrier against 
S. enteritidis infection and its sequelae. The data in this thesis showed that cal-
cium has a dual protective function. This phenomenon of providing protective 
effects via more than one (defence) mechanism can be hypothesized for other 
dietary components as well.
The major questions which remain to be answered concern the patho-
physiological mechanism or route by which the intestinal epithelial layer is 
protected by the calcium supplementation and the severity of diarrhoea is dimin-
ished. More specifically, what generic mechanisms in the intestinal epithelium 
are affected by reduction of the luminal cytotoxicity. These questions are presum-
ably also relevant to explain the previously shown beneficial effects of calcium 
in amelioration of intestinal inflammation and related symptoms observed in a 
rat IBD model (23). It is also important to elucidate quantitative and qualitative 
microbial factors responsible for the protective effects of calcium supplementa-
tion on Salmonella colonization and translocation. The proposed role for endog-
enous lactobacilli (21) could be verified by e.g. by varying the level of lactobacilli 
colonization in rats and subsequent determination of its influence on Salmonella 
colonization. Unpublished results from a Salmonella-infection study in rats with 
variable levels of lactobacilli by oral bile acid supplementation, however, showed 
that a reduced number of lactobacilli did not affect Salmonella colonization or 
translocation. An alternative approach is to study the efficacy of oral probiotics 
to improve intestinal resistance to Salmonella infection. For selection of bacterial 
species, particularly able to compete with S. enteritidis for adhesion to epithelial 
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cells, in vitro competition assays might be included in the screening phase. How-
ever, predictive power of these particular in vitro experiments for in vivo efficacy 
is speculative, as these assays do not reflect the complex multi-factorial inter-
actions that occur in vivo where heterogeneous multi-cellular systems mutually 
interact with microorganisms. 
Human studies have shown similar luminal cytotoxicity reducing prop-
erties of calcium supplementation (19,20) as found in the rat studies presented 
in this theses. Hence, the proposed protective mechanism of calcium in rats is 
likely to be of relevance to humans too and should be further investigated. Espe-
cially, studies addressing the effect of dietary calcium on intestinal permeability, 
diarrhoea, and intestinal microbial composition are welcomed as these generic 
functionalities are presumed relevant for several intestinal disorders, especially 
resistance to infectious disease and intestinal inflammation.
Tannic acid
Tannic acid reduced diarrhoea as well as epithelial permeability in clindamycin-
pretreated infected rats (Chapter 6). We can only speculate about the mechanism 
of these protective effects on epithelial function. The results presented in this 
thesis suggest that the observed protective effects of tannic acid are not related to 
the composition of the microbiota since antibiotic pretreatment of rats did not 
abolish these effects. Moreover, the protective effects were not associated with 
changes in luminal cytotoxicity and therefore also this mechanism possibly is 
not involved in terms of the observed protection. 
Up to now polyphenols have been suggested to strengthen the intesti-
nal epithelial barrier by their possible antioxidative and scavanging or immun-
modulatory properties (24,25). The research presented in this thesis opens up 
a more differentiated avenue of bioactivity in infection-related barrier dysfunc-
tioning. Polyphenol research related to intestinal defence against infection pre-
dominantly concerns in vitro research, and mainly focusses on the antimicrobial 
properties of these compounds (26,27). As the study presented in this thesis 
(Chapter 6) could not reproduce the antibacterial effects, shown in vitro (26,27), 
of hydrolysable tannins like tannic acid in vivo, this indicated that these anti-
microbial effects might not be applicable to the in vivo situation and should be 
interpreted and extrapolated carefully. 
Mechanistic studies on the epithelial barrier strengthening properties of 
tannic acid and other polyphenolic compounds are needed. An initial approach 
would be to expose enterocytes, cultured in an in vitro transwell system, apically 
to cytotoxic surfactants in the absence or presence of tannic acid or gallic acid. It 
would also be of interest to determine structure-function effects of polyphenols 
on the tight junction function or cystic fibrosis transmembrane conductance 
regulator (CFTR) inhibition in vivo or ex vivo in these tissues.
The concentration of tannic acid used in our rat study can be extrap-
olated to the human intake. Therefore it would be interesting to perform a 
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controlled tannic acid or gallic acid dietary intervention in humans that use anti-
biotics in order to investigate whether these compounds reduce infection sever-
ity and diarrhoea in humans. 
CONCLUSION
The question how diet can modulate intestinal Salmonella infection cannot be 
answered in a simple way. This thesis shows that protection by a single dietary 
component can affect multiple pathophysiological consequences of a gastro-
intestinal disorder (Fig 1, Table 1). As multiple sequelae are affected this also 
suggests that multiple mechanisms are involved in dietary modulation of host 
defence, which may be interrelated with other defence or pathophysiological 
mechanisms. The protective properties of dietary calcium supplementation on 
Salmonella infection and its sequelae involve at least two (patho)physiological 
routes related to infection. One of these routes can be modulated depending on 
microbiota-associated host defence status (Table 1). The ‘second route’ is inde-
pendent of the microbiota as functional protective properties on diarrhoea and 
intestinal permeability are maintained after use of antibiotics. Understanding 
the underlying mechanisms of protective effects is very important, especially in 
order to judge whether dietary effects observed in the acute infection model can 
be extrapolated to more chronic disorders.
Table 1. Overview of the observed protective effects of dietary components investigated in either  
the regular or clindamycin-pretreated Salmonella enteritidis-infection model in rats.
Infection model Supplemented 
dietary compound 
(mmol/kg)
Diarrhoea Intestinal 
Salmonella 
colonization
Salmonella
translocation
Infection-
induced 
increase of 
intestinal 
permeability
Ileal  
inflammation
Regular
Calcium (120) Yes1 Yes Yes Yes No
Cystine (12.3) No2 No Yes Yes No
Clindamycin preteated
Calcium (120) Yes No No Yes nd3
Tannic acid (2.2) Yes No No Yes nd
1 Protective effect
2 No protective effect
3 Not determined
This thesis provides new insight into which nutrient-sensitive host 
defence mechanisms are important in Salmonella infection. The indigenous 
microbiota is very important with respect to colonization resistance and pre-
vention of translocation of pathogens. Currently, there is keen scientific and 
commercial interest in nutritional modulation of the gut microbiota, e.g. by 
CHAPTER 7
127
probiotics and prebiotics, and progress can be achieved if microbiota profiling 
data are linked to clinically relevant functional effects in the same studies. Also 
other dietary components, like we showed in the case of calcium, can modulate 
gut microbial composition or function. Intestinal glutathione levels do not seem 
to modulate protection against intestinal infection, although they play a role in 
the magnitude of the inflammatory response. As a disproportionate inflamma-
tory response is also a key factor of chronic inflammation in IBD, it is worth-
while to further explore the role of mucosal glutathione in the orchestration of 
the inflammatory response as it might identify new targets for therapeutic inter-
vention even by dietary means.
Part of this thesis is dedicated to biomarker discovery and we identi-
fied PAP protein as a potential candidate useful in animal and human disease. 
Further studies are needed to fully understand its function and its role as a non-
invasive biomarker. Moreover, this thesis provides intervention models in which 
(dietary) investigations can be refined by using more sensitive infection models 
in rats with a compromised host defence mechanism. 
To conclude, the research presented in this thesis showed that broaden-
ing the scope for other types of nutrients or food components than pre- and pro-
biotics is worthwhile. Candidates like cystine and tannic acid showed promising 
results and indicated that there are many options for future research in dietary 
modulation of intestinal infection. This research area is important because of the 
growing resistance of bacterial pathogens to generally applied antibiotics and, 
therefore, the increasing demand to rely on well functioning host defences.
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Intestinal infections are widespread and still an emerging public health problem. 
The growing resistance of bacterial pathogens, including Salmonella species, to 
generally applied antibiotics makes diet an attractive tool to increase intestinal 
defence against these threats. In Chapter 1 the current knowledge about defence 
mechanisms to protect against intestinal foodborne infections has been 
reviewed, including dietary components that might improve resistance against 
Salmonella infection. From this review it can be concluded that there are, besides 
pre- and probiotics, dietary components that may increase resistance to Salmo-
nella infection and its sequelae. Dietary interventions in the established S. enter-
itidis infection model in rats are essential to first evaluate the potential of these 
dietary components to ultimately improve resistance to intestinal infection in 
humans. In addition to studying the efficacy of diet in improving infection resis-
tance, investigations using the Salmonella infection model can also be used to 
identify new potential biomarkers of intestinal health. 
In Chapter 2 pancreatitis associated protein (PAP), also known as RegIIIβ 
in mice, was evaluated as potential new biomarker. Ileal and faecal protein levels 
were associated with infection severity in rats. Also in mice levels increased in the 
ileal mucosa after intestinal infection (Chapter 3). Mechanistic studies in mice 
described in Chapter 3 revealed that RegIIIβ protein plays a protective role 
against infection with the Gram-negative S. enteritidis but not against the Gram-
positive Listeria monocytogenes. The protective effect is associated with binding 
of this protein to the bacterium. Future studies are needed to reveal if and how 
this association might determine its protective function. In addition to the 
mechanistic rodent studies it is important for biomarker validation to show 
human relevance. Therefore, faecal PAP levels were investigated in human fae-
ces. In Chapter 4 it is described that PAP levels were increased in human faeces 
after oral infection with enterotoxigenic Escherichia coli (ETEC), as shown in 
rodents that were infected with other pathogenic bacteria. Faecal PAP levels 
were also elevated in faeces of ulcerative colitis (UC) patients, but not in those of 
Crohn’s disease (CD) patients. In these human studies faecal PAP levels were not 
proportional to faecal calprotectin, which is an established marker for intestinal 
inflammation. Taken together, these results indicate that faecal PAP probably has 
potential as a new non-invasive biomarker of intestinal infectious and/or inflam-
matory conditions in humans; however more research is needed on its exact 
function and specificity, preferably in combination with other gut biomarkers 
e.g. calprotectin. Our preliminary results suggest that it is neither a biomarker 
for intestinal inflammation nor for intestinal infection only. Follow-up studies 
are needed to determine the value of PAP for monitoring intestinal disease activ-
ity and/or its response to therapeutic or dietary interventions, and discriminat-
ing between UC and CD. 
Some of the intestinal defence mechanisms are suggested to be crucial 
for the course of Salmonella infection; however in vivo evidence is often lacking. 
Therefore to answer part of the question “which host defence mechanisms are 
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important during Salmonella infection?”, the effects of glutathione depletion 
during Salmonella infection and its relevance for gut barrier function were stud-
ied as described in Chapter 5. This in vivo study showed that this defence mecha-
nism is not substantially involved in colonization and translocation of 
Salmonella. It does, however, play an important role in the magnitude of the 
immune response. The latter association and the underlying mechanism need to 
be further investigated, especially in the context of hyper-immune responses 
during intestinal diseases, such as inflammatory bowel disease, which is associ-
ated with deceased glutathione levels. Dietary cysteine is known to be essential 
for gluthathione synthesis and might be involved in various host defence mecha-
nisms. To answer the question “what dietary components can modulate intesti-
nal Salmonella infection?” the protective effect of dietary cystine, which is the 
more stable variant of cysteine, on Salmonella infection was investigated in rats 
(Chapter 5). Dietary cystine did not increase hepatic or ileal glutathione levels 
compared to rats fed a control diet adequate in sulphur-containing amino acids. 
However, dietary cystine preserved (paracellular) gut barrier function and inhib-
ited Salmonella translocation in infected rats. These studies reveal a protective 
function of dietary cystine that seems unrelated to glutathione levels and defi-
nitely has potential for further human research to improve gut health.
In Chapter 6 the role of the microbiota-related host defence during Sal-
monella infection was investigated in Salmonella infected rats that were pre-
treated with oral clindamycin. It has been shown previously that such a 
pretreatment disturbs the gut microbiota ecosystem and leads to increased 
pathogen colonization. The study described in Chapter 6 shows that the epithe-
lial barrier is negatively affected by clindamycin pretreatment, which results in 
barrier defects, and these defects are associated with high luminal cytotoxicity. 
Therefore, it is an interesting new insight that some of the negative effects of 
antibiotic treatment may be counteracted by focussing on the luminal cytotoxic-
ity. Further studies are needed to confirm whether these symptoms also occur in 
humans. 
The infection model with a compromised microbiota-related host 
defence was also used to investigate protective properties of dietary calcium and 
tannic acid. Dietary calcium inhibits Salmonella colonization and translocation 
in rats with a normal defence status (Chapter 2). Due to the study described in 
Chapter 6 we now know that these effects of dietary calcium crucially depend on 
the intestinal microbiota. In contrast, reduction of the luminal cytotoxicity asso-
ciated with a preserved paracellular epithelial barrier and reduced diarrhoea are 
protective properties of dietary calcium that are maintained in the antibiotic pre-
treated infection model. Therefore these protective effects are possibly not main-
tained via the microbiota, but probably arise via reduction of luminal cytotoxicity. 
Similarly, tannic acid reduces diarrhoea and preserves epithelial permeability in 
clindamycin pretreated infected rats. These effects were not associated with 
reduced luminal cytotoxicity and the mode of action of tannic acid points to 
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improvement or enforcement of the intestinal epithelial lining. Currently we can 
only speculate about the mechanism of protection by tannic acid; future studies, 
e.g. with epithelial cells exposed to tannic acid, should provide more informa-
tion. Antimicrobial activity that has been described for polyphenols like tannic 
acid in vitro seemed not to be present in vivo; therefore this study underlines the 
importance of evaluation of such effects in an in vivo model. 
In conclusion, the studies described in this thesis indicate that nutrients 
or food components other than pre- and probiotics can improve resistance to 
intestinal infection. Candidates like cystine and tannic acid showed promising 
results and indicated that there are many options for future research in dietary 
modulation to improve defence to intestinal infectious disease. This research 
area is of growing importance, because of the increasing resistance of bacterial 
pathogens to generally applied antibiotics and, therefore, the increasing demand 
to rely on a well functioning host defence.
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Darminfecties komen wereldwijd voor en zijn nog steeds een groeiend probleem 
voor de volksgezondheid. Een belangrijk probleem is de toenemende resistentie 
van bacteriële pathogenen, zoals Salmonella, tegen de doorgaans gebruikte anti-
biotica. Het verbeteren van de darmweerstand tegen deze bedreigingen met 
behulp van voeding is daarom een aantrekkelijke methode. In Hoofdstuk 1 wordt 
de huidige kennis met betrekking tot de weerstandsmechanismen ter bescher-
ming tegen darminfecties (veroorzaakt door bacteriële voedselinfecties) bespro-
ken, inclusief voedingscomponenten die mogelijk de weerstand van de gastheer 
tegen een Salmonella infectie kunnen verhogen. Uit dit literatuuroverzicht kun-
nen we concluderen dat er, naast pre- en probiotica, voedingscomponenten zijn 
die de weerstand kunnen verhogen tegen een Salmonella infectie en/of de bijbe-
horende gevolgen kunnen verminderen. Om de potentie van voedingcomponen-
ten, die uiteindelijk infectieweerstand in de mens kunnen vergroten, te evalueren 
is het essentieel om eerst voedingsinterventies in een diermodel uit te voeren. In 
dit proefschrift is dat het gevestigde Salmonella infectiemodel in ratten. Naast 
het bestuderen van de werkzaamheid van voeding om de weerstand van de gast-
heer te verhogen tegen infectie, kan het onderzoek met behulp van het Salmo-
nella infectiemodel ook worden gebuikt om nieuwe potentiële biomarkers van 
darmgezondheid te identificeren. 
In Hoofdstuk 2 werd het eiwit pancreatitis associated protein(PAP) 
geëvalueerd als mogelijke nieuwe biomarker. In ratten zijn de eiwitconcentraties 
in het ileum en feces geassocieerd met de mate van infectie. De homoloog van 
dit eiwit in muizen, genaamd RegIIIβ, nam ook toe in hoeveelheid eiwit in de 
ileummucosa na darminfectie (Hoofdstuk 3). Studies in muizen naar het wer-
kingsmechanisme van dit eiwit, beschreven in Hoofdstuk 3, onthulden dat 
RegIIIβ een beschermende rol speelt tegen Gram-negatieve S. enterititdis infec-
tie, maar niet tegen Gram-positieve Listeria monocytogenes infectie. Het bescher-
mende effect is geassocieerd met de binding van het eiwit aan de bacterie. 
Verdere studies zijn nodig om te achterhalen hoe deze associatie de bescher-
mende functie bepaald. Naast de mechanistische studies in knaagdieren is het 
voor biomarkervalidatie van belang om humane relevantie aan te tonen. Daarom 
werd in humane feces de PAP concentratie onderzocht. In Hoofdstuk 4 staat 
beschreven dat de PAP concentraties toenamen in humane feces na orale infectie 
met enterotoxigenic Escherichia coli (ETEC), hetzelfde fenomeen dat werd 
geconstateerd in knaagdieren die werden geïnfecteerd met andere pathogene 
bacteriën. Fecale PAP concentraties namen ook toe in feces van patiënten met 
colitis ulcerosa (UC), maar niet in feces van patiënten met de ziekte van Crohn 
(CD). In deze humane studies nam fecale PAP niet proportioneel toe met fecale 
calprotectine, hetgeen een gevestigde marker voor darmontsteking is. Samenvat-
tend geven deze resultaten aan dat fecale PAP potentie heeft als nieuwe biomar-
ker voor darminfectie en/of darmontsteking gerelateerde condities in de mens; 
hoewel meer onderzoek moet worden gedaan om de exacte functie en specifici-
teit te bepalen, bij voorkeur in combinatie met andere darmbiomarkers zoals 
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bijvoorbeeld calprotectine. Onze preliminaire resultaten suggereren dat het geen 
biomarker voor darmontsteking is en ook niet voor een op zich staande darm-
infectie. Vervolgstudies zijn nodig om de waarde van PAP als biomarker te bepa-
len in het kader van 1) de activiteit van darmaandoeningen en/of de respons op 
medische of voedings interventies te monitoren en 2) het onderscheid te maken 
tussen UC en CD. 
In de literatuur wordt gesuggereerd dat sommige weerstandsmechanis-
men een cruciale rol te spelen tijdens een Salmonella infectie hoewel hier vaak 
geen in vivo bewijs voor is. Om een deel van de vraag “Welke weersstandsmecha-
nismen zijn belangrijk tijdens Salmonella infectie?” te beantwoorden, werden in 
Hoofdstuk 5 de effecten van glutathiondepletie tijdens een Salmonella infectie en 
de relevantie voor de darmbarrière functie bestudeerd. Deze in vivo studie liet 
zien dat dit weerstandsmechanisme geen substantiële rol speelt in colonisatie en 
translocatie van Salmonella. Het speelt echter wel een belangrijke rol bij de reac-
tie van het immuunsysteem. Deze associatie en het onderliggende mechanisme 
moeten verder worden onderzocht, met name in de context van de hyper-
immuunreactie tijdens darmziekten zoals chronische darmontsteking (inflam-
matory bowel disease;IBD), hetgeen ook wordt geassocieerd met verlaagde 
glutathion gehaltes. Cysteïne uit voeding is essentieel voor glutathion synthese 
en zou een belangrijke rol kunnen spelen in verschillende weerstandsmechanis-
men van de gastheer. Om de vraag “Welke voedingscomponenten kunnen een 
Salmonella geassocieerde darminfectie moduleren?” deels te beantwoorden, 
werd het beschermende effect van cystine (stabiele variant van cysteïne) tegen 
Salmonella infectie onderzocht (Hoofdstuk 5). Cystine in voeding van ratten was 
niet in staat glutathion te verhogen in de lever of het ileum vergeleken met ratten 
die een controle dieet kregen dat adequaat was in zwavelhoudende aminozuren. 
Cystine in voeding hield echter wel de (paracellulaire) darmbarrièrefunctie in 
stand en verlaagde de translocatie van Salmonella in geïnfecteerde ratten. Deze 
studie legde een beschermende functie van cystine bloot die schijnbaar niet gere-
lateerd is aan glutathion gehaltes en zeker potentie heeft voor verder humaan 
onderzoek om de darmgezondheid te verbeteren.
In Hoofdstuk 6 werd de rol van de microbiota-gerelateerde weerstand 
van de gastheer tijdens Salmonella infectie onderzocht in Salmonella geïnfec-
teerde ratten die een orale clindamycine voorbehandeling kregen. Uit voorgaand 
onderzoek bleek dat een dergelijke voorbehandeling het microbiota-ecosysteem 
van de darm verstoord en leidt tot een verhoogde colonisatie van pathogenen. 
De studie besproken in Hoofdstuk 6 laat zien dat de darmbarrière negatief word 
beïnvloed door de clindamycine behandeling, hetgeen resulteert in barrière-
defecten en deze defecten zijn geassocieerd met een hoge luminale cytotoxiteit. 
Het is een interessant nieuw inzicht dat sommige negatieve effecten van antibio-
tica behandeling mogelijk kunnen worden tegengegaan door te focussen op de 
luminale cytotoxiteit. Verdere studies zijn nodig om humane relevantie van deze 
symptomen te bevestigen. Het infectiemodel met de gecompromitteerde 
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microbiota-geassocieerde weerstand werd tevens gebruikt om de beschermende 
effecten van calcium in voeding en tannic acid te onderzoeken. Calcium remt 
Salmonella colonisatie en translocatie in ratten met een normale weerstand 
(Hoofdstuk 2). Door de studie, beschreven in Hoofdstuk 6, weten wij nu dat deze 
effecten van calcium sterk afhangen van de microbiota in de darm. Daarentegen 
zijn andere beschermende effecten van calcium staande gebleven in dit infectie 
model. Dit zijn reductie van de luminale cytotoxiteit geassocieerd met een in 
stand gehouden epitheliale barrière en een afname van diarree. Dit geeft aan dat 
deze beschermende effecten wellicht niet tot stand komen via de microbiota 
maar waarschijnlijk via reductie van de luminale cytotoxiteit. Tannic acid redu-
ceert en behoudt ook de epitheliale barrièrefunctie in geïnfecteerde ratten die 
werden voorbehandeld met clindamycine. Deze effecten waren echter niet geas-
socieerd met een gereduceerde luminale cytotoxiteit, en het werkingsmecha-
nisme lijkt toegewijd te zijn aan de verbetering of versterking van het 
darmepitheel. Op dit moment kunnen we alleen maar speculeren over het 
mechanisme van bescherming door tannic acid; verdere studies met bijvoor-
beeld epitheelcellen die bloot worden gesteld aan tannic acid moeten meer 
inzicht geven. In vitro antimicrobiële activiteit die voorheen werd beschreven 
voor polyfenolen zoals tannic acid leek niet aanwezig in vivo. Deze studie geeft 
dus het belang aan van evaluatie van dit soort effecten in een in vivo model.
Samenvattend tonen de studies die in dit proefschrift beschreven staan 
aan dat nutriënten of voedingscomponenten anders dan pre- en probiotica de 
weerstand tegen darminfectie kunnen verbeteren. Kandidaten zoals cystine en 
tannic acid lieten veelbelovende resultaten zien en gaven aan dat er meerdere 
opties voor toekomstig voedingsonderzoek zijn ter verbetering van de weerstand 
tegen darminfecties. Het belang van dit onderzoeksgebied is groeiende, omdat er 
steeds meer bacteriële pathogenen resistent zijn tegen de doorgaans gebruikte 
antibiotica. Hierdoor is er een groeiende vraag naar een goed functionerende 
weerstand van de gastheer.
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Na ruim 5 jaar ligt hier dan mijn proefschrift. De eerste 2 jaar van het onderzoek 
waren niet bijzonder vruchtbaar maar het leek wel of dit vooral in het laatste jaar 
werd vergoed. Toch heb ik altijd met veel plezier aan het onderzoek gewerkt en 
werd het doorzetten beloond, ookal moest er nog veel worden gedaan na het 
einde van mijn contract. Wetenschap is nou eenmaal niet in bochten te wringen! 
Ik ben erg blij met het resultaat, dat ik natuurlijk nooit in mijn eentje had kun-
nen bereiken. Daarom wil ik graag de kans grijpen om alle mensen te bedanken 
die de afgelopen jaren een belangrijke rol hebben gespeeld.
Mijn promotor Prof. Dr. Robert-Jan Brummer. Beste Robert-Jan, harte-
lijk dank dat ik je AIO mocht zijn. In de beginjaren vond ik het nogal eens lastig 
om bepaalde ideeen te verwoorden. Het grappige was dat jij het altijd onmidde-
lijk begreep. Het was altijd prettig om even uit te “zoomen” op alle proeven tij-
dens onze meetings om dicht bij de essentie van het onderzoek te blijven. In de 
loop van de jaren is er nogal wat veranderd en kreeg jij een nieuwe uitdaging in 
Zweden. Gelukkig kon ik altijd nog bij je terecht voor raad en daad.
Dr. Ingeborg Bovee-Oudenhoven. Beste Ingeborg, jij bent mijn directe 
begeleider geweest en was jouw bijdrage als co-promotor cruciaal. Ik wil je 
bedanken voor alles wat ik van je heb geleerd de afgelopen jaren. Dankzij jouw 
toomloze inzet lukte het om na wat schrikmomentjes toch nog de knockoutmui-
zen naar Nederland te halen. Hiermee hebben we een geweldige studie gedaan, 
waar we wellicht in de toekomst nog meer van gaan horen.
Dr. R. van der Meer. Beste Roelof, dank voor al je inzichten, ideëen en 
aanstekelijke enthousiasme in de wetenschap. Jouw kritsch oog heb ik altijd erg 
gewaardeerd en ook erg veel van geleerd.
Dit proefschrift is onderdeel van het A011 project binnen het TI Food 
and Nutrition. Het A011-team: Marloes, Carolien en Arjan. Marloes, het was fijn 
om deze periode met je te delen. De ups en downs zijn we goed doorgekomen. Ik 
denk wij elkaar perfect aanvullen op inhoudelijk én persoonlijk vlak (en natuur-
lijk onze passie voor muziek!). Carolien en Arjan zonder jullie was dit boekje er 
nooit geweest. Carolien, jouw enthousiasme en missie om nieuwe dingen met 
beide handen aan te pakken heb ik altijd erg gewaardeerd. En niet te vergeten je 
vrolijkheid op het lab! Arjan altijd de vaste hand in experimenten en hebben we 
regelmatig in het weekend op het lab moeten staan. Om maar niet te praten over 
de honderden platen die we hebben moeten gieten (en dan ook weer uitplaten...
én tellen). Ik ben dan ook erg blij dat je me ook op mijn promotiedag bij wilt 
staan, dank! Graag wil ik ook alle TI Food and Nutrition (ex)collega’s binnen 
Programma 1 bedanken voor alle nuttige meetings. Onder andere ook veel dank 
aan Wendy, Evelien en Jaap. Het was fijn om met jullie het “PAP”-avontuur te 
starten gevoed met goede discussies en enthousiasme! Daarnaast wil ik ook 
graag de experts van verschillende bedrijven binnen het TI Food and Nutrition 
bedanken voor de betrokkenheid bij het onderzoek in de vorm van goede dis-
cussies en nuttige comments. Het was mij een eer om op de valreep ook nog een 
“exemplificatie-project” uit te voeren.
ACKNOWLEDGMENTS/DANKWOORD
141
De leden van de beoordelingscommissie wil ik graag bedanken voor de 
tijd die ze hebben genomen voor het bestuderen van mijn proefschrift. Naast 
voorzitter Prof. C. Bruggeman bestaat deze uit Prof. A. Bast, Dr. D. Jonkers, Dr. 
M. van Nieuwenhoven en Prof. R. Witkamp.
De rest van het “nuts-team” van Nizo Food Research in Ede: Hans, San-
dra, Corinne, Harro en Rianne. Bedankt voor alle hulp, goede discussies en 
opbouwende kritiek. Denise, jij was onderdeel van de nuts maar gevoelsmatig 
ook onderdeel van het A011-team. Altijd kon ik met vragen bij jou terecht en 
werkt jouw passie voor onderzoek aanstekelijk. Dank je voor al je hulp en 
enthousiasme! 
Ook wil ik allle andere mensen van het Nizo bedanken van de afdeling 
Health (and Safety), maar ook alle andere mensen (o.a. van de dinsdagmiddag-
meetings). Naar mijn idee is het erg goed voor onderzoek en de mens zelf om 
wetenschappelijke resultaten met een breed georiënteerd publiek te bespreken.
Also my non-dutch collegues at Nizo, thank you for the good times and 
nice discussions! Er zijn ook aardig wat (ex-)Nizo-ers waar ik nog regelmatig 
mee geniet: Saskia, Iris, Gabriele, Mariela, Jolanda, Jacqueline, Roger en Marieke. 
Dank jullie voor alle leuke etentjes, borrels en/of sauna-momenten.
Wilma, Judith, Pam, Renee, Bert en andere CKP-ers bedankt voor alle 
zorg, hulp en nuttige tips tijdens mijn proeven! Het was niet altijd even fijn wan-
neer een oxidatie-gevoelig-voer pas aan het eind van de dag mocht worden gege-
ven. Of wanneer ik weer eens in het weekend jullie hulp nodig had. Mijn dank is 
groot voor jullie enorme inzet!
Linda Loonen, Jan Dekker en Jerry Wells (Host Microbe Interactomics, 
Wageningen University) heel erg bedankt voor onze fijne en vruchtbare samen-
werking. Onze meeting waren altijd erg prettig en maakten mij alleen nog maar 
meer enthousiast. Linda, ik vond het erg leuk om met jou je eerste grote studie 
uit te voeren en de resultaten mogen er zeker zijn!
Dear Mathias Chamaillard and Juan Iovanna, thank you for giving us 
the opportunity to investigate the role of RegIIIβ in infection. Also for you parti-
cipation in the discussion about the results, I hope we will have more of these 
discussions in future.
Dank ook aan Henrike Hamer en Gerard Dijkstra voor het beschikbaar 
stellen van fecale monsters van IBD patienten en het enthousiasme om de poten-
tie van PAP als biomarker te onderzoeken.
Al mijn lieve vrienden: dank voor de heerlijke momenten! Soms was 
mijn tijd wat schaars maar gelukkig maakte de quality-time zo nu en dan alles 
weer goed! Een van mijn vrienden staat zelfs als paranifm naast me! Remco ik 
ben blij dat je me op deze dag bij wilt staan. De afgelopen jaren kon ik altijd bij 
jou en Wiesje terecht voor een goed gesprek of zomaar. Meestal kon deze honge-
rige AIO na een dag hard werken gewoon bij jullie aanschuiven. Het is nu hele-
maal compleet nu Luana er ook is, ik ben een trotse tante W! Paul en Jet dank 
voor alle fijne momenten onder het genot van het heerlijke portugeese klimaat. 
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Paul dank voor al je hulp met het voltooien van dit boekje! Daniel heel erg 
bedankt voor je hulp bij de afronding, ik hoop in de toekomst jou, Gabriele en 
Johanna nog vaak te zien. Bjorn en Renée niet alleen dank voor alle gezellige en 
fijne momenten, maar ook dank voor het ontwerpen van de prachtige cover van 
dit proefschift.
Ook wil ik mijn ouders en familie bedanken. Mijn dierbare oom en 
tante die altijd interesse hadden in mijn promotieonderzoek (ik mis jullie..). 
Mijn lieve “schoonouders” en “schoonfamilie” die ik eigenlijk gewoon als mijn 
familie beschouw: bedankt voor alle steun, begrip, interesse en fijne momenten. 
Mijn ouders, dank voor jullie steun en interesse. Toen ik klein was 
vroeg ik me altijd af waarom mijn moeder bijna al mijn vragen kon beant-
woorden en nam ik me voor later ook zoveel te weten. Volgens mij ben ik al 
een aardig eind op weg lieve mam! Mijn lieve zussen heel erg veel dank voor 
alle fijne momenten. 
Dan ten slotte deze ereplaats. Die is maar voor 1 persoon weggelegd, 
lieve Rob jij luisterde kritisch naar mijn presentaties en gaf ijzersterke comments. 
Ik kan niet in een paar woorden uiten waar ik jou allemaal voor zou willen 
bedanken. Maar vooral dank je voor wie je bent, en zoals jij zelf ooit verwoordde, 
“thanks for all good times!”.
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Marleen T.J. van Ampting was born on January the 19th 1978 in Doetinchem, 
the Netherlands and grew up in adjacent small village named Wehl. After com-
pleting secondary school in 1996 at the St. Ludgercollege in Doetinchem she 
studied medical laboratory research (HLO) and obtained her B.Sc. degree in 
2002 at the Institute of Life Sciences and Chemistry at “Hogeschool van Utrecht”. 
During her B.Sc. internship in the laboratory of Prof. S. Landfear at the Oregon 
Health and Sciences University in Portland, Oregon, in the United States of 
America she cloned and functionally characterized a newly discovered mem-
brane protein of the parasite Trypanosoma brucei brucei. 
She continued her education with a M.Sc. study biomedical sciences at 
the “Vrije Universiteit” in Amsterdam. She performed her first internship under 
supervision of Dr. P. Nuijten and Dr. D. Schuijffel at Intervet International, where 
she investigated specific in vivo expressed antigens of Ornithobaterium rhinotra-
cheale. Her second internship was in the laboratory of Prof. Dr. J. Luirink at the 
Vrije Universiteit where she investigated, under supervision of Dr. W. Jong, E. 
coli targeting pathways to transport heterologous proteins to the periplasm, after 
which she graduated in 2005. In March 2005 she started as a Ph.D. student at 
Nizo food research (and Maastricht University), under supervision of Dr. I. 
Bovee-Oudenhoven working on a project from TI Food and Nutrion (TIFN, for-
merly known as WCFS) entitled “dietary modulation of intestinal infection and 
mucosal inflammation”. The research performed during this period is presented 
in this thesis entitled: “Dietary interventions and intestinal defence to protect 
against Salmonella infection”. She presented results at several national and inter-
national conferences and in 2008 she received a travel award at the European 
mucosal immunology meeting. 
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